Library › Lymphoid neoplasms and lymph node pathology: WHO 5th edition and ICC 2022 classification, flow cytometry, reactive lymphadenopathy, lymphomas, plasma cell and histiocytic neoplasms and spleen
Lymphoid neoplasms and lymph node pathology: WHO 5th edition and ICC 2022 classification, flow cytometry, reactive lymphadenopathy, lymphomas, plasma cell and histiocytic neoplasms and spleen
Last reviewed 2026-11-17 by a board-certified pathologist. 190 references.
Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology
Definition. Lymphoid neoplasms are clonal proliferations of B cells, T cells or NK cells at precursor or mature stages of differentiation. They are classified by integrating morphology, immunophenotype, genetics and clinical features (Alaggio 2022; Campo 2022). Two classifications were published in 2022: the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) and the International Consensus Classification (ICC). Both replace the revised 4th edition of the WHO classification (WHO-HAEM4R, 2017) (Ferry 2024).
Immunophenotyping. Flow cytometry measures surface and cytoplasmic antigens on large numbers of single cells in suspension. Immunohistochemistry (IHC) shows antigen expression in tissue architecture on formalin-fixed, paraffin-embedded sections. The CAP lymphoid template reports the two separately because flow cytometry is typically more sensitive, the antibodies differ, and IHC detects cytoplasmic antigens that can be negative on surface analysis (CAP 2026).
Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (myeloid flow cytometry, AML measurable residual disease and the myeloid WHO-HAEM5/ICC frame) Related page: AML, Myelodysplasia-Related, AML Defined by Differentiation, Myeloid Neoplasms Post Cytotoxic Therapy and of Down Syndrome, Myeloid Sarcoma, BPDCN and Acute Leukemias of Ambiguous Lineage (lineage assignment in mixed-phenotype acute leukemia) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (lymphocyte subset reference intervals by age, ALPS laboratory criteria and double-negative T cells) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (PNH flow cytometry) Related page: Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products (CD34 enumeration) Related page: Flow Cytometry, FISH, Microbiology and Electron Microscopy on Cytology Specimens (flow cytometry and FISH on fine-needle aspiration material) Related page: Lymph Node FNA Triage for Flow Cytometry, Cultures and Molecular Testing (allocation of fine-needle aspiration material) Related page: Sydney System and WHO Reporting System for Lymph Node Cytopathology (Sydney and WHO reporting categories for lymph node cytology) Related page: Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow (reactive and tumour-like lesions of lymph node) Related page: B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease (B- and T-lymphoblastic leukemia/lymphoma and B-ALL measurable residual disease) Related page: Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases (plasma cell neoplasms, next-generation flow MRD in myeloma and the CAP plasma cell template)
WHO 5th edition and ICC 2022: structure of the two lymphoid classifications
- WHO-HAEM5. Entities are arranged in a hierarchy of category, family/class, entity/type and subtype. Diagnostic criteria are divided into essential and desirable criteria. A family-level diagnosis is permitted when resources or material are insufficient for a definitive diagnosis. No provisional entities were created (Alaggio 2022).
- Order within WHO-HAEM5. Precursor neoplasms precede mature neoplasms. Within a family, entities run from indolent to aggressive (Alaggio 2022).
- New WHO-HAEM5 content. Tumour-like lesions form a new category (Table 1). Germline predisposition syndromes associated with lymphoid neoplasms, such as ataxia telangiectasia, have dedicated chapters (Alaggio 2022).
- ICC. The ICC retains provisional entities, marked in its tables. The definitions of most entities are unchanged from WHO-HAEM4R, while diagnostic criteria and recommended ancillary studies are refined (Campo 2022).
- Histiocytic and dendritic cell neoplasms. Histiocytic and dendritic cell neoplasms are covered in the WHO-HAEM5 myeloid summary (Khoury 2022) and in the ICC mature lymphoid report (Campo 2022). Follicular dendritic cell sarcoma and fibroblastic reticular cell tumour moved to the WHO-HAEM5 chapter of stroma-derived neoplasms of lymphoid tissues (Khoury 2022).
Key differences between WHO-HAEM5 and ICC 2022 for lymphoid, plasma cell and histiocytic neoplasms, with the WHO-HAEM4R rule
Table 1. Entity names and rules that differ between WHO-HAEM5 (Alaggio 2022; Khoury 2022; Ferry 2024) and ICC 2022 (Campo 2022; Duffield 2023; Ferry 2024), with WHO-HAEM4R (2017) as stated in Alaggio 2022, Campo 2022, Duffield 2023 and Ferry 2024.
| Topic | WHO-HAEM5 (2022) | ICC 2022 | WHO-HAEM4R (2017), previous rule | Unit |
|---|---|---|---|---|
| Lesions that mimic lymphoma | Tumour-like lesions with B-cell predominance and with T-cell predominance, first classified in this edition | Not classified as a category; multicentric Castleman disease listed with HHV-8-associated lymphoproliferative disorders | Not classified as a category; multicentric Castleman disease listed with HHV8-associated disorders | Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow |
| B-ALL with hypodiploidy | Single type: B-ALL with hypodiploidy | Two entities: B-ALL, low hypodiploid (32–39 chromosomes) and B-ALL, near haploid (24–31 chromosomes) | B-ALL with hypodiploidy | B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease |
| BCR::ABL1-positive B-ALL | One type: B-ALL with BCR::ABL1 fusion | Subdivided into lymphoid-only and multilineage involvement | B-ALL with t(9;22)(q34;q11.2); BCR-ABL1 | B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease |
| Newer B-ALL drivers (DUX4, MEF2D, ZNF384, NUTM1, MYC, PAX5 P80R) | Grouped under B-ALL with other defined genetic abnormalities | Separate entities, with further provisional entities defined by gene expression | Not included | B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease |
| Early T-precursor ALL | Early T-precursor lymphoblastic leukaemia/lymphoma | ETP-ALL, BCL11B-activated, and ETP-ALL, NOS; eight provisional T-ALL entities | Early T-cell precursor lymphoblastic leukaemia | B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease |
| NK-lymphoblastic leukemia/lymphoma | Not listed | Provisional entity | Provisional entity | B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease |
| B-cell prolymphocytic leukemia | Deleted; cases reassigned to a mantle cell lymphoma variant, prolymphocytic progression of CLL/SLL (CD5-positive non-mantle B-cell neoplasm with >15% prolymphocytes in blood and/or marrow) or splenic B-cell lymphoma/leukaemia with prominent nucleoli (SBLPN) | Retained, after rigorous exclusion of transformed CLL, mantle cell lymphoma and splenic marginal zone lymphoma | Entity | Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia |
| Hairy cell leukemia variant | Absorbed into SBLPN | Retained under splenic B-cell lymphoma/leukemia, unclassifiable | Retained under splenic B-cell lymphoma/leukemia, unclassifiable | Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia |
| Follicular lymphoma grading | Classic FL (cFL), with grading optional; follicular large B-cell lymphoma (FLBL; largely equals FL grade 3B); FL with uncommon features (uFL) | Grades 1–2, 3A and 3B retained | Grades 1–2, 3A and 3B | Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia |
| In situ lesions | In situ follicular B-cell neoplasm; in situ mantle cell neoplasm | In situ follicular neoplasia; in situ mantle cell neoplasia | In situ follicular neoplasia; in situ mantle cell neoplasia | Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia |
| Diffuse BCL2-rearrangement-negative follicle center lymphoma | FL with predominantly diffuse growth pattern, a subset of uFL | BCL2-R-negative, CD23-positive follicle center lymphoma | Largely diffuse cases lacking BCL2 rearrangement, often inguinal, with CD23 and 1p36 loss, recognized within FL | Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia |
| Primary cutaneous marginal zone lymphoma | Separate entity: primary cutaneous marginal zone lymphoma | Separate entity: primary cutaneous marginal zone lymphoproliferative disorder | Included in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia |
| Pediatric nodal marginal zone lymphoma | Distinct entity | Listed under the nodal marginal zone lymphoma heading (Campo 2022; Ferry 2024) | Discussed within nodal marginal zone lymphoma | Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia |
| MYC and BCL2 rearrangements | Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2) | High-grade B-cell lymphoma with MYC and BCL2 rearrangements | High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements | Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging |
| MYC and BCL6 rearrangements without BCL2 | Classified as DLBCL, NOS or HGBL, NOS by cytomorphology | High-grade B-cell lymphoma with MYC and BCL6 rearrangements (provisional) | Included in HGBL with MYC and BCL2 and/or BCL6 rearrangements | Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging |
| 11q aberration | High-grade B-cell lymphoma with 11q aberration | Large B-cell lymphoma with 11q aberration (provisional) | Burkitt-like lymphoma with 11q aberration | Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging |
| Fibrin-associated lymphoma | Fibrin-associated large B-cell lymphoma, a separate entity | Fibrin-associated DLBCL, a subtype of DLBCL associated with chronic inflammation | Subtype of DLBCL associated with chronic inflammation | Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging |
| HHV8-negative effusion-based lymphoma | Fluid overload-associated large B-cell lymphoma | HHV-8 and EBV-negative primary effusion-based lymphoma (provisional) | Noted in the differential diagnosis of primary effusion lymphoma; not an entity | Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging |
| Lymphomas of immune-privileged sites | Primary large B-cell lymphoma of immune-privileged sites (CNS, vitreoretina, testis) | Primary DLBCL of the CNS; primary DLBCL of the testis as a separate entity | Primary DLBCL of the CNS | Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging |
| Nodular lymphocyte predominant lymphoma | Nodular lymphocyte predominant Hodgkin lymphoma, retained within Hodgkin lymphoma | Nodular lymphocyte predominant B-cell lymphoma; Fan patterns A–C (grade 1) separated from D–F (grade 2) | Nodular lymphocyte predominant Hodgkin lymphoma | Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging |
| Immunodeficiency-associated proliferations | Framework of hyperplasias, polymorphic lymphoproliferative disorders and lymphomas arising in immune deficiency/dysregulation, named by histology, virus and immunodeficiency setting | Posttransplant lymphoproliferative disorder categories (nondestructive, polymorphic, monomorphic, classic Hodgkin lymphoma type) and other iatrogenic immunodeficiency-associated disorders | Posttransplant lymphoproliferative disorder categories | Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging |
| Follicular helper T-cell lymphomas | Nodal T-follicular helper cell lymphoma, angioimmunoblastic-type, follicular-type and NOS | Follicular helper T-cell lymphoma, angioimmunoblastic type, follicular type and NOS | Angioimmunoblastic T-cell lymphoma; follicular T-cell lymphoma; nodal peripheral T-cell lymphoma with TFH phenotype | Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas |
| EBV-positive nodal T/NK lymphoma | EBV-positive nodal T- and NK-cell lymphoma | Primary nodal EBV-positive T-cell/NK-cell lymphoma (provisional) | Variant of peripheral T-cell lymphoma, NOS | Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas |
| Chronic NK-cell proliferation | NK-large granular lymphocytic leukaemia | Chronic lymphoproliferative disorder of NK cells | Chronic lymphoproliferative disorder of NK cells | Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas |
| Indolent T-cell proliferation of the GI tract | Indolent T-cell lymphoma of the gastrointestinal tract | Indolent clonal T-cell lymphoproliferative disorder of the gastrointestinal tract | Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract | Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas |
| Type II refractory celiac disease | Discussed; not listed as an entity | Listed as a precursor of enteropathy-associated T-cell lymphoma | Discussed; not listed | Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas |
| Myeloma name and subclassification | Plasma cell myeloma | Multiple myeloma, NOS, or multiple myeloma with a CCND family, MAF family or NSD2 translocation, or with hyperdiploidy | Plasma cell myeloma | Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases |
| Monoclonal gammopathies | IgM MGUS, non-IgM MGUS, monoclonal gammopathy of renal significance and cold agglutinin disease as entities | IgM MGUS, plasma cell type and NOS; primary cold agglutinin disease; MGRS recognized but not a separate entity | IgM and non-IgM MGUS; MGRS and cold agglutinin disease not included | Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases |
| Paraneoplastic plasma cell syndromes | POEMS, TEMPI and AESOP syndromes | POEMS and TEMPI syndromes in a 2024 WHO/ICC comparison (Ferry 2024); not named in the ICC report (Campo 2022) | POEMS syndrome; TEMPI syndrome (provisional) | Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases |
| Rosai-Dorfman disease and ALK-positive histiocytosis | Rosai-Dorfman disease and ALK-positive histiocytosis added | Rosai-Dorfman-Destombes disease (a subset neoplastic) and ALK-positive histiocytosis added | Not included | Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen |
| EBV-positive inflammatory dendritic cell tumour | EBV-positive inflammatory follicular dendritic cell sarcoma | EBV-positive inflammatory follicular dendritic cell/fibroblastic reticular cell tumor | Inflammatory pseudotumour-like follicular/fibroblastic dendritic cell sarcoma | Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen |
Changes shared by both systems. Both rename B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma as mediastinal grey (gray-) zone lymphoma. Both recognize an indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract and reclassify primary cutaneous acral CD8-positive T-cell lymphoma as a lymphoproliferative disorder (Ferry 2024). In addition, WHO-HAEM5 prefers the term Richter transformation to Richter syndrome and adds EBV-positive and EBV-negative subtypes of Burkitt lymphoma to the three epidemiologic variants (Alaggio 2022).
CAP Precursor and Mature Lymphoid Malignancies template, version 1.0.0.2 (September 2026)
The case summary covers precursor and mature B-, T- and NK-cell neoplasms in blood, marrow, nodal and extranodal sites. Hodgkin lymphoma is included as a mature B-cell neoplasm. Clinical staging and prognostic classifications were removed because they are performed by the managing physician (CAP 2026).
Table 2. Elements of the CAP lymphoid case summary, version 1.0.0.2 (CAP 2026).
| Element | Content |
|---|---|
| Site(s) of involvement | Bone marrow and blood with percent neoplastic cells; anterior mediastinum; lymph node; cutaneous; extranodal or mucosal site; other |
| Final integrated diagnosis | WHO-HAEM5 types for precursor B-cell, mature B-cell, Hodgkin, precursor T-cell and mature T- and NK-cell neoplasms and for lymphoid proliferations associated with immune deficiency and dysregulation; "pending additional studies" options for precursor neoplasms |
| Optional pre-neoplastic proliferations | Monoclonal B-cell lymphocytosis, CLL-type low-count, CLL-type and non-CLL-type, with absolute clonal count in × 10⁹/L |
| Immunodeficiency-associated lesions | Name of lesion, virus status and type of immunodeficiency (optional) |
| Possible transformation | Not applicable; no evidence of transformation; lymphoma favored to represent transformation from an indolent lymphoma |
| Immunohistochemistry | Not performed, performed with results, or pending |
| Flow cytometry | Not performed; no aberrancy detected at the sensitivity of the assay; abnormal lymphoid population with immunophenotype; pending |
| Conventional cytogenetics and FISH | Not performed, normal, abnormal (specified) or pending; loci tested for FISH |
| Molecular alterations detected | Listed alterations (for example MYD88, BRAF, TP53, IGHV mutated or unmutated, KMT2A rearrangement) with method and variant allele frequency; "Not performed" option |
- Change in version 1.0.0.2. The molecular alterations question gained a "Not performed" answer, and BCR::ABL1 p190, p210 and unspecified transcripts became separate answers (CAP 2026).
- Exclusions. Myeloid/lymphoid neoplasms with eosinophilia, acute leukemias of ambiguous lineage and plasmacytoid dendritic cell neoplasms are reported with the myeloid template. AL amyloidosis, monoclonal immunoglobulin deposition disease and heavy chain disease are reported with the Plasma Cell Malignancies template, version 1.0.0.1 (September 2025) (CAP 2026), taught in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases. Tumour-like lesions are excluded because they are not neoplasms (CAP 2026).
- Flow cytometry reporting. Expression is reported semiquantitatively, with dim, moderate, bright and heterogeneous patterns (CD20 dim+, CD20+, CD20++, CD20−/+ het) (CAP 2026).
Principles of flow cytometry: fluidics, optics, scatter and fluorochromes
- Instrument systems. A conventional flow cytometer has fluidic, optical and electronic systems. Pressurized sheath fluid delivers the sample stream and focuses cells single file at the laser interrogation point. Lasers excite the cells; photomultiplier tubes (PMTs) or photodiodes detect light; dichroic and bandpass filters route each wavelength band to its detector; the electronics digitize the signal into an .fcs data file (McKinnon 2018).
- Light scatter. Forward scatter (FSC) indicates relative cell size. Side scatter (SSC), measured at 90°, indicates internal complexity or granularity. Scatter is independent of fluorescence (McKinnon 2018).
- Lasers. Common laser lines are 405 nm (violet), 488 nm (blue), 561 nm (green-yellow), 640 nm (red) and 355 nm (ultraviolet). The EuroFlow 8-color instruments used 405/407, 488 and 633/635 nm lasers (McKinnon 2018; Kalina 2012).
- Spillover and compensation. Each fluorochrome emits into detectors assigned to other fluorochromes. Compensation subtracts this spillover. Compensation matrices are set from single-stained tubes, using normal blood leukocytes or antibody-capture beads for antigens absent from blood (Kalina 2012). Tandem dyes differ from lot to lot in energy transfer efficiency, which complicates compensation (McKinnon 2018). APC-Cy7 degrades over time, particularly with formaldehyde fixatives, producing false-positive events in the APC channel (Kalina 2012).
- Spectral cytometry. A spectral analyzer records the full emission spectrum of each fluorochrome as a spectral fingerprint and mathematically unmixes the signals (McKinnon 2018).
- Mass cytometry. Antibodies are tagged with lanthanide metals and read by time-of-flight mass spectrometry. There is no scatter signal, no autofluorescence and no spectral overlap, so no compensation is needed. Cells are destroyed and acquisition is about 1,000 cells per second, compared with 10,000 for a fluorescence cytometer (McKinnon 2018).
- Viability dyes. Exclusion dyes (propidium iodide, DAPI) cannot be fixed and suit unfixed samples analyzed immediately. Amine-reactive fixable viability dyes survive fixation and permeabilization (McKinnon 2018).
- Acoustic focusing and cell sorting. Acoustic focusing uses ultrasonic waves to align cells, which allows higher sample input with less clogging. A cell sorter breaks the stream into droplets, charges the droplets that contain gated cells and deflects them with metal plates into collection tubes, slides or plates (McKinnon 2018).
Table 3. Fluorochrome classes used in clinical flow cytometry (McKinnon 2018).
| Class | Examples | Properties |
|---|---|---|
| Small organic molecules | Fluorescein, Alexa Fluor 488, Pacific Blue, Alexa Fluor 647 | Consistent spectra; small Stokes shift (about 50–100 nm); stable |
| Phycobiliproteins | PE, APC, PerCP | Large proteins (PE 240,000 Da); Stokes shift 75–200 nm; 1:1 protein-to-fluorochrome ratio suits quantitative work; photobleach |
| Tandem dyes | PE-Cy7, APC-Cy7, PE-Texas Red | Energy transfer from donor to acceptor; very bright; less stable than the donor; lot-to-lot variation |
| Polymer dyes | Brilliant Violet, Brilliant Ultraviolet | Brightness close to phycobiliproteins; photostable; excited by a single laser line |
Specimens and sample preparation for lymphoid immunophenotyping
- Specimen types. Blood, bone marrow, fine-needle aspirates, lymphoid and other tissue biopsies, cerebrospinal fluid and vitreous are suitable specimens. Pleural effusions and fine-needle aspirates are acceptable for panels designed for blood and marrow (van Dongen 2012; Kalina 2012).
- Validation of specimen handling. Each validated assay specifies sample type, instrument platform, anticoagulant restrictions and sample stability. Processing conditions (lyse, wash, fix, permeabilize, staining before or after lysis, time and temperature) are validated in detail (Tangri 2013).
- Erythrocyte lysis and staining. Erythrocytes are lysed with ammonium chloride or commercial lysing solutions. Intracellular antigens (cytoplasmic CD3, myeloperoxidase, nuclear TdT) require fixation and permeabilization (Kalina 2012). EuroFlow adopted a stain-lyse-wash procedure with FACS Lysing Solution for surface markers; washing and fixation reduced fluorescence intensity, and washing caused some loss of lymphocytes (Kalina 2012).
- Surface immunoglobulin. Plasma immunoglobulin neutralizes anti-light-chain antibodies. Surface κ, λ and μ staining is therefore preceded by 2 washes with 10 mL of buffer (Kalina 2012).
Gating strategy and panel design for lymphoid neoplasms
- CD45 versus SSC. CD45 separates mature lymphocytes (CD45 bright, low SSC) from immature cells. With CD19 and CD20, CD45 separates mature B cells (CD19+, CD20 bright, CD45 bright) from B-cell precursors (CD19+, CD20 negative to dim, CD45 dim). NK cells are CD45 bright, low-SSC events lacking CD19 and surface CD3, typically CD56 positive (van Dongen 2012).
- CD45-negative blasts. CD45 is negative in up to 12.9% of pediatric B-ALL and 3.7% of T-ALL. A gate restricted to CD45-positive events excludes these blasts, so ungated plots are reviewed when blasts are suspected but not found (Dorfman 2025).
- Sequential and Boolean gating. Populations are selected step by step (for example, singlets, then CD19-positive events, then κ versus λ). Gates combined by Boolean logic define a population by several criteria at once. Two-parameter dot-plot gating remains standard (McKinnon 2018).
- 2006 Bethesda International Consensus. The Clinical Cytometry Society meeting defined the medical indications for diagnostic flow cytometry in hematolymphoid neoplasia by unanimous expert agreement (Davis 2007). A companion committee identified the cell lineages to evaluate for each indication, a consensus reagent set for the initial evaluation of each lineage and the elements of a flow cytometry report (Wood 2007).
- EuroFlow design. Each 8-color tube combines backbone markers, placed at the same fluorochrome position in every tube of a panel to locate the target population, with characterization markers. Single-tube screening panels precede multi-tube classification panels within an algorithm entered from clinical and laboratory findings. Panels were built in 2 to 7 design-evaluation-redesign rounds against reference databases of normal and malignant cells (van Dongen 2012).
- EuroFlow lymphoid screening tube (LST). The LST places 12 markers in 8 colors, 4 fluorochromes each carrying 2 markers: CD20 and CD4; CD45; CD8 and surface λ; CD56 and surface κ; CD5; CD19 and TCRγδ; surface CD3; and CD38 (van Dongen 2012). It detects aberrant mature B, T and NK cells in blood, marrow, lymph node and other tissues and fluids (van Dongen 2012).
Validation and quality control of flow cytometric assays
- ICSH/ICCS 2013 guidelines. A 5-part guideline addresses validation of cell-based fluorescence assays (Davis 2013). Assays are classified as quantitative, quasi-quantitative or qualitative. The intended use defines the validation, and sensitivity and specificity, when applicable, determine the number of samples required (Tangri 2013). Part V gives performance criteria for quasi-quantitative and qualitative assays, which lack fully characterized cellular reference materials (Wood 2013).
- CLSI H62. CLSI H62, Validation of Assays Performed by Flow Cytometry, 1st edition (October 27, 2021), is FDA-recognized. It covers instrument qualification and standardization, assay optimization, analytical validation and examination-phase QC. Lymphocyte immunophenotyping and neoplastic cell analysis are covered by CLSI H42 and H43 (CLSI 2021).
- PMT voltage. The optimal PMT voltage lies at the beginning of the plateau of the robust coefficient of variation (rCV) of a dim bead plotted against voltage. This minimizes electronic noise and preserves dynamic range (Kalina 2012).
- Daily instrument monitoring. After a 30-minute laser warm-up, 8-peak Rainbow beads are acquired, and the mean fluorescence intensity of the brightest peak in each channel is compared with its target value (Kalina 2012).
- Reagent performance. Antibody conjugates are compared by mean fluorescence intensity and stain index, the difference between positive and negative mean fluorescence intensity divided by 2 standard deviations of the negative population (Kalina 2012).
- Limits of detection and quantitation. In the EuroFlow next-generation flow (NGF) myeloma MRD method, the limit of detection (LOD) is ≥20 abnormal plasma cells and the lower limit of quantitation (LLOQ) is ≥50 abnormal plasma cells among 10⁷ events, giving <2 × 10⁻⁶ and <5 × 10⁻⁶ (Flores-Montero 2017). "MRD-negative" is interpreted only against the LOD of the assay used (Luo 2026).
CD markers used in lymphoid immunophenotyping, by lineage
Table 4. Lineage and characterization markers in lymphoid flow cytometry. Myeloid and monocytic markers and their use in acute leukemia are taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition; histiocytic and dendritic cell markers in tissue in Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen.
| Population | Identification markers | Characterization and aberrancy markers | Sources |
|---|---|---|---|
| Mature B cells | CD19, CD20 (bright), CD45 (bright), surface κ or λ | Normal B cells: CD5−, CD43−, CD79b+, CD81+. CLL cells: CD5 dim, CD19 dim, CD20 dim, CD43 dim, CD79b−, CD81 dim, with attenuated surface light chain | van Dongen 2012; Aruga 2024 |
| Small B-cell neoplasm differential | CD19, CD20, CD45 | CLL essential markers: CD5, CD19, CD20, CD23, surface or cytoplasmic κ and λ; additional: CD10, CD43, CD79b, CD81, CD200, ROR1. CD200 separates mantle cell lymphoma from other B-cell neoplasms. CD11c, CD103 and CD305 (LAIR1) identify hairy cell leukemia, with CD25 added for its distinction from HCL variant | Alaggio 2022; van Dongen 2012 |
| B-cell precursors | CD19, CD22, cytoplasmic CD79a, CD10, CD34, TdT, CD38 (bright) | CD20 and CD45 increase and CD10, CD34 and TdT decrease with maturation | Dorfman 2025 |
| T cells | Surface CD3, CD2, CD5, CD7, CD4, CD8, TCRγδ | TRBC1 and TRBC2 on TCRαβ cells; decreased or absent CD7 in many mature T-cell neoplasms; CD26 in the Sézary panel | Horna 2024; Dorfman 2025; van Dongen 2012 |
| Precursor T cells | Cytoplasmic CD3 (lineage-defining), CD7, TdT, CD1a, CD99, CD34 | CD4/CD8 double positive or double negative; HLA-DR negative | Dorfman 2025; CAP 2026 |
| NK cells | CD45 bright, low SSC, CD56, absence of surface CD3 and CD19 | CD2, CD7, CD16, CD57, CD94, HLA-DR, CD11c, CD25, cytoplasmic perforin and granzyme B | van Dongen 2012 |
| Plasma cells | CD38, CD138, CD229, cytoplasmic κ or λ | CD19, CD45, CD56, CD81, CD27, CD117, CD28 | Flores-Montero 2017; Pires 2025 |
| Plasmacytoid dendritic cells | CD123, TCF4, TCL1, CD303, CD304, with CD4 and/or CD56 | Expected negative: CD3, CD14, CD19, CD34, lysozyme, myeloperoxidase | Khoury 2022 |
FMC7 and the Matutes score. FMC7 is an epitope of CD20, and ERIC/ESCCA left it out of the harmonised CLL panel. That panel requires CD19, CD5, CD20, CD23, κ and λ and recommends CD43, CD79b, CD81, CD200, CD10 and ROR1 (Rawstron 2018). The Matutes score assigns 1 point each for weak surface immunoglobulin, CD5, CD23, absent FMC7 and weak or absent CD22 (later replaced by CD79b). Most CLL score 4 or 5, other B-cell neoplasms score below 4, and some atypical CLL score 3 (Jalal 2021). In the original 400 cases, 87% of CLL scored 4 or 5, and 89% of other B-cell leukemias scored 0 or 1 (Robak 2023).
Lineage-defining markers in acute leukemia. Lineage-assignment criteria and mixed-phenotype acute leukemia are taught in AML, Myelodysplasia-Related, AML Defined by Differentiation, Myeloid Neoplasms Post Cytotoxic Therapy and of Down Syndrome, Myeloid Sarcoma, BPDCN and Acute Leukemias of Ambiguous Lineage.
B-cell clonality by flow cytometry: light chain restriction
- Principle. Restriction of surface κ or λ light chain within a gated B-cell population indicates monotypia, the routine surrogate of B-cell clonality (Horna 2024).
- Thresholds. In an 11-case CLL MRD study, an abnormal distribution was a κ:λ ratio >3 or <0.5 with more than 20 single-positive events, or surface light chain-negative events >70% (Aruga 2024).
- ERIC/ESCCA CLL criterion. The harmonised CLL panel requires weak, restricted κ or λ on CD20-positive B cells, with CD19, CD5, CD20 (weak) and CD23 (Rawstron 2018).
- Gating on abnormal B cells. Polytypic background B cells dilute a small clone. Restriction is assessed on B cells selected by aberrant markers (for example, CD5 dim, CD20 dim and CD79b negative in CLL) (Aruga 2024).
- Surface light chain-negative B cells. Normal and neoplastic B-cell precursors lack surface κ and λ (Dorfman 2025). Absent surface light chain on a mature-appearing B-cell population is an abnormal finding in the CLL MRD criteria above (Aruga 2024).
- Light chain intensity in atypical CLL. Atypical CLL expresses surface light chain more strongly than typical CLL (Aruga 2024).
T-cell clonality by flow cytometry
- Immunophenotypic aberrancy. Neoplastic T cells are identified by abnormal antigen expression or by expansion of a subset. Similar atypical subsets occur in reactive settings, and some leukemic T-cell neoplasms lack overt aberrancy (Horna 2024).
- TCR Vβ repertoire. Flow cytometric analysis of TCR Vβ families detects a restricted T-cell population. It is labor-intensive, costly, difficult to interpret and of limited sensitivity (Horna 2024).
- TRBC1 and TRBC2. TCRβ rearrangement uses 1 of 2 mutually exclusive constant region genes, TRBC1 or TRBC2. The JOVI.1 antibody recognizes TRBC1, and an engineered antibody recognizes TRBC2. Dual staining on a TRBC1-versus-TRBC2 plot assesses TRBC restriction as κ and λ are assessed for B cells (Horna 2024).
- Normal TRBC distribution. In healthy donors the median TRBC2:TRBC1 ratio was 1.6 (interquartile range 1.3–2.0) for TCRαβ T cells, 1.3 for CD4-positive and 1.8 for CD8-positive T cells. Clonality thresholds were >85% TRBC1- or TRBC2-positive events (TRBC2:TRBC1 <0.18 or >5.7) on gated subsets of at least 200 events (Horna 2024).
- Performance. All neoplastic T-cell populations were TRBC-restricted except 8 cases (13%) that lacked TRBC expression. T-cell clones of uncertain significance occurred in 13% of specimens without T-cell neoplasia and were smaller than neoplastic clones (median 4.7% versus 69% of lymphocytes). TRBC1-only staining produced spurious TRBC1-dim subsets in 15% of specimens, all resolved by dual staining (Horna 2024).
- γδ T cells. TRBC staining applies to TCRαβ T cells; an anti-TCRγδ antibody gates TCRαβ cells by exclusion (Horna 2024).
- Immature T cells. Surface TRBC1 testing requires surface CD3. In T-lymphoblastic leukemia/lymphoma, cytoplasmic TRBC1 shows a monotypic pattern, while thymocytes and indolent T-lymphoblastic proliferation show polytypic surface TRBC1 (Dorfman 2025).
- Molecular clonality. Multiplex PCR for clonal TCR gene rearrangement lacks immunophenotypic information and can give false-positive results with aging and inflammation (Horna 2024).
Plasma cell flow cytometry
- Identification. Plasma cells are identified by CD38 and CD138 with their scatter properties. Clonality is shown by cytoplasmic κ or λ restriction (Pires 2025).
- Aberrant phenotype. Neoplastic plasma cells are CD38 intermediate to high and CD138 positive and usually lack CD19, CD27 and CD81 (Pires 2025). The myeloma phenotype, including CD56, and the markers that best separate neoplastic from normal plasma cells are taught in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases.
- Hemodilution. Discrepancies between flow cytometric and morphologic plasma cell counts arise mostly from the order of sample collection and from coagulated, aged or hemodiluted samples. Erythroblasts, myeloid and B-cell precursors and mast cells serve as internal controls; their low or absent values indicate hemodilution (Pires 2025).
- Anti-CD38 therapy. A multi-epitope CD38 antibody is used in MRD panels to avoid interference from daratumumab and other anti-CD38 therapeutic antibodies (Pires 2025).
- Next-generation flow MRD. The EuroFlow NGF method, myeloma MRD and IMWG response criteria are taught in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases.
Lymphocyte subset enumeration: single-platform and dual-platform CD4 counts
- Single-platform technology. Absolute counts are measured from 1 tube on 1 instrument. Internal calibrator beads of known number are added, CD45 gating identifies lymphocytes, and absolute counts and percentages are calculated from the ratio of cells to beads (Mandy 2003).
- Dual-platform technology. The absolute count is derived from 2 instruments: the percentage of CD4-positive cells by flow cytometry multiplied by the absolute lymphocyte count from a hematology analyzer (Mandy 2003; Glencross 2002).
- Error in dual-platform counts. Mismatch between lymphocyte identification on the 2 instruments is the main source of inaccuracy. Using total leukocytes as the denominator (CD45 PanLeucogating) gave CD4 counts that agreed closely with the single-platform volumetric method (R² = 0.990) (Glencross 2002).
- HIV. The CDC guidelines address CD4 absolute counts and percentages in persons infected with HIV (Mandy 2003). Age-specific reference intervals and subset patterns in inborn errors of immunity are taught in Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency.
Hematogones and B lymphoblasts
Hematogones are normal marrow B-cell precursors. They were found in 528 of 662 consecutive marrow specimens (79.8%). Their number declines with age, but many adults have relatively high numbers. Of all specimens, 8% contained ≥5% hematogones: 24.6% of specimens from patients younger than 16 years and 6.3% from those 16 years and older. Increased hematogones were most frequent in lymphoma, marrow regeneration, immune cytopenias and AIDS. Density gradient processing gave higher hematogone percentages than erythrocyte lysis (McKenna 2001).
Maturation stages. Early (type I) hematogones are CD19, CD10, CD34, CD38 and TdT positive, CD45 dim and CD20 negative. Intermediate (type II) hematogones lose CD34 and TdT, lower CD10 and gain CD20 and CD45. Late (type III) hematogones lose CD10, lower CD38 and further increase CD20 and CD45 (Dorfman 2025).
Table 5. Hematogones compared with B lymphoblasts (McKenna 2001; Dorfman 2025).
| Feature | Hematogones | B lymphoblasts |
|---|---|---|
| Antigen pattern | Continuous maturation spectrum of CD10, CD20, CD34, CD38, CD45 and TdT; no aberrancy | Maturation arrest; 1 to 11 immunophenotypic aberrancies in precursor B-ALL |
| CD45 | Intermediate, variable | Absent, intermediate or bright |
| CD10 | Moderate | Brighter or absent |
| CD38 | Bright | Weak or absent in some cases |
| CD20 | Variable across the spectrum | Positive, variable or absent |
| CD34 | Subset positive | Positive or negative |
| CD34 and CD123 | Discordant: early CD34+/CD123−, late CD34−/CD123+ | Concordant: both positive in most cases, both negative in a minority |
| Myeloid antigens | Negative | One or more in some cases |
| Additional MRD markers | Not expressed | CD304, CD73 and CD86 in a significant proportion of cases |
Hematogones complicate MRD assessment after B-ALL therapy (Dorfman 2025), taught in B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease.
Technical and biologic sources of error in lymphoid flow cytometry
Table 6. Sources of error in lymphoid flow cytometry.
| Source of error | Effect | Prevention or recognition | Sources |
|---|---|---|---|
| Doublets | Two cells read as 1 event with combined antigens | FSC area versus FSC height singlet gate | Kalina 2012 |
| Dead cells | Nonviable cells included in the analyzed population | Exclusion dyes or fixable viability dyes | McKinnon 2018 |
| CD45-negative blasts | Blasts excluded by a CD45-positive gate | Review of ungated plots | Dorfman 2025 |
| Hemodilution | Underestimation of plasma cells and blasts | First-pull aspirate; erythroblasts, mast cells and precursors as internal controls | Pires 2025 |
| Plasma immunoglobulin | Interference with surface light chain staining | Two washes before light chain staining | Kalina 2012 |
| Spillover and tandem dye degradation | False-positive events in a secondary channel | Compensation from single-stained controls; monitoring of APC-Cy7 stability | Kalina 2012 |
| Washing and fixation | Lower fluorescence intensity; loss of lymphocytes | Validated stain-lyse-wash protocol | Kalina 2012 |
| CD19 or CD22 loss after targeted B-ALL therapy | B-lineage cells negative for the targeted antigen | Alternative B-cell gating markers, taught in B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease | Dorfman 2025 |
| Anti-CD38 therapy (daratumumab) | Loss of CD38 for plasma cell gating | Multi-epitope CD38 antibody | Pires 2025 |
| Hematogones | Mistaken for residual B-ALL | Maturation spectrum; no aberrancy | McKenna 2001; Dorfman 2025 |
| Small T-cell clones of uncertain significance | TRBC-restricted subset without neoplasia | Clone size and immunophenotype | Horna 2024 |
Immunohistochemistry in hematopathology
IHC identifies lineage and maturation stage, detects protein surrogates of specific genetic alterations, measures proliferation and identifies therapeutic targets. It is performed on formalin-fixed, paraffin-embedded tissue (Cho 2022).
Table 7. Recommended IHC panels by lymphoma group (Cho 2022).
| Lymphoma group | Essential markers | Optional markers |
|---|---|---|
| DLBCL and variants | CD3, CD20, Ki-67, CD10, BCL6, MUM1, BCL2, MYC, EBV in situ hybridization | CD79a, CD30, CD23, ALK, CD138 |
| Small or low-grade B-cell lymphomas | CD3, CD20, Ki-67, BCL2, CD10 | CD5, cyclin D1, SOX11, CD23, CD21, CD138, κ, λ, CD79a, IgD, IgG, IgM |
| T- and NK-cell lymphomas | CD3, CD20, Ki-67, EBV in situ hybridization | CD4, CD8, CD56, CD30, ALK, TIA-1, granzyme B, PD-1, CXCL13, CD10, BCL6, ICOS, CD2, CD5, CD7, CD21, βF1, TCRδ |
| Precursor (lymphoblastic) lymphomas | CD3, CD20, CD79a, Ki-67, TdT, CD99 | CD10, CD19, PAX5, CD5 |
| Hodgkin lymphomas | CD3, CD20, Ki-67, CD30, CD15, PAX5, EBV in situ hybridization | OCT2, BOB1, EMA |
Hans algorithm and double-expressor status in DLBCL
- Hans algorithm. CD10, BCL6 and MUM1 were applied to a 152-case tissue microarray. The algorithm assigned 42% of cases to the germinal center B-cell-like (GCB) group and 58% to the non-GCB group, with 5-year overall survival of 76% and 34%. Non-GCB phenotype and a high International Prognostic Index (3–5) were independent adverse predictors (Hans 2004).
- Cutoffs and sequence. Each marker is positive when ≥30% of tumor cells stain (Cho 2022; Oh 2011). CD10 ≥30% classifies a case as GCB regardless of the other 2 markers. A CD10-negative case is GCB when BCL6 is ≥30% and MUM1 is <30%; other combinations are non-GCB (Cho 2022).
- Limits. The ICC keeps cell-of-origin designation in DLBCL, NOS but considers it insufficient for the biologic complexity of the disease. Morphologic variants and the double-expressor phenotype (MYC and BCL2 protein) have weak adverse prognostic impact and are de-emphasized (Campo 2022).
- Double-expressor cutoffs. BCL2 ≥50% and MYC ≥40% define the double-expressor phenotype (Cho 2022).
- MYC protein and translocation. MYC IHC correlates poorly with MYC translocation, and one review does not recommend it as a screen for MYC FISH (Cho 2022). FISH testing strategy for high-grade B-cell lymphoma is taught in Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging.
Diagnostic markers for specific lymphoid neoplasms
Table 8. Selected IHC and in situ hybridization markers and their diagnostic use.
| Marker | Diagnostic use | Sources |
|---|---|---|
| CD20 and CD79a | Pan-B-cell markers; CD79a identifies B lineage when CD20 is lost after rituximab or with plasmacytic differentiation | Cho 2022 |
| Cyclin D1 | Mantle cell lymphoma; IGH::CCND1 and cyclin D1-negative cases are taught in Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia. Pitfalls: cyclin D1 is expressed in about 50%–70% of hairy cell leukemia (Zhou 2020) and in plasma cell myeloma with t(11;14) (taught in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases), and strong cyclin D1 without CCND1 rearrangement by FISH can reflect cryptic IGK or IGL enhancer rearrangement with CCND1 (Alaggio 2022) | Alaggio 2022; Zhou 2020 |
| SOX11 | Mantle cell lymphoma, including cyclin D1-negative cases; sensitivity 82% and specificity 99% for mantle cell lymphoma in 354 small B-cell lymphomas; negative in leukemic non-nodal mantle cell lymphoma; also strongly expressed in B- and T-lymphoblastic neoplasms and in half of childhood Burkitt lymphomas | Rangan 2022; Alaggio 2022; Dictor 2009 |
| LEF1 | Positive in 98% of CLL/SLL; negative in lymphoplasmacytic lymphoma; LEF1 overexpression is a surrogate for DUSP22 rearrangement in ALK-negative anaplastic large cell lymphoma | Rangan 2022; Alaggio 2022 |
| CD10 and BCL2 | Coexpression supports follicular lymphoma; BCL2 is negative in normal germinal center cells; CD10 negativity is more frequent at higher grade | Cho 2022 |
| Annexin A1 | Specific for hairy cell leukemia among 500 B-cell tumors | Falini 2004 |
| BRAF V600E (VE1) | Cytoplasmic staining in all 12 hairy cell leukemias; negative in HCL variant, splenic and other marginal zone lymphomas | Wang 2014 |
| CD30 | Strong membranous and Golgi staining in classic Hodgkin lymphoma; strong diffuse staining in anaplastic large cell lymphoma | Cho 2022 |
| CD15 and PAX5 | CD15 with CD30 supports classic Hodgkin lymphoma; PAX5 is weakly positive in Hodgkin/Reed-Sternberg cells | Cho 2022 |
| ALK | Separates ALK-positive from ALK-negative anaplastic large cell lymphoma; strongly positive in ALK-positive large B-cell lymphoma | Cho 2022 |
| PD-1, CXCL13, ICOS, CD10, BCL6 | T-follicular helper markers, individually of limited sensitivity and specificity | Cho 2022 |
| CD21 | Expanded follicular dendritic cell meshworks in angioimmunoblastic T-cell lymphoma | Cho 2022 |
| TCL1 | Expressed in T-prolymphocytic leukemia, with TCL1A or MTCP1 structural variants | Alaggio 2022 |
| TdT and CD99 | Confirm a precursor lymphoid neoplasm; lineage then assigned with CD3, CD79a, PAX5 or CD19 | Cho 2022 |
| EBV-encoded RNA (EBER) in situ hybridization | EBV-positive DLBCL when >80% of tumor cells are positive without immunodeficiency; positive in almost all extranodal NK/T-cell lymphomas; double staining with CD3 or CD20 assigns the lineage of EBV-positive cells | Cho 2022 |
| κ and λ (IHC or in situ hybridization) | Clonality of plasma cells in lymphomas with plasmacytic differentiation | Cho 2022 |
Light chain ratio in tissue. One review gives a κ:λ ratio >4:1 or a λ:κ ratio >2:1 among plasma cells as evidence of monoclonality (Cho 2022).
Limits of IHC. CD5 staining of background T cells is present in virtually all B-cell lymphomas, and a diffuse pattern on tumor cells is required to call CD5 positive in CLL/SLL. CD23 is expressed in other small B-cell lymphomas and does not establish CLL/SLL alone (Cho 2022).
Hans cell-of-origin and double-expressor classifier for diffuse large B-cell lymphoma
Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow
Definition. Benign lymphadenopathy is a common biopsy finding that can be confused with lymphoma. It is separated into morphologic patterns, each with its own differential diagnosis among lymphomas (Weiss 2013). WHO-HAEM5 classifies non-neoplastic mimics of lymphoma for the first time, as tumour-like lesions with B-cell predominance (reactive B-cell-rich lymphoid proliferations, IgG4-related disease, unicentric, idiopathic multicentric and KSHV/HHV8-associated multicentric Castleman disease) and with T-cell predominance (Kikuchi-Fujimoto disease, indolent T-lymphoblastic proliferation, autoimmune lymphoproliferative syndrome) (Alaggio 2022). The ICC does not classify these lesions as a category (Ferry 2024).
Reactive B-cell-rich proliferations in WHO-HAEM5. The chapter covers progressive transformation of germinal centers, infectious mononucleosis, florid reactive lymphoid hyperplasia (lymphoma-like lesion) of the female genital tract and systemic lupus erythematosus (Alaggio 2022).
Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (WHO-HAEM5 and ICC frame, flow cytometry and immunohistochemistry methods) Related page: Normal and Reactive Lymph Node Cytology (normal lymph node on cytology) Related page: Pattern Approach to Lymph Node Cytology (pattern approach to lymph node fine-needle aspiration) Related page: Granulomatous Lymphadenitis (Cytology) (granulomatous and necrotizing lymphadenitis on cytology) Related page: Metastatic Carcinoma in Lymph Nodes (Cytology) (metastatic carcinoma in lymph node aspirates and immunohistochemistry by primary site) Related page: Metastatic Melanoma in Lymph Nodes (Cytology) (metastatic melanoma in lymph node aspirates) Related page: Spleen and Thymus FNA and Pediatric Lymph Node Cytology (pediatric lymph node, spleen and thymus aspiration) Related page: Lymph Node FNA Triage for Flow Cytometry, Cultures and Molecular Testing (allocation of fine-needle aspiration material) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (ALPS laboratory criteria and double-negative T cells) Related page: Autoantibody Testing in Systemic Autoimmune Rheumatic Diseases: ANA, ENA, Anti-dsDNA, Myositis Antibodies, Rheumatoid Factor and Anti-CCP (lupus serology) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (organ-specific IgG4-positive plasma cell thresholds) Related page: Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases (POEMS syndrome and POEMS-associated Castleman disease)
Normal lymph node compartments
The lymph node is divided into cortex, paracortex and medulla. The lymphoid lobule, supported by a reticular meshwork, is the basic functional and anatomic unit (Willard-Mack 2006). In reactive germinal centers, centroblasts and centrocytes express CD10 and BCL6 and lack BCL2 (Cho 2022).
- Capsule and sinuses. Afferent lymphatics enter through the capsule into the subcapsular (marginal) sinus, which is lined by macrophages exposed to afferent lymph. Lymph traverses the trabecular (cortical) and medullary sinuses and leaves through the efferent lymphatic at the hilum. Sinuses contain histiocytes, lymphocytes, plasma cells and granulocytes (Elieh-Ali-Komi 2025).
- Cortex. The outer cortex holds the B-cell follicles. Primary follicles contain small naive B cells, and secondary follicles form after antigen stimulation. Germinal centers have a dark zone and a light zone, where B cells retrieve antigen presented by follicular dendritic cells, and macrophages that clear apoptotic B cells mature into tingible-body macrophages (Elieh-Ali-Komi 2025).
- Paracortex. The T-cell zone between follicles contains small T cells, immunoblasts, interdigitating and plasmacytoid dendritic cells and high endothelial venules, the cuboidal-lined vessels through which blood lymphocytes enter the node. Fibroblastic reticular cells surround the venules and support the architecture (Elieh-Ali-Komi 2025).
- Medulla. Near the hilum, medullary cords contain abundant plasma cells, macrophages and memory T cells between the medullary sinuses (Elieh-Ali-Komi 2025).
Triage of lymph node biopsies for suspected lymphoma
- Excision and core needle biopsy. Among 179 patients with newly diagnosed lymphoma, core needle biopsy gave a definitive diagnosis in 74% and surgical excision in 98%. Inconclusive core biopsies were more frequent in indolent lymphomas, with few tissue cores, and in axillary, inguinal and extranodal sites. Grade 3–4 complications occurred in 1% of core biopsies and 5% of excisions (Mogensen 2026).
- Castleman disease. Excision of the largest or most PET-avid node is preferred. Fine-needle aspiration is not used to diagnose Castleman disease, and core biopsy mainly excludes neoplastic and infectious causes; one study found a 2% diagnostic yield for Castleman disease on core biopsy. The node is sent for lymphoma processing, including flow cytometry (Chen 2026).
- Fresh tissue for flow cytometry. Validated specimen types are listed in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology, and allocation of aspirate material in Lymph Node FNA Triage for Flow Cytometry, Cultures and Molecular Testing.
Reactive lymphadenopathy patterns
Table 1. Reactive patterns and representative causes.
| Pattern | Representative causes | Sources |
|---|---|---|
| Follicular hyperplasia | Nonspecific reactive hyperplasia; toxoplasmosis; syphilis; IgG4-related lymphadenopathy; plasmacytic Castleman disease; ALPS | Weiss 2013; Ventura 2021; Gutierrez-Lanz 2024; Song 2021; Chen 2026; Lim 1998 |
| Progressive transformation of germinal centers | Reactive follicular hyperplasia in children and adults; patients with Hodgkin lymphoma | Hicks 2002 |
| Paracortical (interfollicular) hyperplasia | Infectious mononucleosis; dermatopathic lymphadenopathy; ALPS; syphilis | Weiss 2013; Ravindran 2018; Lim 1998; Gutierrez-Lanz 2024 |
| Sinus distension by monocytoid B cells | Toxoplasmosis | Ventura 2021 |
| Foreign body reaction | Silicone from ruptured breast implants | Yao 2026; Kim 2026 |
| Necrosis without neutrophils | Kikuchi-Fujimoto disease; lupus lymphadenitis | Weiss 2013; Mahajan 2023 |
| Necrotizing lymphadenitis in immunosuppressed patients | Herpes simplex virus | Malik 2024 |
| Necrotizing granulomas with microabscesses | Cat-scratch disease; tularemia | Lamps 2004; Jabcuga 2016; Oršolić 2024 |
| Noncaseating epithelioid granulomas | Sarcoid-like reaction to tumor (13.8% of Hodgkin lymphoma) | Fujita 2026 |
| Polymorphous infiltrate with immunoblastic proliferation | Infectious mononucleosis | Louissaint 2012 |
Follicular hyperplasia compared with follicular lymphoma
Follicular hyperplasia is the most common reactive pattern, seen particularly in children and young adults and most often in cervical and axillary nodes. No single histologic feature separates it from follicular lymphoma. Older age, generalized lymphadenopathy, follicle density with back-to-back follicles (over 75% of follicular lymphomas) and diffuse areas favor lymphoma. Tingible-body macrophages, a sharply demarcated mantle zone and germinal center polarity, which Ki-67 can reveal, favor hyperplasia. BCL2 is negative in reactive germinal centers and positive in about 90% of follicular lymphomas. BCL2-positive T-helper cells and BCL2-positive primary follicles mimic lymphoma, and CD3, BCL6 or CD10, and IgD separate them. Rare florid hyperplasia in young patients shows light chain restriction by flow cytometry (Weiss 2013).
Table 2. Follicular hyperplasia compared with follicular lymphoma (Weiss 2013; Cho 2022; Alaggio 2022).
| Feature | Reactive follicular hyperplasia | Follicular lymphoma |
|---|---|---|
| Germinal center BCL2 | Negative | Positive in about 90%, with CD10 coexpression; CD10 can be lost, more often at higher grade |
| Light chains and IG genes | Polytypic | Monotypic; clonal IG rearrangement |
| IGH::BCL2 t(14;18)(q32;q21) | Absent | Present in about 85% of classic FL (Alaggio 2022); detail in Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia |
| Ki-67 and polarity | Higher proliferation fraction; polarized germinal centers | Lower proliferation fraction; no polarity |
BCL2-negative and BCL2-rearrangement-negative follicular lymphoma, grading by system, Ki-67 and in situ follicular B-cell neoplasm are taught in Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia.
Progressive transformation of germinal centers
- Morphology. PTGC occurs in 10%–15% of enlarged lymph nodes with reactive follicular hyperplasia. A PTGC nodule is 3 to 5 times the size of a reactive follicle, with mantle zone small B cells infiltrating the residual germinal center. PTGC nodules are relatively well defined, and NLPHL nodules are more irregular (Hicks 2002).
- Immunophenotype. Infiltrating B cells express CD19, CD20 and CD79a and lack the germinal center markers CD10 and BCL6 (Keyrouz 2026). The immunophenotype of the nodules can be identical in PTGC and NLPHL (CD45, CD20 positive; CD15, CD30 negative) (Hicks 2002).
- Patterns. Five immunoarchitectural patterns reflect progressive dismantling of germinal centers. Pattern 5, which resembles a naïve B-cell follicle, was more frequent with synchronous NLPHL (14 of 23) than in PTGC without lymphoma (30 of 93) (Hartmann 2015).
- Clinical associations. PTGC occurs in children (20%, mean age 11 years) and in 30%–35% of adults with Hodgkin lymphoma, before, with or after the lymphoma. Recurrence is more common in children (50% versus 23%). About half of cases are cervical. PTGC is not a premalignant condition (Hicks 2002). In a pediatric series (median age 11.5 years), SLE, Castleman disease and ALPS occurred in 24% (Keyrouz 2026). NLPHL is taught in Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging.
Dermatopathic lymphadenopathy
Dermatopathic lymphadenopathy is a reactive pattern in patients with rashes or inflammatory skin disease. The paracortex is expanded by Langerhans cells (CD1a and langerin positive), pigment-laden histiocytes and small lymphocytes. Florid cases mimic Langerhans cell histiocytosis, which is distinguished by a sinus-based infiltrate of Langerhans cells (Ravindran 2018). Involvement by mycosis fungoides is taught in Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas, and Langerhans cell histiocytosis in Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen.
Silicone lymphadenopathy
Silicone migrates from implants to regional nodes, most often the axillary nodes after breast augmentation (Kim 2026). Rupture of the implant shell produces nodes with abundant silicone-filled vacuoles in a lymphocytic background and numerous multinucleated giant cells containing silicone. The painless axillary mass mimics occult breast carcinoma (Yao 2026). On fine-needle aspiration, the foreign body reaction can be misread as metastatic carcinoma (Kim 2026).
Sinus histiocytosis, lipogranulomas and joint prosthesis debris
- Lipogranulomatous lymphadenopathy. Lipid from endogenous sources (tumors, hematomas, cholesterol deposits, fat embolism and fat necrosis) produces vacuolated histiocytes, round empty spaces and numerous multinucleated giant cells. The same picture follows lymphography. In a reported node, sinus histiocytosis accompanied multifocal subcapsular and sinusoidal lipogranulomas, and giant cells in the aspirate were a source of error on fine-needle aspiration (González-Peramato 2002).
- Joint prosthesis wear debris. Pelvic nodes removed 3–20 years after total hip arthroplasty contained polyethylene or metal debris, with effacement of the architecture by a histiocytic infiltrate. Histiocytes on the side of the prosthesis expressed HLA-DR, IL-1β, TNF-α and IL-6 (Hicks 1996). Birefringent polyethylene under polarized light identifies the sinus histiocytic reaction, which has been mistaken for metastatic prostatic carcinoma in pelvic nodes (Lecuit 1999).
- Massive sinus expansion by S100-positive histiocytes with emperipolesis is Rosai-Dorfman disease, taught in Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen.
Infectious lymphadenitis
Toxoplasma lymphadenitis (Piringer-Kuchinka lymphadenitis)
- Histologic triad. Marked follicular hyperplasia, small irregular clusters of epithelioid histiocytes encroaching on germinal centers, and sinus distension by monocytoid B cells (Ventura 2021).
- Specificity. Leishmaniasis, cytomegalovirus infection, infectious mononucleosis and early cat-scratch disease show similar features, and serology confirms the diagnosis (Ventura 2021). Four of 100 molecularly proven Bartonella henselae lymphadenitides showed the triad (Jabcuga 2016).
- Organisms. Bradyzoite-filled cysts are found in fewer than 1 of 100 cases (Armed Forces Institute of Pathology series); a cyst in Piringer-Kuchinka lymphadenitis is sufficient evidence for the diagnosis (Ventura 2021).
- Clinical setting. In immunocompetent patients, infection usually causes solitary cervical lymphadenopathy, and node enlargement persisting for months raises clinical concern for lymphoma (Ventura 2021).
Cat-scratch disease and other necrotizing granulomatous lymphadenitis
- Cat-scratch disease. B. henselae is the most common cause of chronic lymphadenopathy in children and adolescents, presenting as subacute regional lymphadenitis with an inoculation site from a cat scratch or bite. The hallmark lesion is granulomatous inflammation with a central stellate microabscess (Lamps 2004).
- Morphologic range. Of 100 PCR-proven cases (median age 26.5 years; 92% in lymph nodes, most often cervical), 57 had necrotizing granulomas with microabscesses. The other 43 lacked microabscesses: 23 resembled fungal or mycobacterial lymphadenitis, 6 Kikuchi lymphadenitis and 4 toxoplasma lymphadenitis (Jabcuga 2016).
- Diagnosis. Lesions contain neutrophils, lymphocytes and debris; Warthin-Starry silver stain shows small dark bacilli. IgG titers ≥256 strongly suggest active or recent infection, and B. henselae and B. quintana cross-react in IgG assays (Oršolić 2024). PCR on fixed tissue confirms the organism (Jabcuga 2016).
- Tularemia. Francisella tularensis produces small, sometimes confluent granulomatous foci that can caseate and be mistaken for tuberculosis, and necrotic foci can coalesce into abscesses (Oršolić 2024).
- Lymphogranuloma venereum and its mimic. Stellate abscesses in an inguinal node suggest lymphogranuloma venereum. In a reported case with this pattern, PCR was negative for Chlamydia trachomatis and positive for Treponema pallidum, and spirochete staining confirmed syphilitic lymphadenitis (Wessels 2016).
- Mycobacterial and fungal lymphadenitis. Cytologic features and stains are taught in Granulomatous Lymphadenitis (Cytology).
Infectious mononucleosis in lymph node and tonsil
In 18 consultation cases of acute EBV infection biopsied for suspected lymphoma (median age 18 years; 15 from Waldeyer ring), all showed architectural distortion by a polymorphous infiltrate with immunoblasts, sometimes in sheets. Reed-Sternberg-like cells were present in 8 (44%) and were CD30 positive, CD15 negative, BOB1 positive and OCT2 positive. Immunoblasts were CD20-positive B cells with a post-germinal center phenotype (MUM1 positive, CD10 negative, BCL6 negative) and polytypic light chains in 81% (Louissaint 2012). EBER in situ hybridization with the clinical findings usually establishes the diagnosis (Weiss 2013). EBER labels a mixture of small and large cells in infectious mononucleosis (Weiss 2013).
Syphilitic lymphadenitis
Characteristic findings are a thickened capsule with a plasma cell-rich infiltrate, reactive follicular and paracortical hyperplasia with prominent lymphoplasmacytic infiltrate, and vasculitis. Treponema pallidum immunohistochemistry is the preferred method for detecting spirochetes and cross-reacts with other treponemal and commensal spirochetes (Gutierrez-Lanz 2024).
Other infections in lymph node
Table 3. Other infectious causes of lymphadenopathy with pathologic relevance.
| Infection | Lymph node findings and pathologic relevance | Sources |
|---|---|---|
| Herpes simplex virus | Necrotizing lymphadenitis confirmed by HSV immunohistochemistry; mimics Richter transformation in patients with CLL/SLL | Malik 2024 |
| Cytomegalovirus | Follicular hyperplasia (92%) and monocytoid cell proliferation (83%) in 24 nodes; viral inclusions seen in only 8% of patients, so CMV immunohistochemistry establishes the diagnosis; can resemble toxoplasma lymphadenitis; uncontrolled infection excludes iMCD | Yu 2021; Ventura 2021; Fajgenbaum 2017 |
| Leishmaniasis | Can resemble toxoplasma lymphadenitis | Ventura 2021 |
| Whipple disease (Tropheryma whipplei) | Effacement by sheets of foamy CD68- and CD163-positive histiocytes without granulomas or necrosis; PAS-positive, diastase-resistant intracytoplasmic granules; mimics a lymphoproliferative disorder or sarcoidosis on PET | Amin 2025 |
| HIV | Florid follicular hyperplasia with large centroblast-rich germinal centers and absent or greatly diminished mantle zones; follicle lysis; follicular involution and a diffuse pattern in AIDS; uncontrolled infection excludes iMCD; KSHV/HHV8-associated multicentric Castleman disease occurs typically with HIV or other immunodeficiency | Weiss 2013; Paiva 1996; Fajgenbaum 2017; Chen 2026 |
| Mycobacteria and fungi | Necrotizing granulomas; mimicked by cat-scratch disease and tularemia | Jabcuga 2016; Oršolić 2024 |
HIV lymphadenopathy stages. In 31 cervical node biopsies from HIV-positive patients, the patterns were follicular hyperplasia without follicular fragmentation (4), follicular hyperplasia with fragmentation (16), follicular involution (6) and a diffuse pattern (5). Germinal center disruption by follicle lysis began in the light zone. Follicular hyperplasia predominated in patients without AIDS, and follicular involution and the diffuse pattern in patients with AIDS (Paiva 1996). Follicle lysis is disruption of the follicular dendritic cell network, which breaks into clusters that disperse into the parafollicular area and sinuses (Mori 1994).
Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis)
- Clinical features. Kikuchi-Fujimoto disease (KFD) is a self-limited disorder of uncertain cause, usually with tender posterior cervical lymphadenopathy, most often unilateral, and low-grade fever (Mahajan 2023). The typical patient is a young woman (Alaggio 2022). Skin involvement occurs in 30%–40%, and generalized lymphadenopathy in 1%–22% (Mahajan 2023).
- Histology. Paracortical foci of necrosis with abundant karyorrhectic debris and few or no neutrophils, crescentic histiocytes, immunoblasts and plasmacytoid cells. Phases are proliferative (more than 30%), necrotizing (50%, most common) and xanthomatous (less than 20%) (Mahajan 2023; Weiss 2013).
- Immunophenotype. CD8-positive cytotoxic T cells predominate, with CD68-positive histiocytes. Many CD123-positive plasmacytoid dendritic cells and myeloperoxidase-positive histiocytes are present (Alaggio 2022; Mahajan 2023).
- Lymphoma mimic. Sheets of T immunoblasts and histiocytes with apoptosis mimic peripheral T-cell lymphoma, NOS. A circumscribed, nonexpansile infiltrate favors KFD (Alaggio 2022). Necrosis in Hodgkin lymphoma includes neutrophils and CD15- and CD30-positive Reed-Sternberg cells (Mahajan 2023).
- Relationship to lupus. The histologic distinction is given in Table 4. Of 55 patients with KFD and connective tissue disease, 50 had SLE: onset was simultaneous in 40%, SLE preceded KFD in 35% and followed it in 25% (Mahajan 2023).
Table 4. Kikuchi-Fujimoto disease compared with lupus lymphadenitis (Mahajan 2023; Alaggio 2022).
| Feature | Kikuchi-Fujimoto disease | Lupus lymphadenitis |
|---|---|---|
| Necrosis with immunoblasts | Present | Present; indistinguishable from KFD |
| Neutrophils | Absent | Absent |
| Hematoxylin bodies | Absent | Present; the key distinguishing feature |
| CD30-positive activated CD8 T cells around necrosis | More numerous | Fewer |
Autoimmune lymphadenopathy
- Lupus lymphadenitis. The histologic distinction from KFD is given in Table 4. Lupus serology is taught in Autoantibody Testing in Systemic Autoimmune Rheumatic Diseases: ANA, ENA, Anti-dsDNA, Myositis Antibodies, Rheumatoid Factor and Anti-CCP.
- Rheumatoid arthritis, adult-onset Still disease and juvenile idiopathic arthritis. Lymphadenopathy in these diseases mimics idiopathic multicentric Castleman disease; each must be excluded on full clinical criteria before iMCD is diagnosed, and autoantibodies alone do not exclude iMCD (Fajgenbaum 2017).
IgG4-related lymphadenopathy
- Definition. IgG4-related disease is a fibroinflammatory condition with tumefactive lesions at multiple sites, a characteristic histology and often elevated serum IgG4. Diagnosis rests on the histologic appearance (dense lymphoplasmacytic infiltrate, storiform fibrosis and obliterative phlebitis) together with increased IgG4-positive plasma cells; tissue counts and IgG4:IgG ratios are secondary (Deshpande 2012).
- Lymph nodes. IgG4-related lymphadenopathy is a reactive follicular hyperplasia in which the etiology can be suggested by IgG and IgG4 immunostains (Weiss 2013). It overlaps histologically with Castleman disease (Alaggio 2022). Storiform fibrosis and phlebitis were absent in nodal IgG4-related disease, which showed mixed mature and immature plasma cells, eosinophils, small lymphocytes and immunoblasts in expanded interfollicular areas (Nishikori 2025). One case showed follicular hyperplasia with focal PTGC and intrafollicular plasmacytosis, >100 IgG4-positive plasma cells per high-power field and an IgG4:IgG ratio of 80%–90% (Song 2021).
- Histologic patterns. Five patterns share increased IgG4-positive plasma cells with an IgG4:IgG ratio >40%. Pattern 1 resembles plasmacytic multicentric Castleman disease. Pattern 2 is reactive follicular hyperplasia. Pattern 3 is interfollicular expansion by high endothelial venules, immunoblasts, small lymphocytes, plasma cells and eosinophils. Pattern 4 shows transformed germinal centers 2 to 4 times the size of background follicles, resembling PTGC. Pattern 5, inflammatory pseudotumor-like sclerosis, is the least common. Nodal IgG4-positive plasma cells alone do not establish IgG4-related disease, which requires extranodal disease (Rodolfi 2024).
- Pathologic thresholds used for nodes. Studies of iMCD-IPL used >100 IgG4-positive cells per high-power field with an IgG4:IgG ratio >40%, counted in the 3 interfollicular high-power fields with the highest density (Nishikori 2025). Other sources use >50 per high-power field with a ratio >40% (Weiss 2013; Chen 2026).
- Overlap with plasmacytic iMCD. Of 39 iMCD cases of the idiopathic plasmacytic lymphadenopathy (IPL) type, 13 (33.3%) met the >100 per high-power field and >40% criteria. iMCD-IPL showed sheets of mature plasma cells and hemosiderin, persistent C-reactive protein elevation and a lower IgG4:IgG ratio (mean 36.8% versus 81.6%) (Nishikori 2025).
- 2019 ACR/EULAR classification criteria. Classification has 3 steps: involvement of at least 1 of 11 organs in a manner consistent with IgG4-related disease; no exclusion criterion among 32 clinical, serologic, radiologic and pathologic items; and a weighted inclusion score across 8 domains. A threshold of 20 points gave 99.2% specificity and 85.5% sensitivity in the first validation cohort (Wallace 2020).
- Organ thresholds. Organ-specific IgG4-positive cell thresholds are taught in Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts.
Castleman disease
WHO-HAEM5 recognizes 3 clinicopathologically distinct entities among the tumour-like lesions with B-cell predominance: unicentric Castleman disease (UCD), idiopathic multicentric Castleman disease (iMCD) and KSHV/HHV8-associated multicentric Castleman disease. Classification integrates histologic, hematologic, immunologic and clinical findings (Alaggio 2022). Prognosis and therapy follow the clinical classification more than the histologic subtype (Chen 2026).
Table 5. Clinical subtypes of Castleman disease (Chen 2026; Fajgenbaum 2017; Alaggio 2022).
| Subtype | Defining features | Lymph node histology |
|---|---|---|
| Unicentric Castleman disease | One region of enlarged nodes; rarely systemic symptoms; often cured by resection; can be associated with an MCD-like inflammatory state, paraneoplastic pemphigus, bronchiolitis obliterans or AA amyloidosis | Histology still termed hyaline vascular in UCD (hypervascular in iMCD) |
| Oligocentric and asymptomatic multicentric Castleman disease | Several neighboring regions (oligocentric) or more distributed nodes (asymptomatic MCD) without systemic symptoms | Castleman histology |
| KSHV/HHV8-associated multicentric Castleman disease | HIV or other immunodeficiency; LANA-1-positive by immunohistochemistry; HHV8 viremia in some patients | Castleman histology with LANA-1-positive cells |
| POEMS-associated multicentric Castleman disease | Monoclonal plasma cell disorder with polyneuropathy (POEMS); not classified as iMCD | Castleman histology |
| iMCD with TAFRO | Thrombocytopenia, anasarca, fever, reticulin fibrosis or renal dysfunction, organomegaly; acute onset; marrow reticulin fibrosis and megakaryocytic hyperplasia | Small nodes; often hypervascular; extramedullary hematopoiesis |
| iMCD, idiopathic plasmacytic lymphadenopathy (IPL) | Severe polyclonal hypergammaglobulinemia; platelets normal or increased; indolent course | Plasmacytic; often IgG4-enriched, sometimes meeting IgG4-related disease thresholds |
| iMCD, NOS | Meets iMCD criteria without TAFRO or IPL features | Plasmacytic or mixed |
Histologic spectrum. Hypervascular histology (formerly hyaline vascular, a term still used for UCD) shows atrophic germinal centers with fewer germinal center B cells, penetrating germinal center vessels (lollipop sign), expanded mantle zones in concentric rings (onion skin) and twinning of germinal centers. Plasmacytic histology shows sheets of polyclonal interfollicular plasma cells with follicular hyperplasia. Mixed histology has features of both (Chen 2026). Follicular dendritic cell prominence is part of the iMCD spectrum (Fajgenbaum 2017). These features also occur in reactive nodes in autoimmune disease, infection and malignancy, and interobserver variability in subtyping is high (Chen 2026).
Table 6. Consensus diagnostic criteria for idiopathic multicentric Castleman disease (Fajgenbaum 2017). Both major criteria, at least 2 of 11 minor criteria including at least 1 laboratory criterion, and exclusion of each mimic are required.
| Criterion group | Items |
|---|---|
| Major 1: lymph node histology | Features of the iMCD spectrum on an excisional biopsy, with grade 2–3 regressed germinal centers or plasmacytosis: regressed or atrophic germinal centers with onion-skin mantles; follicular dendritic cell prominence; vascularity with lollipop vessels; sheetlike polytypic interfollicular plasmacytosis; hyperplastic germinal centers |
| Major 2: multicentricity | Enlarged nodes ≥1 cm in short-axis diameter in ≥2 lymph node stations |
| Minor, laboratory | C-reactive protein >10 mg/L or ESR >15 mm/h; anemia (hemoglobin <12.5 g/dL in males, <11.5 g/dL in females); platelets <150 or >400 × 10⁹/L; albumin <3.5 g/dL; eGFR <60 mL/min/1.73 m² or proteinuria; polyclonal hypergammaglobulinemia (γ globulin or IgG >1,700 mg/dL) |
| Minor, clinical | Constitutional symptoms; hepatomegaly and/or splenomegaly; edema, anasarca, ascites or pleural effusion; eruptive cherry hemangiomatosis or violaceous papules; lymphocytic interstitial pneumonitis |
| Exclusions: infection | HHV8 (LANA-1-positive immunohistochemistry establishes HHV8-associated MCD); clinical EBV lymphoproliferative disorders; other uncontrolled infections (CMV, toxoplasmosis, HIV, active tuberculosis) |
| Exclusions: autoimmune or autoinflammatory | SLE; rheumatoid arthritis; adult-onset Still disease; juvenile idiopathic arthritis; ALPS |
| Exclusions: malignant or lymphoproliferative | Lymphoma; multiple myeloma; primary lymph node plasmacytoma; follicular dendritic cell sarcoma; POEMS syndrome |
C-reactive protein evaluation is mandatory, and ESR is accepted only when C-reactive protein is unavailable. Elevated IL-6, soluble IL-2 receptor, VEGF, IgA, IgE, LDH or β2-microglobulin and marrow reticulin fibrosis support the diagnosis without being required (Fajgenbaum 2017). POEMS syndrome is taught in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases.
Autoimmune lymphoproliferative syndrome in lymph node
ALPS is associated with autoimmunity and germline or somatic alterations of genes in FAS-mediated apoptosis. Nodal and extranodal infiltrates of CD4- and CD8-negative T cells can appear as atypical medium-sized cells with clear cytoplasm, and young age and a nondestructive infiltrate favor a benign process (Alaggio 2022). In 16 lymph nodes, interfollicular areas were expanded by TCRαβ-positive, CD3-positive, CD4-negative, CD8-negative (double-negative) T cells that were CD45RO negative, expressed perforin, TIA-1 and CD57, and lacked CD25. Most nodes also showed florid follicular hyperplasia, often with focal PTGC, and polyclonal plasmacytosis. Spleens were enlarged more than 10 times normal size (Lim 1998). Laboratory criteria and double-negative T-cell thresholds are taught in Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency.
Granulomatous lymphadenitis
- Sarcoid-like reaction to tumor. Noncaseating epithelioid granulomas occur in 13.8% of Hodgkin lymphomas. When granulomas dominate and neoplastic cells are scarce, a first biopsy can be misread as sarcoidosis (Fujita 2026).
- Cytology. Granulomatous lymphadenitis on aspiration is taught in Granulomatous Lymphadenitis (Cytology).
Post-vaccination and drug-related lymphadenopathy
- COVID-19 mRNA vaccine. Axillary or supraclavicular lymphadenopathy appeared within days of a first Pfizer-BioNTech dose. The nodes were reactive and composed predominantly of CD8-positive T cells with atypia and numerous mitoses. A vaccination history, sudden onset and regression over days separate it from viral lymphadenitis and lymphoma (García-Molina 2021).
- Vaccine-associated Kikuchi-Fujimoto disease. KFD has been reported after influenza, Japanese encephalitis, HPV and SARS-CoV-2 vaccination, with causality uncertain (Mahajan 2023).
- Phenytoin (Dilantin)-associated lymphadenopathy. In 25 lymph node lesions suspected to be related to Dilantin, 15 were benign and were classified by the presence or absence of immunoblastic hyperplasia, 7 were non-Hodgkin lymphoma and 3 were Hodgkin lymphoma. In 2 of 5 patients with sequential biopsies, paracortical hyperplasia progressed to lymphoma, and the histologic patterns were heterogeneous and nonspecific (Abbondanzo 1995).
Benign inclusions in lymph nodes
- Types. Glandular and nonglandular epithelium and melanocytic nevi occur in lymph nodes, mostly as incidental findings. Nodal nevi are found more often in sentinel nodes of patients with melanoma and are not found in deep visceral nodes (Müller 2021).
- Axillary nodes. Nodal nevus is the most common heterotopia in axillary nodes. Benign squamous and glandular epithelial inclusion cysts in sentinel nodes have been misdiagnosed as metastatic carcinoma, particularly on frozen section (Sigei 2020).
- Müllerian inclusions. Endosalpingiosis-type glands with ciliated cuboidal to columnar cells occur in pelvic nodes of women and rarely of men. They are positive for PAX8, WT1, estrogen receptor and progesterone receptor (Gallan 2016).
- Mesothelial inclusions. In 10 patients with ovarian tumors, massive ascites and mesothelial hyperplasia, benign mesothelial cells occupied the subcapsular, trabecular and medullary sinuses of pelvic and para-aortic nodes and were present in intranodal and extranodal lymphatics. Immunohistochemistry separates them from metastatic carcinoma and mesothelioma (Kim 2015a).
- Ectopic decidua. Decidual reaction in pelvic nodes occurs during pregnancy and can mimic metastatic squamous cell carcinoma at frozen section (Dharan 2009). Decidualized intranodal endometriosis forms sheets of large, uniform, round cells with abundant eosinophilic cytoplasm (Kim 2015b).
- Cytology. Inclusions and metastatic carcinoma on aspiration are compared in Metastatic Carcinoma in Lymph Nodes (Cytology).
Metastases to lymph nodes
- Small-volume metastases. Definitions of isolated tumor cells and micrometastases are organ-specific and follow the AJCC and CAP protocols for each site, as taught in Colorectal Cancer Staging, CAP Reporting, Biomarkers and Neoadjuvant Response and the other organ staging units. Agreement among breast pathologists on isolated tumor cell classification rose from 67.6% to 98.0% after training on standardized histologic criteria (Turner 2008). In breast carcinoma, for example, isolated tumor cells are single cells or clusters ≤0.2 mm or fewer than 200 cells in a single cross-section, and micrometastases measure >0.2 mm to ≤2 mm, as taught in Breast Cancer Staging, Margins, Sentinel Lymph Nodes and Post-Neoadjuvant Assessment.
- Immunohistochemistry by likely primary. In metastases diagnosed on marrow aspirates, TTF1 supports lung, NKX3.1 prostate, GATA3 breast, PAX8 renal, SOX10 melanoma, and CD99 with NKX2.2 Ewing sarcoma (Kaspi 2025). Panels for carcinoma and melanoma are taught in Metastatic Carcinoma in Lymph Nodes (Cytology) and Metastatic Melanoma in Lymph Nodes (Cytology).
Metastatic tumors in bone marrow
- Frequency. Bone marrow metastases occur in less than 10% of patients with metastatic cancer, most often from lung, breast and prostate carcinoma. In 1%–2% of cases they present as an apparent hematologic disorder with cytopenias, predominantly anemia and thrombocytopenia (Kaspi 2025).
- Morphology. Carcinomas form cohesive clusters. Small cell lung carcinoma, neuroblastoma, retinoblastoma and Ewing sarcoma appear as small round cells with high nuclear-to-cytoplasmic ratios, often in clusters (Kaspi 2025).
- Flow cytometry. Nonhematopoietic cells lack CD45. A CD45-negative, CD19-negative, CD3-negative, CD56-positive population in a young patient's aspirate was Ewing sarcoma, positive for CD99 and NKX2.2 (Kaspi 2025).
- Aspirate and trephine. The trephine biopsy is preferred for characterizing nonhematopoietic cells. The aspirate gives faster results and allowed the initial diagnosis in 7 of 21 cases, while scant tumor cells on smears limit immunocytochemistry (Kaspi 2025).
- Ewing sarcoma. The marrow is involved in 5%–17% of metastatic Ewing sarcoma, after bone (30%–40%) and lung (50%) (Kaspi 2025).
B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease
Definition. Lymphoblastic leukemia/lymphoma is a neoplasm of precursor B or T lineage lymphoid cells that usually involves blood and marrow and may involve nodal and extranodal sites (Dorfman 2025). B-lymphoblastic leukemia/lymphoma and T-lymphoblastic leukemia/lymphoma are abbreviated B-ALL and T-ALL in both systems. WHO-HAEM5 classifies B-ALL by ploidy changes, chromosomal rearrangements and other genetic drivers (Alaggio 2022), and the ICC adds entities defined by gene expression clustering and transcriptome sequencing (Duffield 2023).
Leukemia and lymphoma. Leukemia is used when blood and marrow are the primary sites, and lymphoma when nodes or extranodal sites are primary. Historically, leukemia denoted 25% or more marrow blasts, and treatment protocols use 25% when both sites are involved; the CAP case summary reports leukemia and lymphoma as a single category with the percentage of neoplastic cells (CAP 2026). Lymphoblastic leukemia has no minimum blast percentage in blood or marrow (Dorfman 2025). For T-ALL, a diagnosis below 20% blasts is made with care (CAP 2026).
Epidemiology. B-ALL is about 85% of pediatric and 75% of adult lymphoblastic leukemias. T-ALL is the remainder of the leukemias but 85%–90% of lymphoblastic lymphomas, typically presenting as a mediastinal mass (Dorfman 2025).
Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (WHO-HAEM5 and ICC frame, flow cytometry methods, hematogones and lymphoid CD markers) Related page: AML, Myelodysplasia-Related, AML Defined by Differentiation, Myeloid Neoplasms Post Cytotoxic Therapy and of Down Syndrome, Myeloid Sarcoma, BPDCN and Acute Leukemias of Ambiguous Lineage (mixed-phenotype acute leukemia and lineage assignment criteria) Related page: Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms (lymphoid blast phase of CML) Related page: Mastocytosis, Hypereosinophilic Syndrome and Myeloid/Lymphoid Neoplasms with Tyrosine Kinase Fusions, Chronic Myelomonocytic Leukemia and Other MDS/MPN (myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions presenting as lymphoblastic neoplasms) Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (AML measurable residual disease and germline predisposition to myeloid neoplasms) Related page: Lymphoblastic Lymphoma in Cytology (lymphoblastic lymphoma, MYC-rearranged B-ALL, indolent T-lymphoblastic proliferation and ETP-ALL on cytology) Related page: Leukemia, Lymphoma and Plasma Cell Neoplasms in CSF (CSF involvement by leukemia) Related page: Thymoma and Thymic Carcinoma on FNA (thymoma and thymic lymphocytes on cytology)
Classification of B-lymphoblastic leukemia/lymphoma: WHO-HAEM5 and ICC 2022
- WHO-HAEM5. B-ALL can be diagnosed at the family level on morphology and immunophenotype as B-ALL, not further classified. B-ALL, NOS is reserved for cases unclassifiable after comprehensive testing. Names state the molecular event so that any detection method can be used. B-ALL with BCR::ABL1-like features became a definite entity, and B-ALL with ETV6::RUNX1-like features and B-ALL with TCF3::HLF fusion were added. B-ALL with DUX4, MEF2D, ZNF384 or NUTM1 rearrangement, IG::MYC fusion, PAX5alt or PAX5 p.P80R is grouped under B-ALL with other defined genetic abnormalities (Alaggio 2022).
- ICC. BCR::ABL1-positive B-ALL is subdivided by lymphoid-only or multilineage involvement, BCR::ABL1-like B-ALL into 3 subtypes, and hypodiploid B-ALL into low hypodiploid and near haploid. Nine new entities are defined by rearrangements or single-gene mutations, and further provisional entities require gene expression studies for definitive identification (Duffield 2023).
Table 1. B-ALL genetic types in WHO-HAEM5 (Alaggio 2022; CAP 2026) and ICC 2022 (Duffield 2023), with WHO-HAEM4R names (Alaggio 2022), frequency and prognosis.
| Genetic group | WHO-HAEM5 | ICC 2022 | WHO-HAEM4R | Frequency, clinical features and prognosis |
|---|---|---|---|---|
| High hyperdiploidy | B-ALL with high hyperdiploidy (51–65 chromosomes) | B-ALL, hyperdiploid | B-ALL with hyperdiploidy | Up to 30% of childhood ALL; young children with low WBC; favorable (Inaba 2020; CAP 2026) |
| Hypodiploidy | B-ALL with hypodiploidy (<44 chromosomes) | B-ALL, low hypodiploid (32–39 chromosomes); B-ALL, near haploid (24–31 chromosomes) | B-ALL with hypodiploidy | Low hypodiploidy about 1% of children and >10% of adults, with TP53 mutations, inherited in about half of affected children; near haploidy about 2% of pediatric ALL; both unfavorable (Inaba 2020; Duffield 2023) |
| iAMP21 | B-ALL with iAMP21 | B-ALL with iAMP21 | B-ALL with iAMP21 | Older children; poor prognosis improved by intensive therapy (Inaba 2020) |
| BCR::ABL1 | B-ALL with BCR::ABL1 fusion | B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1, with lymphoid-only or multilineage involvement | B-ALL with t(9;22)(q34;q11.2); BCR-ABL1 | p190 and p210 transcripts; outcome improved by tyrosine kinase inhibitors (Inaba 2020; Luo 2026) |
| BCR::ABL1-like | B-ALL with BCR::ABL1-like features | BCR::ABL1-like, ABL1-class rearranged; JAK-STAT activated; NOS | B-ALL, BCR-ABL1-like (provisional) | Gene expression profile of BCR::ABL1-positive ALL without the fusion; poor prognosis; targetable kinase lesions (Duffield 2023; Alaggio 2022) |
| KMT2A | B-ALL with KMT2A rearrangement | B-ALL with t(v;11q23.3)/KMT2A rearranged | B-ALL with t(v;11q23.3); KMT2A-rearranged | Common in infants; more than 80 partners, most often AFF1 (t(4;11)); very poor prognosis (Inaba 2020) |
| ETV6::RUNX1 | B-ALL with ETV6::RUNX1 fusion | B-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1 | B-ALL with t(12;21)(p13.2;q22.1); ETV6-RUNX1 | Most common translocation in childhood B-ALL; cryptic on karyotype; favorable (Inaba 2020) |
| ETV6::RUNX1-like | B-ALL with ETV6::RUNX1-like features | Provisional entity | Not included | Gene expression and CD27-positive, CD44-dim phenotype of ETV6::RUNX1 ALL without the fusion; mostly children (Duffield 2023; Inaba 2020) |
| TCF3::PBX1 | B-ALL with TCF3::PBX1 fusion | B-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1 | B-ALL with t(1;19)(q23;p13.3); TCF3-PBX1 | More common in African American children; CNS relapse and inferior outcomes with older treatment regimens; the adverse effect is absent with contemporary regimens (Inaba 2020) |
| IGH::IL3 | B-ALL with IGH::IL3 fusion | B-ALL with t(5;14)(q31.1;q32.3)/IL3::IGH | B-ALL with t(5;14)(q31.1;q32.1); IGH/IL3 | Eosinophilia raises the possibility (Duffield 2023) |
| TCF3::HLF or TCF4::HLF | B-ALL with TCF3::HLF fusion | B-ALL with HLF rearrangement | Not included | Exceptionally rare; children; very poor prognosis (Duffield 2023) |
| DUX4 | Other defined genetic abnormalities | B-ALL with DUX4 rearrangement | Not included | 5%–10% of B-ALL, highest in adolescents and young adults; excellent prognosis even with IKZF1 deletion; CD371 with CD2 (Duffield 2023) |
| ZNF384 | Other defined genetic abnormalities | B-ALL with ZNF384 rearrangement | Not included | 5%–10%; lineage ambiguity, presenting as B-ALL or B/myeloid MPAL; prognosis by partner (EP300 best, TCF3 worst) (Duffield 2023) |
| MEF2D | Other defined genetic abnormalities | B-ALL with MEF2D rearrangement | Not included | 3%–5%; poor; cytoplasmic μ, dim CD10, moderate CD38 (Duffield 2023) |
| MYC | Other defined genetic abnormalities (IG::MYC fusion) | B-ALL with MYC rearrangement | Not included | 2%–5%, higher in adults; poor; unmutated IGHV; avoided as a diagnosis in patients with prior mature B-cell lymphoma (Duffield 2023) |
| NUTM1 | Other defined genetic abnormalities | B-ALL with NUTM1 rearrangement | Not included | Mostly infants without KMT2A rearrangement; favorable; NUT immunohistochemistry positive (Duffield 2023) |
| PAX5 p.P80R | Other defined genetic abnormalities | B-ALL with PAX5 P80R | Not included | 2%–5%, more common in adults; relatively good prognosis (Duffield 2023) |
| PAX5alt | Other defined genetic abnormalities | Provisional entity | Not included | About 10% of children and adults (Duffield 2023) |
Additional ICC entities. The ICC also defines B-ALL with UBTF::ATXN7L3/PAN3,CDX2 (CDX2/UBTF; <1%, adolescent and young adult females, poor prognosis) and B-ALL with IKZF1 N159Y (<1%, intermediate prognosis), and lists ZEB2 H1038R/IGH::CEBPE, KMT2A-rearranged-like and ZNF384-rearranged-like B-ALL as provisional (Duffield 2023).
B-lymphoblastic leukemia/lymphoma: morphology and immunophenotype
- Essential features of B-ALL, NOS (WHO-HAEM5, CAP summary). Effaced node or diffuse organ infiltration by monomorphic blasts with a B immunophenotype (CD19, CD22, cytoplasmic CD79a and/or PAX5), markers of immaturity (TdT, CD34 and/or CD99) and absent surface immunoglobulin. CD34 and TdT are absent in rare cases (CAP 2026).
- Flow cytometry. Blasts express CD19, CD79a and CD22 with TdT, CD34, dim CD45, dim to absent CD20 and no surface κ or λ (Dorfman 2025).
- Maturation stages. Pro-B (CD19, cytoplasmic CD79a, cytoplasmic CD22, TdT; CD10 and IgM negative), common-B (CD10 positive, IgM negative) and pre-B (cytoplasmic or surface IgM positive) (Dorfman 2025).
- Myeloid antigens. 86.5% of B-ALL expressed at least 1 myeloid antigen, usually partial or dim: CD13 in 54.5%, CD33 in 43.0%, CD15 in 36.0% and CD11b in 20.0% (Dorfman 2025).
- Myeloperoxidase. B-ALL is usually negative for moderate to high myeloperoxidase by flow cytometry, cytochemistry or IHC. High-level myeloperoxidase on blasts with B-cell markers favors B/myeloid mixed-phenotype acute leukemia or AML (Dorfman 2025). Lineage criteria are taught in AML, Myelodysplasia-Related, AML Defined by Differentiation, Myeloid Neoplasms Post Cytotoxic Therapy and of Down Syndrome, Myeloid Sarcoma, BPDCN and Acute Leukemias of Ambiguous Lineage.
- PAX5. B-ALL is PAX5 positive, and PAX5 is one of the B-lineage markers in the essential criteria (CAP 2026). On tissue, PAX5, CD79a or CD19 establishes B lineage when CD3 and CD20 are negative (Cho 2022).
- CD45-negative B-ALL. CD45 is negative in up to 12.9% of pediatric B-ALL, most often at the common-B stage (15.1%) (Dorfman 2025). Gating is taught in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology.
- IHC on tissue. TdT and CD99 confirm a precursor neoplasm. B-LBL often lacks CD20, so CD79a, PAX5 or CD19 establishes B lineage when CD3 and CD20 are negative (Cho 2022).
- Mimics. AML with t(8;21)(q22;q22.1) expresses PAX5 (75%), CD19 (81%) and CD79a (24%) and is excluded from mixed-phenotype acute leukemia (Dorfman 2025). TdT is usually positive in B-ALL and rarely positive in aggressive mature B-cell lymphoma (Duffield 2023).
Table 2. Immunophenotypes associated with B-ALL genetic subtypes (Dorfman 2025; Duffield 2023). Genetic testing is required for the definitive subtype.
| Genetic subtype | Associated immunophenotype |
|---|---|
| BCR::ABL1 | CD13 and CD33 coexpression; decreased CD9 and CD81 |
| BCR::ABL1-like, JAK-STAT activated with CRLF2 rearrangement | CRLF2 overexpression |
| KMT2A rearrangement | CD19 positive, CD10 negative, CD24 negative, TdT negative; CD15 and CD65 positive |
| ETV6::RUNX1 and ETV6::RUNX1-like | CD27 positive, CD44 dim or negative; CD9, CD20 and CD66c often negative; CD13 and CD33 positive |
| TCF3::PBX1 | Strong CD9; dim to negative CD34 and CD20; cytoplasmic μ; CD58 and CD81 overexpression |
| DUX4 rearrangement | CD371 with CD2; monocytic switch with CD14 after induction |
| MEF2D rearrangement | Cytoplasmic μ, dim CD10, CD38 positive |
| MYC rearrangement | CD34 negative; dim surface light chain in some cases |
| NUTM1 rearrangement | NUT immunohistochemistry positive; CD15 in a subset |
BCR::ABL1-positive and BCR::ABL1-like B-ALL
- BCR::ABL1-positive B-ALL. Lymphoid-only and multilineage cases cannot be separated by immunophenotype or by p190 versus p210 transcript. In multilineage disease the fusion is present in non-B cells, the transformed cell is a multipotent progenitor, and the disease resembles CML in lymphoid blast phase; a higher tumor burden by BCR::ABL1 transcripts than by flow cytometry after therapy suggests it (Duffield 2023). Without a history of CML, multilineage disease and CML in lymphoid blast phase are difficult to separate, and splenomegaly favors CML in lymphoid blast phase (Duffield 2023). Lymphoid blast phase is taught in Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms.
- MRD in BCR::ABL1-positive ALL. Persistent BCR::ABL1 transcripts with undetectable MRD by Ig/TR assays can reflect a non-lymphoblast clone and do not by themselves justify treatment escalation (Luo 2026).
- BCR::ABL1-like B-ALL. The gene expression profile resembles BCR::ABL1-positive ALL without the fusion. ABL1-class fusions involve ABL1, ABL2, CSF1R or PDGFRB and respond to imatinib and dasatinib. JAK-STAT activation is most often from CRLF2 rearrangement to IGH or P2RY8, less often JAK2 fusions, EPOR rearrangements, IL7R or CRLF2 F232C mutations; JAK mutations occur in about half of CRLF2-rearranged cases (Duffield 2023). CRLF2 rearrangement is present in 50% of BCR::ABL1-like B-ALL (Dorfman 2025).
- Testing. Gene expression profiling is not commercially available, so FISH and molecular studies for PDGFRB, ABL1, JAK2, EPOR and CRLF2 are used (CAP 2026).
- Adult outcome. In adolescents and young adults treated on CALGB 10403, BCR::ABL1-like disease predicted worse overall survival (hazard ratio 2.08) (Jabbour 2026).
Hypodiploid and hyperdiploid B-ALL
- Masked hypodiploidy. Doubling of a hypodiploid clone gives a hyperdiploid modal number with hypodiploid biology (Duffield 2023). The pattern of gains (diploid and tetrasomic chromosomes, compared with the trisomies of high hyperdiploidy), a flow cytometric DNA index showing 2 peaks and SNP arrays for loss of heterozygosity reveal it (Inaba 2020; CAP 2026).
- Hyperdiploidy definition. High hyperdiploidy is >50 chromosomes or DNA index ≥1.16 (Inaba 2020). FISH for chromosomes X, 4, 6, 10, 14, 17, 18 and 21 helps identify it when the karyotype fails (CAP 2026).
- Germline testing. Low hypodiploidy prompts germline TP53 testing (Duffield 2023).
B-ALL with intrachromosomal amplification of chromosome 21 (iAMP21)
- FISH definition. When extra RUNX1 signals are found, iAMP21 is defined as 5 or more RUNX1 copies in interphase nuclei, or 3 or more extra copies on a single abnormal chromosome 21 in metaphase FISH, with clustering of signals (Rack 2019).
- Detection. iAMP21 was first identified during routine FISH screening for ETV6::RUNX1, and the routine BCR::ABL1, ETV6::RUNX1 and KMT2A probe set also reveals it (Schwab 2018; Rack 2019).
- Structure. The iAMP21 chromosome is a grossly abnormal chromosome 21 with multiple regions of gain, amplification, inversion and deletion, and a common amplified region includes RUNX1 (Schwab 2018).
- Clinical features. iAMP21 accounts for about 2% of B-ALL. Patients are older children (median age 9 years), usually with a low white cell count (Schwab 2018). Carriers of the constitutional Robertsonian translocation rob(15;21) have a more than 2,000-fold increased risk of iAMP21 ALL (Rack 2019).
T-lymphoblastic leukemia/lymphoma
- WHO-HAEM5 and ICC. WHO-HAEM5 retains T-ALL, NOS and early T-precursor lymphoblastic leukaemia/lymphoma, without genetically defined types (Alaggio 2022). The ICC adds ETP-ALL, BCL11B-activated, and 8 provisional T-ALL entities defined by transcription factor deregulation (Duffield 2023).
- Immunophenotype. Cytoplasmic CD3 is lineage defining; CD5, CD7 and CD2 are expressed with TdT and with dim CD45 that is brighter than in B-ALL. HLA-DR is typically negative (Dorfman 2025). Blasts typically show bright CD7, diminished CD5 and variable, often coexpressed, CD4 and CD8 (CAP 2026).
- T-ALL and T-LBL. The distinction is by convention: more than 25% marrow blasts defines T-ALL and less than 25% T-LBL (Leijnen 2026; CAP 2026). T-LBL typically presents as a large anterior mediastinal mass, often with pleural or pericardial effusions, and the male-to-female ratio is about 2.5:1. In 342 T-LBLs, NOTCH1 was altered in 52%, FBXW7 in 24% and CDKN2A (deletion) in 50% (Leijnen 2026).
- Maturation stages. Pro-T: CD7 and cytoplasmic CD3 only. Pre-T: adds CD2 and CD5. Cortical: adds CD1a with CD4/CD8 double positivity, without surface CD3. Medullary: surface CD3 with single CD4 or CD8 (Dorfman 2025).
- Aberrant antigens. CD10 is expressed in 18%–63% and CD79a in about 10% of T-ALL. Myeloid antigens were expressed in 16.3% of 180 pediatric cases, most often CD33 (13%) (Dorfman 2025).
- Mature-appearing T-ALL. TdT or CD34 and strong CD7 separate T-ALL from mature T-cell neoplasms. Rare pediatric T-ALL lacking TdT, CD34, CD1a and CD99 has a poor prognosis (Dorfman 2025).
- IHC on tissue. T-LBL usually expresses CD3 with TdT and CD99 (Cho 2022).
Table 3. Genetic groups of T-ALL (ICC provisional entities, except BCL11B-activated ETP-ALL) (Duffield 2023).
| Group | Frequency and prognosis | Partners and associated features |
|---|---|---|
| TAL1/TAL2 rearranged | 30%–40% | STIL::TAL1 most common; late cortical (CD4 or CD8 positive) phenotype |
| TLX3 rearranged | 20%–25% of children, <5% of adults; good prognosis | CD4/CD8/CD1a-positive phenotype |
| TLX1 rearranged | 5%–10% of children, about 30% of adults; good prognosis | CD4/CD8/CD1a-positive phenotype |
| HOXA dysregulated | 15%–25% | KMT2A rearrangement, PICALM::MLLT10, SET::NUP214; immature phenotype, some meeting ETP criteria |
| LMO1/LMO2 rearranged | About 15% | Immature phenotype; very high LMO expression |
| NKX2 rearranged | <5% of children | NKX2-1, NKX2-2 or NKX2-5 partners |
| SPI1 rearranged | <5% of children; very poor prognosis | HLA-DR expression |
| BHLH, other | <2% | TRB::LYL1; high LMO expression |
| BCL11B-activated | About 30% of ETP-ALL and T/myeloid MPAL | Rearrangement or enhancer amplification; FLT3-ITD |
NOTCH1 and CDKN2A alterations are common throughout T-ALL except ETP-ALL (Duffield 2023).
T-lymphoblastic lymphoma compared with thymus, thymoma and indolent T-lymphoblastic proliferation
- Thymus and thymoma. Non-neoplastic thymocytes show all stages of T-cell development: variable CD3 and CD5, a large CD4/CD8 double-positive population with smeared single-positive cells (a double-tailed comet pattern) and a small double-negative population. T-LBL blasts form tight clusters without variable CD4/CD8 expression, and pan-T antigens can be absent but are not variably expressed (Dorfman 2025).
- TRBC1. Monotypic cytoplasmic TRBC1 separates T-LBL from the polytypic thymocyte pattern (Dorfman 2025); the method is taught in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology.
- Indolent T-lymphoblastic proliferation. A WHO-HAEM5 tumour-like lesion that occurs alone or with follicular dendritic cell proliferations and other malignancies. TdT-positive thymocyte-like cells distort but do not obliterate the architecture, are less atypical than lymphoblasts and lack monoclonal TCR rearrangement (Alaggio 2022). Cytology is taught in Lymphoblastic Lymphoma in Cytology, and thymoma in Thymoma and Thymic Carcinoma on FNA.
Early T-precursor lymphoblastic leukemia/lymphoma
ETP-ALL is about 15% of T-ALL and corresponds to an early stage of T-cell differentiation with a stem cell or myeloid immunophenotype (Dorfman 2025). Its gene expression signature corresponds to early precursor T cells (Alaggio 2022). It is diagnosed by immunophenotype, and the definition is unchanged from WHO-HAEM4R in both systems (Duffield 2023; Alaggio 2022).
Outcome. ETP-ALL was defined in a St. Jude cohort in which 17 of 139 T-ALLs (12.2%) had the ETP immunophenotype; 10-year overall survival was 19% compared with 84% for other T-ALL (Coustan-Smith 2009). With contemporary therapy, outcomes of ETP, near-ETP and non-ETP ALL were comparable in the Children's Oncology Group AALL0434 study (Inaba 2020).
Table 4. Immunophenotypic criteria for ETP-ALL (CAP 2026; Dorfman 2025).
| Marker | Requirement |
|---|---|
| Cytoplasmic CD3 | Positive |
| CD1a and CD8 | Absent (<5% of blasts positive) |
| CD5 | Absent or dim (<75% of blasts positive) |
| Myeloid or stem cell markers | CD11b, CD13, CD33, CD65 or CD117, and/or CD34 or HLA-DR (≥25% of blasts positive) |
| Myeloperoxidase | Negative (<3% of blasts) |
- Near-ETP ALL. Cases with the ETP phenotype but CD5 on ≥75% of blasts are near-ETP ALL, enriched for TLX3 rearrangement and not formally classified (Duffield 2023; Dorfman 2025).
- BCL11B-activated leukemia. About one-third of ETP-ALL has BCL11B activation, in 80% by interchromosomal rearrangement and in the remainder by enhancer amplification. The same lesion occurs in T/myeloid MPAL, AML and acute undifferentiated leukemia (Duffield 2023).
- Mixed-phenotype acute leukemia. High-level myeloperoxidase or monocytic lineage-defining markers in a CD3-positive acute leukemia favor T/myeloid MPAL (Dorfman 2025), taught in AML, Myelodysplasia-Related, AML Defined by Differentiation, Myeloid Neoplasms Post Cytotoxic Therapy and of Down Syndrome, Myeloid Sarcoma, BPDCN and Acute Leukemias of Ambiguous Lineage.
NK-lymphoblastic leukemia/lymphoma
WHO-HAEM4R listed NK-lymphoblastic leukemia/lymphoma as provisional. WHO-HAEM5 does not list it because criteria are unreliable and it overlaps with blastic plasmacytoid dendritic cell neoplasm, CD56-positive T-ALL, CD56-positive AML and acute undifferentiated leukemia (Alaggio 2022). The ICC retains it as a provisional entity (Duffield 2023). In 6 reported cases, blasts were CD56, CD34 and CD7 positive, TdT positive in half, and CD19, CD123 and CD4 negative (Dorfman 2025).
Measurable residual disease in B-ALL
- Required sensitivity. Guidelines recommend MRD assessment with an assay of at least 10⁻⁴ sensitivity at several time points (Luo 2026). Early MRD response is a major prognostic factor (Inaba 2020).
- End of induction. Patients with high-risk genetics remain at risk of relapse even with undetectable or very low (for example, <0.01%) MRD at the end of induction, while low-level MRD can be overcome by later therapy in patients with low-risk features (Inaba 2020). In adolescents and young adults on CALGB 10403, MRD negativity after induction gave 10-year disease-free survival of 83% compared with 40% (Jabbour 2026). In GRAAL-2014/B-QUEST, end-of-induction MRD ≥10⁻⁴, KMT2A rearrangement or IKZF1 intragenic deletion defined high risk (Jabbour 2026).
- Time points. The Children's Oncology Group measured MRD by flow cytometry in day-8 blood and in day-29 (end-of-induction) and end-of-consolidation marrow in 2,143 children with B-ALL. Day-29 marrow MRD was the most important prognostic variable, and day-29 MRD of 0.01%–0.1% gave a 5-year event-free survival of 59% compared with 88% for MRD-negative patients. Detectable MRD at the end of consolidation gave a 5-year event-free survival of 43% (Borowitz 2008). With induction (day 33) followed by consolidation (day 78), B-ALL negative for MRD at both time points had a 5-year event-free survival of 92.3%, compared with 50.1% for MRD ≥10⁻³ on day 78 (Inaba 2020).
Table 5. MRD methods in ALL (Luo 2026).
| Method | Sensitivity | Principle | Limitations |
|---|---|---|---|
| Multiparameter flow cytometry | About 10⁻⁴ to 10⁻⁵ | Leukemia-associated immunophenotype (LAIP) or different-from-normal (DfN) approach | Less sensitive than molecular assays; fresh sample; expertise; immunophenotypic shifts cause false negatives |
| Quantitative PCR for fusion transcripts | About 10⁻⁴ to 10⁻⁵ | BCR::ABL1 p210 reported on the international scale; p190 as a ratio to ABL1 | Limited to BCR::ABL1-positive ALL; does not separate B-lineage from multilineage disease |
| Allele-specific oligonucleotide PCR for Ig/TR rearrangements | About 10⁻⁴ to 10⁻⁵ | Patient-specific primers from the diagnostic clone | Diagnostic sample required; labor-intensive |
| Next-generation sequencing of Ig/TR rearrangements | About 10⁻⁶ | Clonal sequences from the diagnostic sample, reported per 10⁶ nucleated cells | Diagnostic sample required; 7–10 day turnaround; detects nonleukemic clones |
- LAIP and DfN approaches. LAIP tracks the aberrant phenotype found at diagnosis, and therapy-induced antigen shifts can produce false-negative results. DfN uses the normal maturation patterns of B- and T-cell precursors and does not require a diagnostic sample (Luo 2026).
- Flow sensitivity. Six- to eight-color cytometers detect 1 abnormal cell in 10,000 (≤10⁻⁴) in cellular samples, and EuroFlow standardization reaches 10⁻⁵. The first-pull marrow aspirate is used (Luo 2026).
- Hematogones. Residual blasts show discrete, uniform expression of CD10, CD38, CD20 and CD34 and keep the aberrancies present at diagnosis, while hematogones show a continuous maturation spectrum (Dorfman 2025); the full comparison is in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology.
- Antigen loss after targeted therapy. Blinatumomab and CD19 CAR T cells can leave relapsing blasts CD19 dim or negative, and inotuzumab can leave blasts CD22 negative. CD22, CD24 (with CD66b to exclude neutrophils) and CD79a identify B-lineage cells after CD19-directed therapy (Dorfman 2025).
- Lineage switch. B-ALL with ZNF384 or DUX4 rearrangement or PAX5 p.P80R can show monocytic differentiation after therapy, which affects MRD assessment (Alaggio 2022).
- NGS after transplantation and CAR T cells. Pre-transplant NGS MRD predicted post-transplant relapse better than flow cytometry, and none of 22 children negative by NGS before transplantation relapsed. New dominant sequences after transplantation or CAR T cells usually reflect nonleukemic clonal expansions (Luo 2026).
- Blood and marrow. Blood and marrow MRD correlate closely in T-ALL but are discordant in B-ALL, with higher marrow levels (Luo 2026).
- T-ALL MRD by flow cytometry. Abnormal T cells are identified by decreased CD45, CD34, absent or double-positive CD4 and CD8, CD7 overexpression, the diagnostic aberrant myeloid or B-cell markers, CD99 overexpression and reduced CD48 (Dorfman 2025).
Prognostic factors in pediatric and adult ALL
Table 6. Prognostic factors in ALL (Inaba 2020; Jabbour 2026; Duffield 2023).
| Factor | Pediatric ALL | Adult ALL |
|---|---|---|
| Age | Infant or ≥10 years adverse | ≥60 years: increased risk of therapy-related myeloid neoplasms |
| WBC at diagnosis | ≥50 × 10⁹/L adverse | In BCR::ABL1-positive ALL on blinatumomab-ponatinib, WBC ≥70 × 10⁹/L associated with relapse (3-year cumulative incidence 31% versus 6.7%) |
| Favorable genetics | High hyperdiploidy; ETV6::RUNX1 | DUX4 rearrangement (Duffield 2023) |
| Unfavorable genetics | Hypodiploidy; BCR::ABL1 and BCR::ABL1-like; KMT2A, MEF2D, BCL2/MYC rearrangements; TCF3::HLF | BCR::ABL1-like (hazard ratio 2.08 for overall survival); KMT2A rearrangement; IKZF1 deletion |
| MRD | Early response is a major factor; risk at a given level varies by genetics | Induction MRD negativity: 10-year DFS 83% versus 40% |
CNS involvement, T-cell immunophenotype, Hispanic or Black race and male sex are additional adverse clinical factors in pediatric ALL (Inaba 2020).
Central nervous system and testicular involvement in ALL
- CNS status. CNS1, CNS2 and CNS3 are assigned from the cerebrospinal fluid leukocyte count and the presence of blasts on cytospin, as taught in Leukemia, Lymphoma and Plasma Cell Neoplasms in CSF. CNS2 status at diagnosis is associated with worse outcome and a greater risk of CNS relapse, and augmented intrathecal chemotherapy is required. In patients with overt CNS involvement (CNS3), cranial irradiation lowered isolated CNS relapse without changing the cumulative incidence of any event or overall survival in an international meta-analysis (Inaba 2020).
- Testis at diagnosis. Overt testicular involvement is found in 1.1%–2.4% of boys at diagnosis of pediatric ALL and is very rare in adults. It presents as enlargement, irregular swelling or firmness, and color Doppler ultrasonography confirms it. Affected boys more often have age <1 year or ≥10 years, a high white cell count, T-cell phenotype and other extramedullary disease (Nguyen 2021).
- Histology and biopsy. Leukemic cells usually occupy the interstitial space, and seminiferous tubules are infiltrated only in advanced disease. Wedge biopsies at diagnosis found occult involvement in 4 of 20 boys with non-T-ALL and 1 of 4 with T-ALL, and elective testicular biopsy during or after therapy has been discontinued (Nguyen 2021).
- Risk assignment and relapse. Current protocols use overt testicular involvement only as a criterion for higher-risk therapy (Nguyen 2021); one pediatric protocol excluded testicular leukemia from its low-risk group (Chen 2025). With contemporary intensive chemotherapy, the risk of testicular relapse is 2% or lower (Nguyen 2021).
Germline predisposition to ALL
- Constitutional syndromes. Down syndrome is associated with B-ALL with CRLF2 rearrangement, and ataxia telangiectasia with T-ALL. Li-Fraumeni syndrome, constitutional mismatch repair deficiency and DNA repair syndromes such as Nijmegen breakage syndrome increase cancer risk in general (Inaba 2020).
- Predisposing variants. Germline TP53 variants are linked to low hypodiploid B-ALL, ETV6 variants to hyperdiploid ALL, and PAX5 variants to B-ALL with dicentric or isochromosome 9. Germline IKZF1 variants occur in familial B-ALL and immunodeficiency. RUNX1 germline variants predispose to T-ALL and AML, and ETV6 variants to B-ALL and myelodysplasia (Inaba 2020).
- Germline ETV6 and ETV6::RUNX1-like ALL. Some ETV6::RUNX1-like cases carry germline loss-of-function ETV6 variants (Duffield 2023).
- Myeloid germline predisposition is taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition.
Diagnostic workup and CAP reporting of lymphoblastic neoplasms
- Testing sequence. Morphology identifies blasts, and lineage is assigned mainly by flow cytometry. Karyotype gives the modal number and the common translocations. FISH for BCR::ABL1, ETV6::RUNX1, KMT2A and TCF3 follows, then a BCR::ABL1-like panel and MYC break-apart probes, and sequencing-based assays for cryptic rearrangements and mutations (Duffield 2023).
- CAP case summary. B- and T-lymphoblastic leukemia and lymphoma are reported as single categories with WHO-HAEM5 genetic types, "pending additional studies" options, and the percentage of neoplastic cells in blood and marrow. The template is taught in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology.
Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia
Definition and classification. The small B-cell neoplasms are mature B-cell lymphomas and leukemias composed predominantly of small to medium-sized cells. The 5th edition of the WHO Classification of Haematolymphoid Tumours (WHO-HAEM5) groups the mature B-cell neoplasms into 12 families (Alaggio 2022). The small B-cell neoplasms comprise the families of pre-neoplastic and neoplastic small lymphocytic proliferations, splenic B-cell lymphomas and leukemias, lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), follicular lymphoma (FL) and mantle cell lymphoma (MCL), together with the section on transformation of indolent B-cell lymphomas. Transformation is a new WHO-HAEM5 section that the ICC does not address (Zanelli 2024).
Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (WHO-HAEM5 versus ICC frame, flow cytometry methods, light-chain restriction and the IHC panels used below) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (lymphocytosis workup and the monoclonal B-cell lymphocytosis definition) Related page: Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow (follicular hyperplasia versus follicular lymphoma) Related page: Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging (large B-cell lymphoma with IRF4 rearrangement, DLBCL and Lugano staging) Related page: Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases (IgM MGUS, cold agglutinin disease and IgM myeloma) Related page: Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen (splenic patterns of lymphoma and splenectomy handling) Related page: Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia (Cytology) (CLL/SLL on cytology) Related page: Follicular Lymphoma (Cytology) (FL on cytology) Related page: Mantle Cell Lymphoma (Cytology) (MCL on cytology) Related page: Marginal Zone Lymphoma in Cytology (MZL classification, site-specific genetics and MYD88 frequencies on cytology) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (gastric MALT lymphoma, H. pylori and duodenal-type FL in GI biopsies) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (IgM paraprotein, immunofixation and free light chains) Related page: Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products (plasma exchange for hyperviscosity in Waldenström macroglobulinemia) Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (smudge cells and lymphocyte morphology on the smear)
Small B-cell neoplasms in WHO-HAEM5 and ICC 2022, with WHO-HAEM4R as the previous rule
Table 1. Names of small B-cell neoplasms in WHO-HAEM4R (revised 4th edition, 2017), the International Consensus Classification (ICC 2022) and WHO-HAEM5 (Alaggio 2022; Campo 2022; Ferry 2024).
| WHO-HAEM4R (2017, previous rule) | ICC 2022 | WHO-HAEM5 |
|---|---|---|
| Monoclonal B-cell lymphocytosis, CLL type and non-CLL type | MBL, CLL type and non-CLL type | MBL in 3 subtypes: low-count MBL, CLL/SLL-type MBL and non-CLL/SLL-type MBL |
| B-cell prolymphocytic leukemia (B-PLL) | B-PLL retained (>55% prolymphocytes in blood after exclusion of transformed CLL, SMZL, MCL and HCL variant) | Entity deleted; cases reassigned to MCL, prolymphocytic progression of CLL or splenic B-cell lymphoma/leukemia with prominent nucleoli (SBLPN) |
| Splenic B-cell lymphoma/leukemia, unclassifiable, with splenic diffuse red pulp small B-cell lymphoma (SDRPL) and hairy cell leukemia variant (HCLv) as provisional entities | Same category and provisional entities retained | Category removed; SDRPL accepted as an entity; HCLv replaced by SBLPN |
| Extranodal MZL of MALT, including cutaneous cases | EMZL; primary cutaneous marginal zone lymphoproliferative disorder | EMZL; primary cutaneous MZL as a separate entity |
| Nodal MZL with pediatric nodal MZL as a subtype | Pediatric nodal MZL under nodal MZL | Pediatric nodal MZL as a separate entity |
| FL, grades 1–2, 3A and 3B; in situ follicular neoplasia; duodenal-type FL; testicular FL | Same grades; in situ follicular neoplasia; duodenal-type FL; testicular FL; BCL2-rearrangement-negative, CD23-positive follicle center lymphoma | Classic FL (grading optional), follicular large B-cell lymphoma (FLBL), FL with uncommon features; in situ follicular B-cell neoplasm; duodenal-type FL; testicular FL not separate |
| MCL; in situ mantle cell neoplasia; non-nodal MCL | MCL; in situ MCL; leukemic non-nodal MCL | MCL; in situ mantle cell neoplasm; leukemic non-nodal MCL |
Chronic lymphocytic leukemia/small lymphocytic lymphoma and monoclonal B-cell lymphocytosis
Diagnostic thresholds. The iwCLL 2018 guidelines are the current diagnostic and treatment standard (Hallek 2018). CLL requires ≥5,000 B lymphocytes/μL (5 × 10⁹/L) in blood for at least 3 months, with clonality confirmed by flow cytometry (Hallek 2025). Small lymphocytic lymphoma (SLL) requires lymphadenopathy, no cytopenia caused by a clonal marrow infiltrate and a blood B-cell count that does not exceed 5,000/μL. A lymph node biopsy confirms SLL whenever possible (Hallek 2025). Cytopenia caused by a typical marrow infiltrate establishes CLL regardless of the blood B-cell count or nodal involvement (Hallek 2025). MBL progresses to CLL at a rate of 1%–2% per year (Hallek 2025).
Table 2. Monoclonal B-cell lymphocytosis and CLL/SLL thresholds (Alaggio 2022, WHO-HAEM5; Hallek 2025, iwCLL 2018).
| Category | Clonal B-cell count and other criteria |
|---|---|
| Low-count MBL (WHO-HAEM5) | CLL/SLL-phenotype clonal B cells <0.5 × 10⁹/L; no other feature of a B-lymphoproliferative disorder |
| CLL/SLL-type MBL (WHO-HAEM5) | CLL/SLL-phenotype clonal B cells ≥0.5 × 10⁹/L and total B cells <5 × 10⁹/L; no other feature of CLL/SLL |
| Non-CLL/SLL-type MBL (WHO-HAEM5) | Any clonal non-CLL/SLL-phenotype B-cell expansion without symptoms or features of another mature B-cell neoplasm; most cases have marginal zone features |
| CLL (iwCLL 2018) | ≥5 × 10⁹/L clonal B cells for ≥3 months, or cytopenia caused by a typical marrow infiltrate |
| SLL (iwCLL 2018) | Lymphadenopathy, B cells ≤5 × 10⁹/L, no cytopenia from marrow infiltration |
All MBL subtypes are associated with immune impairment, with suboptimal vaccine responses and an increased risk of infection (Alaggio 2022). The 5 × 10⁹/L threshold for CLL/SLL-type MBL identifies people with a very low likelihood of treatment compared with those with B-cell counts of 5–10 × 10⁹/L (Alaggio 2022).
Blood morphology. CLL cells are small mature lymphocytes with a narrow rim of cytoplasm, a dense nucleus without discernible nucleoli and partially aggregated chromatin (Hallek 2025). Larger or atypical cells, cleaved cells and prolymphocytes may make up to 55% of blood lymphocytes. Gumprecht nuclear shadows (smudge cells) are characteristic (Hallek 2025).
Prolymphocytic progression. WHO-HAEM5 defines prolymphocytic progression of CLL/SLL as a CD5-positive non-mantle B-cell neoplasm with >15% prolymphocytes in blood and/or marrow. Cases with <15% prolymphocytes remain CLL/SLL (Alaggio 2022). The ICC retains B-PLL, requiring >55% prolymphocytes in blood and exclusion of transformed CLL, SMZL and MCL (Ferry 2024).
Immunophenotype. CLL cells coexpress CD5 with CD19, CD20 and CD23. Surface immunoglobulin, CD20 and CD79b are expressed at low levels compared with normal B cells, and each clone is restricted to κ or λ (Hallek 2025). The WHO-HAEM5 essential and supplementary CLL markers and the flow cytometry method are in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (Alaggio 2022). CD5 is also expressed by MCL (Hallek 2025). The Matutes score is taught in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology. Nuclear LEF1 is expressed in up to 95% of CLL and is lower in CLL with atypical immunophenotype or morphology. MCL is LEF1-negative (Robak 2023).
Tissue pattern and accelerated CLL/SLL. Accelerated CLL/SLL is commonly defined by the Giné 2010 criteria: proliferation centers broader than a 20× field, Ki-67 >40% or more than 2.4 mitoses within proliferation centers (Moore 2024). Ki-67 was the only immunostain that differed between accelerated or transformed cases and low-grade cases (Moore 2024).
Prognostic markers. WHO-HAEM5 lists del(11q), del(13q), del(17p) and trisomy 12 by FISH, TP53 mutation analysis, IGHV somatic hypermutation status and B-cell receptor stereotyped subset #2 as essential for full prognostic evaluation. Del(13q) is the most common alteration, in about 55% of cases, and isolated del(13q14) usually indicates less aggressive disease (Hallek 2025). Karyotypic complexity and BTK, PLCG2 and BCL2 mutations are desirable before targeted therapy (Alaggio 2022).
- IGHV status. The cutoff for mutated IGHV is <98% identity with the germline sequence (Fend 2024).
- TP53. TP53 alteration, usually biallelic (mutation with del(17p)), is the most important prognostic and predictive parameter and is tested before initiation of therapy. Subclonal mutations with a variant allele frequency <10% also predict poorer outcome (Fend 2024). Del(17p) and/or TP53 mutation predicts shorter time to progression with most targeted agents (Hallek 2025).
- MYD88. About 2%–3% of CLL carry MYD88 mutations, associated with favorable biology (Fend 2024).
- CLL-IPI. The CLL International Prognostic Index weights TP53 deletion and/or mutation, IGHV status, serum β2-microglobulin, clinical stage and age. It separates 4 risk groups and retains its value for progression-free survival with targeted drugs (Hallek 2025).
- IPS-E. The International Prognostic Score for early-stage CLL uses unmutated IGHV, absolute lymphocyte count >15 × 10⁹/L and palpable lymph nodes. The 5-year cumulative risk of starting treatment is 8.4%, 28.4% and 61.2% in the low-, intermediate- and high-risk groups (Hallek 2025).
Table 3. Clinical staging of CLL (Hallek 2025).
| System | Stage or risk group | Definition |
|---|---|---|
| Modified Rai | Low risk (former stage 0) | Lymphocytosis with leukemic cells in blood and/or marrow (lymphoid cells >30%) |
| Modified Rai | Intermediate risk (former stages I–II) | Lymphocytosis with enlarged nodes in any site, splenomegaly and/or hepatomegaly |
| Modified Rai | High risk (former stages III–IV) | Disease-related anemia (hemoglobin <11 g/dL) or thrombocytopenia (platelets <100 × 10⁹/L) |
| Binet | A | Hemoglobin ≥10 g/dL, platelets ≥100 × 10⁹/L and up to 2 involved areas |
| Binet | B | Hemoglobin ≥10 g/dL, platelets ≥100 × 10⁹/L and ≥3 involved areas |
| Binet | C | Hemoglobin <10 g/dL and/or platelets <100 × 10⁹/L |
The 5 Binet areas are head and neck including the Waldeyer ring, axillae, groins including superficial femoral nodes, palpable spleen and palpable liver. Each paired site counts as 1 area, and nodes count when >1 cm (Hallek 2025).
Table 4. iwCLL 2018 criteria for active disease requiring treatment (Hallek 2025).
| Criterion | Definition |
|---|---|
| Progressive marrow failure | Development or worsening of anemia and/or thrombocytopenia; hemoglobin <10 g/dL or platelets <100 × 10⁹/L are generally regarded as indications |
| Splenomegaly | Massive (≥6 cm below the left costal margin), progressive or symptomatic |
| Lymphadenopathy | Massive nodes (≥10 cm in longest diameter), progressive or symptomatic |
| Progressive lymphocytosis | Increase ≥50% over 2 months, or lymphocyte doubling time <6 months |
| Autoimmune complications | Anemia or thrombocytopenia poorly responsive to corticosteroids |
| Extranodal involvement | Symptomatic or functional (for example skin, kidney, lung or spine) |
| Disease-related symptoms | Unintentional weight loss ≥10% within the previous 6 months; significant fatigue (ECOG performance status 2 or worse); fever ≥38.0 °C for ≥2 weeks without infection; night sweats for ≥1 month without infection |
Asymptomatic early-stage disease (Rai 0, Binet A) is monitored without therapy, because early treatment has shown no survival benefit (Hallek 2025). The CLL-IPI does not determine the indication to treat (Hallek 2025).
Richter transformation of CLL/SLL
Definition and terminology. Richter transformation is an aggressive lymphoma arising in a patient with CLL/SLL (Kittai 2025). WHO-HAEM5 recommends "Richter transformation" over "Richter syndrome" (Alaggio 2022). Transformation in WHO-HAEM5 requires a clonally related aggressive lymphoma. A clonally unrelated aggressive lymphoma is a de novo second malignancy, and clonally related cases follow a more aggressive course (Zanelli 2024).
Histologic types. Most Richter transformations are diffuse large B-cell lymphoma (DLBCL). A minority has features of Hodgkin lymphoma (Ferry 2024). The transformed lymphoma generally keeps the phenotype of the indolent lymphoma, such as CD5 and CD23 in cases from CLL (Zanelli 2024).
Table 5. Hodgkin lymphoma-like Richter transformation by system (Ferry 2024).
| ICC 2022 | WHO-HAEM5 |
|---|---|
| Type 1: Hodgkin/Reed–Sternberg (HRS) cells in a background of CLL/SLL | HRS cells without a Hodgkin-type background are regarded as preliminary and are not diagnosed as transformation |
| Type 2: HRS cells in the mixed inflammatory background of sporadic classic Hodgkin lymphoma | Requires a non-neoplastic microenvironment similar to sporadic classic Hodgkin lymphoma |
EBV-positive DLBCL or classic Hodgkin lymphoma after chemotherapy for CLL may be clonally unrelated and may be better classified as a lymphoma associated with immune deficiency and dysregulation (Ferry 2024).
Workup of suspected Richter transformation (ERIC 2025). Patients typically present with rapid clinical decline, worsening B symptoms, elevated lactate dehydrogenase and/or rapidly enlarging lymphadenopathy. PET-CT is recommended for suspected transformation. An excisional biopsy is taken from an accessible lesion, preferably the one with the highest FDG avidity, and the molecular relationship to the original CLL clone is defined (Kittai 2025).
Mantle cell lymphoma, in situ mantle cell neoplasm and leukemic non-nodal MCL
Genetics. The IGH::CCND1 fusion of t(11;14)(q13;q32) is present in ≥95% of MCL (cyclin D1-positive MCL). IGK or IGL occasionally serve as the CCND1 partner, and MCL with strong cyclin D1 but no CCND1 rearrangement by FISH carry cryptic IGK or IGL enhancer rearrangements (Alaggio 2022). Cyclin D1-negative MCL carries CCND2, CCND3 or CCNE rearrangements (Alaggio 2022). These rearrangements are demonstrated by FISH or other techniques, because immunohistochemistry is unreliable in this setting (Fend 2024).
Morphology and phenotype. MCL grows in a nodular or diffuse pattern, and about 20% of cases show blastoid morphology. The cells express surface IgM and IgD, CD5, CD19 and CD22 and are negative for CD3, CD23, CD10 and CD11c (Ladha 2019). Conventional MCL derives from naive B cells with unmutated IGHV and is usually SOX11-positive (Fend 2024). Blastoid MCL loses CD5 in 25%–28% of cases and may express CD10 and BCL6 aberrantly (Zanelli 2024). CD5-positive DLBCL is separated from pleomorphic and blastoid MCL by the absence of cyclin D1 and SOX11 (Zanelli 2024).
Table 6. Mantle cell neoplasms in WHO-HAEM5 (Alaggio 2022; Fend 2024).
| Entity (ICC term where different) | Defining features |
|---|---|
| In situ mantle cell neoplasm (in situ MCL in the ICC; in situ mantle cell neoplasia in WHO-HAEM4R) | Rare, usually incidental colonization of follicle mantle zones by B cells with an IG::CCND1 fusion and cyclin D1 overexpression |
| MCL | IGH::CCND1 in ≥95%; naive B-cell derivation with unmutated IGHV; usually SOX11-positive |
| Leukemic non-nodal MCL | Blood, marrow and spleen involvement with little or no lymphadenopathy; mostly asymptomatic; SOX11-negative, low Ki-67, frequent CD5 loss; biased IGHV1-8 usage with higher somatic hypermutation; fewer genetic alterations; better outcome |
Prognosis. Established high-risk features are pleomorphic or blastoid cytology, a high Ki-67 index, p53 expression and TP53 mutation (Alaggio 2022). TP53 mutation is associated with a more aggressive course, higher proliferation and frequent blastoid morphology in both conventional and non-nodal MCL (Fend 2024). The simplified MCL International Prognostic Index (MIPI) scores age, ECOG performance status, LDH relative to the upper limit of normal and white cell count. A score of 0–3 is low risk (5-year overall survival 60%), 4–5 intermediate risk (median overall survival 51 months) and 6–11 high risk (median 29 months). Ki-67 >30% is an adverse marker (Radhakrishnan 2022).
Follicular lymphoma: WHO-HAEM5 and ICC 2022, with WHO-HAEM4R as the previous rule
Definition. FL is a neoplasm of germinal center B cells composed of centrocytes and centroblasts with an at least partially follicular growth pattern in both WHO-HAEM5 and the ICC (Kurz 2023). About 85% of FL have at least a partly follicular pattern, centrocytes and centroblasts and t(14;18)(q32;q21) with IGH::BCL2. WHO-HAEM5 names these classic FL (cFL) (Alaggio 2022).
Table 7. Follicular lymphoma subtyping and grading by system (Alaggio 2022; Ferry 2024; Kurz 2023; Khanlari 2022).
| Feature | WHO-HAEM4R (previous rule) | ICC 2022 | WHO-HAEM5 |
|---|---|---|---|
| Grading | Mandatory; centroblasts counted per high-power field (×40 objective, 0.159 mm²); grades 1 and 2 (up to 15 centroblasts per field) not separated | Grades 1–2, 3A and 3B retained | Optional, and pertinent only to cFL |
| Grade 3A | >15 centroblasts per field with centrocytes present | Retained | Within cFL |
| Grade 3B | >15 centroblasts per field in solid aggregates with no or very rare centrocytes | FL grade 3B retained | Follicular large B-cell lymphoma (FLBL) |
| Predominantly diffuse, BCL2-rearrangement-negative, CD23-positive cases | Noted as rare inguinal tumors with 1p36 loss | BCL2-rearrangement-negative, CD23-positive follicle center lymphoma as an entity | uFL with predominantly diffuse growth |
Diffuse areas and uncommon cytology. WHO-HAEM4R recommended the diagnosis "DLBCL with follicular lymphoma" for cFL grade 3A with a focal or extensive diffuse pattern. WHO-HAEM5 no longer designates these diffuse areas automatically as DLBCL and refers treatment decisions to multidisciplinary review (Alaggio 2022; Ferry 2024). WHO-HAEM5 also introduces FL with uncommon features (uFL), which comprises a blastoid or large centrocyte subset and a predominantly diffuse subset (Alaggio 2022).
Reasons for optional grading. Grading is poorly reproducible because of sampling (core needle biopsy versus excision), variable recognition of centroblasts, counting methods and the changing size of a 40× high-power field. Outcomes of grades 1, 2 and 3A do not differ significantly with modern therapy (Alaggio 2022). A diffuse area with 15 centroblasts per high-power field is still composed mainly of centrocytes and would not meet conventional criteria for DLBCL (Ferry 2024).
FL with uncommon features. Blastoid and large centrocyte variants more often show variant immunophenotypes and genotypes and may have inferior survival. They are distinguished from large B-cell lymphoma with IRF4 rearrangement (Alaggio 2022). FL with predominantly diffuse growth often forms a large inguinal tumor, expresses CD23, lacks IGH::BCL2 and carries STAT6 mutations with 1p36 deletion or TNFRSF14 mutation (Alaggio 2022). Deletion or copy-neutral loss of heterozygosity of 1p36 occurs in 50%–90% of these cases (Kurz 2023).
Histology of cFL. Numerous closely packed follicles of similar appearance replace the node, with variable diffuse areas, extracapsular spread or sclerosis (Kurz 2023). About 10%–15% of morphologically typical cFL lack IGH::BCL2. These cases have more frequent STAT6 and fewer KMT2D mutations (Kurz 2023). The mutational profile is dominated by epigenetic regulators, and transformation is associated with TP53 mutations and MYC translocations (Fend 2024). EZH2 mutation testing is relevant before tazemetostat therapy (Fend 2024). Circulating t(14;18)-positive B cells are found at very low levels in >70% of healthy adults (Kurz 2023).
Table 8. Special follicular lymphomas and related lesions (Kurz 2023; Alaggio 2022; Fend 2024).
| Entity | Defining features |
|---|---|
| In situ follicular B-cell neoplasm (WHO-HAEM5; in situ follicular neoplasia in WHO-HAEM4R and ICC) | Partial or complete colonization of reactive germinal centers by CD10-positive B cells with IGH::BCL2 and strong BCL2; about 2% of lymph nodes in larger series; usually recognized only on BCL2 staining; most cases are not followed by FL |
| Pediatric-type FL | Localized nodal disease in children and adolescents, mostly head and neck nodes; purely follicular growth with large expansile, often serpiginous follicles; high proliferation; no BCL2, BCL6, MYC or IRF4 rearrangement; proof of clonality required; TNFRSF14 (1p36) and MAP2K1 alterations; 1%–2% of childhood non-Hodgkin lymphoma |
| Duodenal-type FL | Mainly the second part of the duodenum; small granular lesions or polyps up to 2 cm, often incidental at endoscopy; very indolent and localized for years |
| Primary cutaneous follicle center lymphoma | Recognized as a separate entity in all 3 systems |
Pediatric-type FL excludes extranodal presentation and diffuse large-cell areas, and its cells lack strong uniform MUM1. These features separate it from large B-cell lymphoma with IRF4 rearrangement (Zanelli 2024). WHO-HAEM5 does not list testicular FL separately because of its rarity and overlap with pediatric-type FL (Ferry 2024).
Transformation and prognosis. Transformation of FL, usually to DLBCL, occurs at about 2% per year and indicates an inferior prognosis (Kurz 2023). Relapse within 2 years of therapy predicts inferior outcome. The FL International Prognostic Index (FLIPI) and the clinicogenetic m7-FLIPI predict survival (Kurz 2023). FL with concurrent MYC and BCL2 rearrangements is less aggressive than DLBCL/HGBL with these rearrangements and is excluded from that category in all 3 systems (Ferry 2024).
Marginal zone lymphomas
Classification. Extranodal MZL of mucosa-associated lymphoid tissue (EMZL), nodal MZL (NMZL), primary cutaneous MZL and pediatric nodal MZL are named by system in Table 1 (Alaggio 2022; Ferry 2024). The reasons for the ICC and WHO-HAEM5 positions are in Marginal Zone Lymphoma in Cytology.
Histology and phenotype. EMZL consists of small B cells with centrocyte-like or monocytoid morphology, variable plasmacytic differentiation, colonization of reactive follicles and lymphoepithelial lesions. The cells express CD20, CD79a and PAX5, frequently show surface IgM and are usually negative for CD5, CD10 and cyclin D1 (Skafi 2026). Plasmacytic differentiation and reactive follicles are common to EMZL, NMZL and primary cutaneous MZL (Alaggio 2022). In nodal or marrow-based small B-cell lymphomas, KLF2, NOTCH1/NOTCH2, PTPRD, BIRC3, TRAF3, CARD11 and IRF8 mutations favor MZL (Fend 2024).
Genetics with clinical impact. Trisomies 3 and 18 occur in all MZL types. t(11;18)(q21;q21) with BIRC3::MALT1 is recurrent in gastric and pulmonary EMZL and rare elsewhere (Alaggio 2022). Other recurrent EMZL translocations are t(14;18)(q32;q21) IGH::MALT1, t(1;14)(p22;q32) IGH::BCL10 and t(3;14)(p14;q32) IGH::FOXP1, all activating NF-κB (Di Rocco 2022; Fend 2024). The effect of these lesions on H. pylori eradication is described in Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine.
Table 12. Site-related pathogens, autoimmune disorders and translocations in EMZL (Di Rocco 2022, Table 1).
| Site | Associated pathogen or autoimmune disorder | Recurrent genetic changes |
|---|---|---|
| Stomach | Helicobacter pylori (in 85% of gastric EMZL); Helicobacter heilmannii | t(11;18) BIRC3::MALT1; t(14;18) IGH::MALT1; t(1;14) IGH::BCL10 |
| Small intestine | Campylobacter jejuni | t(11;18) BIRC3::MALT1; t(1;14) IGH::BCL10 |
| Skin | Borrelia burgdorferi | t(14;18) IGH::MALT1; t(3;14) IGH::FOXP1 |
| Ocular adnexa | Chlamydia psittaci (in 10%–50%); Sjögren syndrome | t(14;18) IGH::MALT1; t(3;14) IGH::FOXP1; TNFAIP3 mutation |
| Lung | Achromobacter xylosoxidans; lymphocytic interstitial pneumonia | t(11;18) BIRC3::MALT1 |
| Salivary gland | Sjögren syndrome and hepatitis C virus (with chronic sialadenitis, in more than 70% of salivary EMZL) | t(14;18) IGH::MALT1; TBL1XR1 and GPR34 mutations |
Trisomies 3 and 18 occur at every site. Among the less frequent sites, salivary gland is the most common, followed by skin (10%), thyroid (5%), liver (3%) and breast (3%). Autoimmune disease is found mostly in non-gastric EMZL, particularly of the salivary gland and ocular adnexa (Di Rocco 2022). Alpha heavy chain disease (immunoproliferative small intestinal disease) is taught in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases.
Splenic B-cell lymphomas and hairy cell leukemia
Classification. WHO-HAEM5 recognizes hairy cell leukemia (HCL), SBLPN, SDRPL and splenic MZL (SMZL) (Alaggio 2022). SBLPN replaces HCL variant and includes CD5-negative B-PLL and rare SMZL with similar morphology. It accounts for about 0.4% of chronic lymphoid malignancies (Alaggio 2022). SBLPN can be diagnosed without splenectomy in a patient with splenomegaly and circulating neoplastic B cells of appropriate morphology (Ferry 2024).
Table 9. Splenic small B-cell neoplasms (Shah 2026; Alaggio 2022; Mirandari 2024).
| Feature | Hairy cell leukemia | SBLPN (WHO-HAEM5) | SDRPL | SMZL |
|---|---|---|---|---|
| Blood cells | Small to medium cells with circumferential hairy projections | Larger cells with prominent nucleoli and irregular or polar projections | Small monomorphic villous cells | Small to medium villous lymphocytes with polar projections |
| Blood count | Pancytopenia with characteristic monocytopenia and neutropenia | Leukocytosis; anemia and thrombocytopenia common; monocytopenia rare | Variable cytopenias | Moderate lymphocytosis |
| Spleen | Diffuse red pulp; white pulp often atrophic | Predominantly red pulp | Diffuse red pulp with effacement of white pulp | White pulp expansion |
| Marrow | "Fried-egg" cells, marked reticulin fibrosis, often a dry tap; diffuse pattern | Infiltration without marked fibrosis | Predominantly intrasinusoidal | Nodular, interstitial or intrasinusoidal |
| Phenotype | CD11c, CD25, CD103, bright CD123, annexin A1 and TRAP positive | CD11c and CD103 positive; CD25, CD123, annexin A1 and TRAP negative | Often CD11c; usually CD25, CD103, CD123 and annexin A1 negative; CD200/CD180 MFI ratio <0.5 | CD5, CD10, CD103, annexin A1 and cyclin D1 negative |
| Genetics | BRAF V600E in ≥95% | BRAF wild type; MAP2K1 mutations frequent | CCND3 mutations in most cases | del(7q) in 14%–44%; KLF2 and NOTCH2 mutations |
Hairy cell leukemia. HCL has a male-to-female ratio of 4:1 (Zhang 2026). Hairy cells home to marrow, splenic red pulp and hepatic sinusoids with minimal nodal involvement (Zhang 2026). They also overexpress cyclin D1 and CD200 (Zhang 2026). Annexin A1 immunostaining of marrow is highly specific at first diagnosis but unsuitable at relapse, because macrophages and T cells express it. BRAF V600E is detected by PCR or sequencing and by immunostaining of paraffin sections (Zhang 2026). Cases using IGHV4-34 may lack BRAF V600E, carry MAP2K1 mutations and resemble HCL variant (Fend 2024). IGHV4-34 usage occurs in about 10% of HCL, 40% of SBLPN and 20% of SMZL and predicts poorer response to purine analogs (Shah 2026). SBLPN is more aggressive than HCL and resistant to single-agent cladribine (Alaggio 2022).
SMZL. SMZL is associated with autoimmune conditions and, in southern Europe and China, with hepatitis C virus infection (Mirandari 2024). KLF2 (12%–42%), NOTCH2 (10%–25%) and TP53 (15%) are the most frequently mutated genes (Mirandari 2024). Splenectomy gives the most reliable separation of the splenic entities. Without it, the marrow pattern helps, but the distinction is often not possible (Alaggio 2022).
Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia
Subtypes. WHO-HAEM5 recognizes IgM-LPL/Waldenström macroglobulinemia (WM) type and non-WM-type LPL. Non-WM LPL is about 5% of LPL and includes IgG or IgA cases, non-secretory LPL and IgM LPL without marrow involvement (Alaggio 2022).
Genetics. MYD88 p.L265P is the hallmark driver in >90% of LPL (Alaggio 2022) and in 95%–97% of WM (Fend 2024). It helps separate LPL from nodal and extranodal MZL with plasmacytic differentiation and from plasma cell myeloma, which generally lack the mutation (Alaggio 2022). IgM myeloma is universally MYD88-negative (Fend 2024). CXCR4 mutations occur in up to 40% of LPL, usually with MYD88 mutation. CXCR4 testing is desirable before BTK inhibitor therapy, because the mutation is associated with shorter time to treatment and ibrutinib resistance (Alaggio 2022). CXCR4-mutated WM shows more marrow infiltration, higher serum IgM, symptomatic hyperviscosity and acquired von Willebrand disease (Růžičková 2026). Del(6q) occurs in 30%–60% of WM (Růžičková 2026). Low-burden IgM MGUS and LPL require sensitive mutation assays (Fend 2024).
Marrow findings. Plasma cells in WM may contain Dutcher bodies. Increased marrow mast cells are a typical histologic finding in WM, and high mast cell density is associated with greater marrow tumor burden (Růžičková 2026).
Table 10. LPL and IgM MGUS thresholds by system (Ferry 2024).
| Item | ICC 2022 | WHO-HAEM5 |
|---|---|---|
| Marrow infiltration for LPL | Abnormal lymphoplasmacytic aggregates may establish LPL even when <10% of marrow cellularity, in the appropriate clinical context | Significant marrow infiltration required, without a numeric threshold |
| IgM MGUS | Laboratory criteria in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands, plus no marrow aggregates sufficient for LPL; LPL type and plasma cell type | IgM MGUS separated from non-IgM MGUS |
| Cold agglutinin disease | Primary cold agglutinin disease | Cold agglutinin disease; no association with MYD88 p.L265P |
Treatment of WM is indicated by hyperviscosity, neuropathy, symptomatic adenopathy or organomegaly, amyloidosis, cryoglobulinemia, cold agglutinin disease, anemia, B symptoms or cytopenia. An IgM level alone is not an indication (Růžičková 2026).
Differential diagnosis of small B-cell lymphomas by phenotype and genetics
Table 11. Distinguishing features of small B-cell neoplasms.
| Neoplasm | Key phenotype | Genetic hallmark | Source |
|---|---|---|---|
| CLL/SLL | CD5 and CD23 positive; dim surface immunoglobulin, CD20 and CD79b | del(13q), trisomy 12, del(11q), del(17p) by FISH; IGHV status | Hallek 2025; Alaggio 2022 |
| MCL | CD5 positive; CD23, CD10 and CD11c negative; cyclin D1 and usually SOX11 positive | IGH::CCND1 in ≥95% | Ladha 2019; Alaggio 2022; Fend 2024 |
| Leukemic non-nodal MCL | SOX11 negative, frequent CD5 loss, low Ki-67 | Mutated IGHV, fewer alterations | Alaggio 2022 |
| cFL | Germinal center B cells; BCL2 positive in IGH::BCL2-positive cases | IGH::BCL2 in about 85% | Alaggio 2022; Kurz 2023 |
| EMZL | CD5, CD10 and cyclin D1 negative; surface IgM | Trisomies 3 and 18; BIRC3::MALT1 in gastric and pulmonary EMZL | Skafi 2026; Alaggio 2022 |
| HCL | CD11c, CD25, CD103, CD123, annexin A1 positive | BRAF V600E | Shah 2026; Alaggio 2022 |
| SMZL | CD5, CD10, CD103 and annexin A1 negative | del(7q); KLF2, NOTCH2 | Shah 2026; Mirandari 2024 |
| LPL/WM | Lymphoplasmacytic cells with IgM paraprotein | MYD88 p.L265P; CXCR4 | Alaggio 2022; Fend 2024 |
Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging
Definition and classification. Large B-cell lymphomas (LBCL) are generally composed of medium-sized to large cells with round to ovoid nuclei and vesicular chromatin. Cases with intermediate-sized or blastoid cells can also belong to this family and require separation from blastoid mantle cell lymphoma and lymphoblastic leukemia/lymphoma (Alaggio 2022). The 5th edition of the WHO Classification of Haematolymphoid Tumours (WHO-HAEM5) recognizes diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) and 17 specific LBCL entities. Several names changed from "diffuse large B-cell lymphoma" to "large B-cell lymphoma" because a diffuse pattern is absent or cannot be assessed in some entities (Alaggio 2022).
Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (WHO-HAEM5 versus ICC frame, IHC panels, double-expressor thresholds and CAP lymphoid reporting elements) Related page: Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia (Richter transformation, transformation of follicular lymphoma and follicular large B-cell lymphoma) Related page: Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow (progressive transformation of germinal centers, infectious mononucleosis and KSHV/HHV8-associated multicentric Castleman disease) Related page: B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease (B-lymphoblastic leukemia/lymphoma, including cases with MYC rearrangement) Related page: Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas (nodal T-follicular helper cell lymphomas with HRS-like B cells and ALK-positive anaplastic large cell lymphoma) Related page: Diffuse Large B-Cell Lymphoma (Cytology) (DLBCL on cytology) Related page: Burkitt Lymphoma (Cytology) (Burkitt lymphoma on cytology) Related page: Classic Hodgkin Lymphoma (Cytology) (classic Hodgkin lymphoma on cytology and limits of flow cytometry) Related page: Lymphoma and Primary Effusion Lymphoma in Serous Effusions (primary effusion lymphoma and fluid overload-associated LBCL in effusions) Related page: Vitreous and Ocular Cytology (vitreoretinal lymphoma) Related page: Leukemia, Lymphoma and Plasma Cell Neoplasms in CSF (CNS lymphoma in cerebrospinal fluid) Related page: Lymphoproliferative and Spindle Cell Lesions on Lung FNA (pulmonary lymphoid lesions on cytology) Related page: Metastases, Lymphoma and Angiosarcoma in Liver FNA (lymphoma in liver FNA) Related page: Metastases and lymphoma in pancreatic cytology (lymphoma in pancreatic FNA) Related page: Lymphoma and Metastatic Carcinoma in Soft Tissue FNA (lymphoma in soft tissue FNA) Related page: Lymphoma, Metastases and Undifferentiated Malignancies in Thyroid FNA (thyroid lymphoma on FNA) Related page: Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy (post-transplant lymphoproliferative disorders in liver allografts) Related page: Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology (post-transplant lymphoproliferative disorders in kidney allografts) Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (transplant context of PTLD) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (inborn errors of immunity) Related page: Diagnostic Enzymes and Serum Tumor Markers (lactate dehydrogenase)
Large B-cell lymphoma entities in WHO-HAEM5 and ICC 2022, with WHO-HAEM4R as the previous rule
Table 1. Large B-cell and related lymphomas whose names or definitions differ between WHO-HAEM4R, the International Consensus Classification (ICC 2022) and WHO-HAEM5 (Campo 2022; Ferry 2024; Alaggio 2022; Zanelli 2024).
| WHO-HAEM4R (2017, previous rule) | ICC 2022 | WHO-HAEM5 |
|---|---|---|
| High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements | HGBL with MYC and BCL2 rearrangements; HGBL with MYC and BCL6 rearrangements (provisional) | DLBCL/HGBL with MYC and BCL2 rearrangements; MYC plus BCL6 cases classified as DLBCL, NOS or HGBL, NOS by morphology |
| Burkitt-like lymphoma with 11q aberration (provisional) | Large B-cell lymphoma with 11q aberration (provisional) | HGBL with 11q aberration |
| EBV-positive DLBCL, NOS | EBV-positive DLBCL, NOS (>80% of tumor cells EBV-positive) | EBV-positive DLBCL (majority of tumor cells EBV-positive) |
| DLBCL associated with chronic inflammation, with fibrin-associated DLBCL as a subtype | Same | DLBCL associated with chronic inflammation; fibrin-associated LBCL as a separate entity |
| HHV8-negative effusion-based lymphoma mentioned in the differential of PEL | HHV8- and EBV-negative primary effusion-based lymphoma | Fluid overload-associated LBCL (EBV-positive cases allowed and reported) |
| Primary DLBCL of the CNS; testicular and vitreoretinal cases within DLBCL, NOS | Primary DLBCL of the CNS; primary DLBCL of the testis | Primary LBCL of immune-privileged sites (CNS, vitreoretina, testis) |
| B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma | Mediastinal gray zone lymphoma (EBV-positive cases excluded) | Mediastinal gray zone lymphoma |
| Large B-cell lymphoma with IRF4 rearrangement (provisional, under FL) | Listed with the follicular lymphomas | Listed with the large B-cell lymphomas |
| HHV8-positive DLBCL, NOS | HHV8-positive DLBCL, NOS | KSHV/HHV8-positive DLBCL |
| Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) | Nodular lymphocyte predominant B-cell lymphoma (NLPBL), placed with the large B-cell lymphomas and graded | NLPHL retained within Hodgkin lymphoma; NLPBL considered acceptable |
Entities with uniform names in all 3 systems are T-cell/histiocyte-rich LBCL, ALK-positive LBCL, plasmablastic lymphoma, primary cutaneous DLBCL leg type, intravascular LBCL, primary mediastinal LBCL, lymphomatoid granulomatosis, HGBL, NOS and Burkitt lymphoma (Ferry 2024).
Diffuse large B-cell lymphoma, NOS
Definition and morphology. DLBCL, NOS is a mature B-cell lymphoma with large-cell morphology that lacks the criteria of a specific LBCL entity (Alaggio 2022). It involves lymph nodes, and 30%–40% of cases are extranodal at presentation (Zanelli 2024). WHO-HAEM5 lists centroblastic, immunoblastic and anaplastic morphologic subtypes. Centroblastic and immunoblastic morphology predominate, and the anaplastic subtype has more pleomorphic cells (Ferry 2024; Zanelli 2024).
Immunophenotype. The cells express CD20, CD79a, PAX5, CD19 and CD45 and usually surface immunoglobulin. CD10, BCL6, BCL2 and IRF4/MUM1 characterize subgroups (Zanelli 2024). CD5 is expressed in 5%–10% of cases, and its adverse impact probably reflects activated B-cell (ABC) derivation. The ICC does not regard CD5-positive DLBCL as a distinct biologic group (Zanelli 2024). Cyclin D1 is expressed in 1%–2% of DLBCL, NOS, and these cases lack SOX11 and a CCND1 translocation (Zanelli 2024).
Cell of origin. WHO-HAEM5 and the ICC both retain the cell-of-origin (COO) classification (Zanelli 2024).
- Gene expression profiling (GEP). GEP, the reference method, separates germinal center B-cell-like (GCB, 40%–50%), ABC (50%–60%) and unclassified (10%–15%) subtypes (Zanelli 2024).
- GCB subtype. Enriched for IGH::BCL2 from t(14;18)(q32;q21); the mutation profile is listed in Diffuse Large B-Cell Lymphoma (Cytology) (Alaggio 2022).
- ABC subtype. Dependent on B-cell receptor and NF-κB signaling, negative for most germinal center markers and positive for IRF4/MUM1. ABC-type DLBCL is enriched for MYD88 and CD79B mutations (Alaggio 2022). It has a worse prognosis with standard therapy (Zanelli 2024).
- Immunohistochemical algorithms. The Hans algorithm uses CD10, BCL6 and MUM1/IRF4, each scored positive at a cutoff of 30% of tumor cells (Oh 2011). Its concordance with GEP is 72%–86%, and 30%–50% of CD10-positive, MUM1-positive cases classified as GCB by Hans are ABC by GEP (Zanelli 2024). The method and the original Hans 2004 cohort are described in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (Hans 2004).
- Molecular clusters. WHO-HAEM5 considered genetic cluster classifications premature (Alaggio 2022).
International Prognostic Index (IPI). The IPI scores 5 adverse factors: age >60 years, elevated LDH, Ann Arbor stage III or IV, ECOG performance status >1 and more than 1 extranodal site. The number of factors assigns low, low-intermediate, high-intermediate and high risk, with 5-year overall survival from about 88% in the low-risk group to 54% in the high-risk group. The revised IPI (R-IPI) uses the same 5 factors in 3 groups: very good (0 factors), good (1–2) and poor (3–5). The NCCN-IPI refines age and LDH categories and counts involvement of marrow, CNS, liver or gastrointestinal tract and lung (Duminuco 2025). In the Hans 2004 cohort, a high IPI (3–5) and the non-GCB phenotype were independent adverse predictors (Hans 2004).
MYC and BCL2 protein (double expressor). MYC is considered positive when ≥40% of tumor nuclei stain and BCL2 when ≥50% of tumor cells stain (Zanelli 2024); the method is in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology. Double-expressor DLBCL without gene rearrangement occurs mainly in the ABC subtype. The poor outcome reported in trials applied to GCB-type double expressors and may reflect TP53 alterations (Zanelli 2024). The ICC de-emphasizes the prognostic significance of double expression alone, and double expression is not a synonym for double-hit lymphoma (Zanelli 2024).
High-grade B-cell lymphomas and LBCL with MYC, BCL2 and BCL6 rearrangements
Table 2. Aggressive B-cell lymphomas with MYC rearrangement or 11q aberration by system (Alaggio 2022; Zanelli 2024; Ferry 2024).
| Genetic finding | WHO-HAEM4R (previous rule) | ICC 2022 | WHO-HAEM5 |
|---|---|---|---|
| MYC and BCL2 rearrangements (with or without BCL6) | HGBL with MYC and BCL2 and/or BCL6 rearrangements (provisional) | HGBL with MYC and BCL2 rearrangements | DLBCL/HGBL with MYC and BCL2 rearrangements, a definite entity that keeps the large, intermediate or blastoid morphology |
| MYC and BCL6 rearrangements without BCL2 | Same category as above | HGBL with MYC and BCL6 rearrangements (provisional; 10%–20% of double-hit cases) | DLBCL, NOS or HGBL, NOS according to cytomorphology |
| 11q gain/loss pattern without MYC rearrangement | Burkitt-like lymphoma with 11q aberration (provisional) | LBCL with 11q aberration (provisional) | HGBL with 11q aberration (definite entity) |
| Blastoid or intermediate morphology without the above | HGBL, NOS | HGBL, NOS | HGBL, NOS |
DLBCL/HGBL with MYC and BCL2 rearrangements. This entity forms 80%–90% of double-hit and triple-hit lymphomas (Zanelli 2024). It has a homogeneous germinal center gene expression profile, a close relationship to FL and dark-zone gene signatures that overlap with Burkitt lymphoma (Alaggio 2022). MYC partners an immunoglobulin locus in about 55% of cases, mainly IGH, less often IGL or IGK. Non-immunoglobulin partners include BCL6 and PAX5 (Zanelli 2024). More than 90% have a GCB phenotype with CD10, BCL6 and BCL2 expression, and 71%–81% are MYC and BCL2 double expressors. A low proliferation index does not exclude the entity (Zanelli 2024). About half of cases are morphologically indistinguishable from DLBCL, NOS, and 5-year survival after R-CHOP is 40%–50% (Zanelli 2024).
TdT expression. TdT is found in 11%–14% of double-hit or triple-hit cases. WHO-HAEM5 and the ICC classify these as DLBCL or HGBL with TdT expression. Such cases have a mature B-cell phenotype, often with surface light chain, and never express CD34. CD34 expression raises the possibility of B-lymphoblastic leukemia/lymphoma (Zanelli 2024).
MYC and BCL6 double-hit cases. These cases more often have a non-GCB phenotype, MUM1-positive and CD10-negative, with MYC in 90% and BCL2 in 20%–80%. In about 30%, BCL6 is the MYC partner (pseudo-double hit) (Zanelli 2024).
HGBL with 11q aberration (LBCL with 11q aberration in the ICC). This aggressive MYC-rearrangement-negative lymphoma has Burkitt-like, intermediate or blastoid morphology. It is CD10-positive, BCL6-positive and BCL2-negative, with a characteristic 11q gain/loss pattern (Alaggio 2022). It occurs mostly in children and young adults in the head and neck or GI tract. Cells are more pleomorphic than in Burkitt lymphoma, and coarse apoptotic debris is characteristic. LMO2 is positive in about 50% and usually negative in Burkitt lymphoma. EBV is not associated (Zanelli 2024). The genetic hallmark is a minimal region of gain at 11q23.3 and loss at 11q24.1. 11q23.3 gain alone does not establish the diagnosis (Zanelli 2024). Its mutational profile resembles GCB-type DLBCL and lacks ID3 and TCF3 alterations, which is the basis of the ICC name (Zanelli 2024; Alaggio 2022).
HGBL, NOS. HGBL, NOS is a heterogeneous diagnosis of exclusion composed of medium-sized or blastoid cells. It occurs mainly in older patients with widespread disease (Zanelli 2024). KMT2D (43%) and TP53 (30%) are the most frequent mutations. Of these cases, 54% carry the double-hit gene expression signature without the rearrangements (Alaggio 2022). About 40% of cases are MYC and BCL2 double expressors. A MYC and BCL2 rearrangement or an 11q aberration excludes the diagnosis (Zanelli 2024).
FISH testing strategy. WHO-HAEM5 and the ICC strongly recommend FISH for MYC, BCL2 and BCL6 in all LBCL. High-grade morphology alone is inadequate for screening, because about 10% of morphologically typical DLBCL carry a MYC rearrangement (Zanelli 2024). Testing starts with a sensitive MYC break-apart probe, followed by BCL2 and BCL6. MYC::IGH dual-fusion probes added to break-apart probes detect 4%–12% of MYC rearrangements missed by break-apart alone (Zanelli 2024). Neither system requires identification of the MYC partner. Copy number gains of MYC, BCL2 or BCL6 are not equivalent to rearrangements (Zanelli 2024). Burkitt-like lymphomas without MYC rearrangement are tested for the 11q gain/loss pattern (Alaggio 2022).
Burkitt lymphoma
Epidemiologic and EBV-defined subtypes. The endemic, sporadic and immunodeficiency-associated subtypes differ in EBV association: about 95% of endemic BL, 20%–30% of sporadic BL and 25%–40% of immunodeficiency-associated BL are EBV-positive (Zanelli 2024). WHO-HAEM5 recommends distinguishing EBV-positive from EBV-negative BL, because the 2 groups differ biologically regardless of epidemiologic setting. The mutational differences between EBV-positive and EBV-negative BL are listed in Burkitt Lymphoma (Cytology).
Clinical sites. Endemic BL affects children in equatorial Africa and South America and involves the jaw and facial bones in younger children and the ileocecal region in older children. Sporadic BL occurs worldwide with age peaks at about 10, 40 and 70 years and favors the abdomen. Immunodeficiency-associated BL occurs mainly with HIV and involves nodes and marrow more often (Zanelli 2024).
Morphology, phenotype and genetics. BL shows a diffuse proliferation of uniform medium-sized cells with round nuclei, multiple small nucleoli and deeply basophilic, lipid-vacuolated cytoplasm on Giemsa staining. Numerous mitoses and a starry-sky pattern are typical (Zanelli 2024). The cells express CD20, CD79a, PAX5, CD19, IgM with light-chain restriction, CD10, BCL6 and strong MYC. BCL2 is negative or rarely weak, and TdT and cyclin D1 are negative (Zanelli 2024). MYC partners IGH in t(8;14)(q24;q32) in about 80%, IGK in t(2;8)(p12;q24) in about 15% and IGL in t(8;22)(q24;q11) in about 5% of cases. A BCL2 or BCL6 translocation excludes BL (Zanelli 2024). The ICC classifies cases previously reported as TdT-positive BL as B-lymphoblastic leukemia/lymphoma with MYC rearrangement (Zanelli 2024). Intensive multi-agent chemotherapy gives overall survival close to 90% (Zanelli 2024). Nearly all Burkitt lymphomas show Ki-67 in almost 100% of cells, and a B-cell lymphoma with a proliferation index below 90% is unlikely to be Burkitt lymphoma (Halcu 2025).
Table 3. Differential diagnosis of Burkitt lymphoma (Zanelli 2024).
| Entity | Distinguishing features |
|---|---|
| B-lymphoblastic leukemia/lymphoma | Scant cytoplasm, absent or barely visible nucleoli; TdT and CD34 positive |
| Blastoid mantle cell lymphoma | Cyclin D1 and SOX11 positive; CD5 not always positive; t(11;14)(q13;q32) |
| HGBL, NOS | Can show BL-like histology and MYC rearrangement; usually CD10 negative and diffusely BCL2 positive |
| DLBCL/HGBL with MYC and BCL2 rearrangements | BCL2 rearrangement present; testing for BCL2 and BCL6 is required in adults with MYC rearrangement |
| HGBL with 11q aberration | More pleomorphic cells; LMO2 positive in about 50%; no MYC rearrangement; 11q gain/loss |
Large B-cell lymphoma subtypes
Table 4. Specific large B-cell lymphomas (Ferry 2024; Alaggio 2022; Zanelli 2024; Liaskas 2025).
| Entity | Defining features |
|---|---|
| T-cell/histiocyte-rich LBCL | Sparse large B cells in abundant T cells and histiocytes; CD8-positive background T cells, no PD-1 rosettes and no follicular dendritic cell meshworks; advanced stage with spleen, liver and marrow involvement (Ding 2024) |
| EBV-positive DLBCL | Most neoplastic cells EBV-positive; no history of lymphoma or specific immunodeficiency other than immunosenescence; ICC requires >80% EBV-positive cells |
| DLBCL associated with chronic inflammation | EBV-positive LBCL in a closed anatomic space after prolonged chronic suppurative inflammation; prototype pyothorax-associated lymphoma; aggressive |
| Fibrin-associated LBCL (WHO-HAEM5 entity) | Almost always EBV-positive; non-mass-forming incidental finding in cysts, pseudocysts, atrial myxoma stroma or blood clots; excellent prognosis after complete excision |
| Fluid overload-associated LBCL (WHO-HAEM5) | Older adults with heart, renal or liver failure or protein-losing enteropathy; body cavity only, most often pleura; mature B-cell phenotype; KSHV/HHV8-negative, EBV-positive in 13%–30%; fairly favorable prognosis |
| Primary mediastinal LBCL | Thymic B-cell origin; young women, median age 35 years; bulky mediastinal mass; B-cell markers with frequent CD30; 9p24.1 amplification and translocation with PD-L1 and PD-L2 overexpression |
| Mediastinal gray zone lymphoma | Spectrum between primary mediastinal LBCL and classic Hodgkin lymphoma; WHO-HAEM5 recognizes classic Hodgkin-like and PMBL-like histology; cases outside the mediastinum are DLBCL, NOS |
| Intravascular LBCL | Lymphoma confined entirely or almost entirely to vessel lumens |
| ALK-positive LBCL | ALK expression with an ALK translocation, most commonly with CLTC (clathrin); poor prognosis |
| Plasmablastic lymphoma | Immunoblastic or plasmablastic cells; CD20 and PAX5 negative (CD20 weak in about 10%); CD38, CD138, MUM1/IRF4, BLIMP1, XBP1 and MYC positive; CD45, CD79a, EMA and CD30 variable; usually EBV-positive with MYC rearrangement; HIV, post-transplant or immunocompetent settings (Lopez 2018) |
| Primary cutaneous DLBCL, leg type | Non-GCB phenotype; the most aggressive primary cutaneous B-cell lymphoma |
| LBCL with IRF4 rearrangement | Children and young adults; Waldeyer ring and cervical nodes; strong MUM1 and BCL6; IG::IRF4; excellent outcome |
| Primary LBCL of immune-privileged sites (WHO-HAEM5) | CNS, vitreoretina and testis in immunocompetent adults usually >60 years; ABC phenotype (CD10-negative, MUM1-positive, BCL6-positive); EBV-negative; concomitant MYD88 and CD79B mutations (full genetic profile in Leukemia, Lymphoma and Plasma Cell Neoplasms in CSF) |
Primary mediastinal LBCL immunophenotype. PMBL expresses pan-B-cell antigens and commonly lacks immunoglobulin. CD30 is expressed in >80% of cases with variable degree and intensity, and CD23, MAL, CD200, PD-L1 and PD-L2 are each positive in ≥70%. CD15 is usually negative (Gibson 2023).
Mediastinal gray zone lymphoma. Classic Hodgkin-like cases show confluent pleomorphic cells in a variable microenvironment with dense fibrosis, uniform strong CD20, PAX5 and at least 1 other B-cell marker, and CD30. PMBL-like cases show monomorphic sheets of cells with strong uniform CD30 and partial or complete loss of B-cell markers, or strong CD15 (Ferry 2024). The ICC excludes EBV-positive cases, and WHO-HAEM5 regards them as extremely rare (Ferry 2024).
Immune-privileged sites. Vitreoretinal LBCL may occur with or after CNS disease, and testicular LBCL tends to relapse in the CNS or the contralateral testis (Alaggio 2022).
KSHV/HHV8-associated B-cell lymphoid proliferations and lymphomas
Table 5. KSHV/HHV8-associated lesions (Ferry 2024; Alaggio 2022).
| Entity | Defining features |
|---|---|
| Primary effusion lymphoma (PEL) and extracavitary PEL | Aggressive KSHV/HHV8-positive large B-cell lymphoma in HIV-positive young to middle-aged men or immunosenescent older adults; pan-B-cell antigens almost always absent; EBV often present, especially with HIV; extracavitary PEL forms a mass, often extranodal |
| KSHV/HHV8-positive DLBCL | Immunocompromised patients; lymph nodes and spleen; IgM-positive and EBV-negative cells |
| KSHV/HHV8-positive germinotropic lymphoproliferative disorder | Older adults without specific immunodeficiency; HHV8-positive large B cells colonize germinal centers; usually EBV coinfected; mostly indolent |
| KSHV/HHV8-associated multicentric Castleman disease | HHV8-positive IgM λ plasmablasts in follicle mantles, with systemic symptoms of hypercytokinemia; HIV-positive and HIV-negative patients |
Distinction between nodal extracavitary PEL and KSHV/HHV8-positive DLBCL is difficult and may be arbitrary, and WHO-HAEM5 recommends multidisciplinary resolution of overlapping cases (Alaggio 2022).
Lymphoid proliferations and lymphomas associated with immune deficiency and dysregulation
WHO-HAEM5 framework. WHO-HAEM5 replaces setting-specific chapters (inborn errors, HIV, post-transplant, other iatrogenic) with a single framework and a 3-part diagnosis: histologic diagnosis, presence or absence of oncogenic virus and the immune deficiency/dysregulation setting (Alaggio 2022). The ICC keeps the WHO-HAEM4R PTLD categories and a separate category of other iatrogenic immunodeficiency-associated lymphoproliferative disorders (Ferry 2024).
Table 6. Immunodeficiency-associated lymphoproliferations by system (Alaggio 2022; Ferry 2024).
| WHO-HAEM4R and ICC 2022 | WHO-HAEM5 |
|---|---|
| Non-destructive PTLD: plasmacytic hyperplasia, infectious mononucleosis-type and florid follicular hyperplasia PTLD | Hyperplasia (type specified) arising in immune deficiency/dysregulation |
| Polymorphic PTLD | Polymorphic lymphoproliferative disorder arising in immune deficiency/dysregulation |
| Monomorphic PTLD (B-cell and T/NK-cell types, classified as the corresponding lymphoma) | Lymphoma arising in immune deficiency/dysregulation, classified as in immunocompetent patients |
| Classic Hodgkin lymphoma PTLD | Classic Hodgkin lymphoma with virus and setting specified |
| EBV-positive mucocutaneous ulcer (outside the immunodeficiency chapter in the ICC) | Mucocutaneous ulcer within the framework |
| EBV-positive polymorphic B-cell lymphoproliferative disorder, NOS (ICC only; with or without known immunodeficiency) | Polymorphic lymphoproliferative disorder when immunodeficiency is known; no equivalent in immunocompetent patients |
Under WHO-HAEM5, an EBV-positive monomorphic PTLD consistent with DLBCL is reported as "DLBCL, EBV-positive, post-transplant" (Ferry 2024). The settings named in the framework are inborn error of immunity, HIV infection, post-transplant (solid organ or marrow), autoimmune disease, iatrogenic or therapy-related immunosuppression and immune senescence (Alaggio 2022). The same histologic lesion can behave differently in different settings, which is why the setting is a required part of the diagnosis (Alaggio 2022).
EBV-positive mucocutaneous ulcer. Both systems describe a typically single ulcer. WHO-HAEM5 accepts multiple lesions within 1 anatomic site, whereas the ICC assigns more than 1 lesion to another EBV-positive lymphoproliferative disorder (Ferry 2024).
Lymphomatoid granulomatosis. Lymphomatoid granulomatosis is an EBV-positive angiocentric and angiodestructive proliferation of large B cells in the lungs and sometimes other extranodal sites. The ICC and WHO-HAEM5 both require absence of a specific underlying immunodeficiency (Ferry 2024). Grading counts EBV-positive large B cells per high-power field: grade 1, fewer than 5; grade 2, 5–50 with focal necrosis; grade 3, more than 50 with extensive necrosis (Ferrara 2024; Lee 2026). Grading of skin lesions is not encouraged, because their pathobiology appears unrelated to EBV. Spontaneous recovery occurs in about 20% of patients with grade 1 disease (Ferrara 2024).
Classic Hodgkin lymphoma-like lesions in immune deficiency. EBV-positive HRS-like cells occur in lymphoproliferations of immune deficiency and in nodal T-follicular helper cell lymphomas. WHO-HAEM5 advises caution before diagnosing classic Hodgkin lymphoma in an immune deficiency setting or in purely extranodal lesions (Alaggio 2022).
Classic Hodgkin lymphoma
Definition of classic Hodgkin lymphoma. Classic Hodgkin lymphoma (CHL) is a group of B-cell neoplasms derived from germinal center B cells, with few tumor cells in a reactive microenvironment rich in immune cells. The defining immunophenotype of Hodgkin and Reed–Sternberg (HRS) cells and the criteria for the 4 subtypes are unchanged from WHO-HAEM4R, and the ICC keeps the same subtypes (Alaggio 2022; Ferry 2024). CHL accounts for about 90%–95% of Hodgkin lymphoma (Carbone 2025). WHO-HAEM5 moved Hodgkin lymphoma next to the mature B-cell neoplasms (Ferry 2024). Subtypes have lost most prognostic relevance with modern treatment and are still reported for epidemiologic and translational purposes (Alaggio 2022).
HRS cells. HRS cells measure 15–45 μm, are binucleated or multinucleated and have large eosinophilic inclusion-like nucleoli. Mononuclear Hodgkin cells, mummified cells, lacunar cells and anaplastic variants also occur (Carbone 2025).
Immunophenotype. HRS cells are strongly CD30-positive and MUM1-positive, CD15-positive in a subset and dimly PAX5-positive. CD20 and CD79a are most often negative but may be variably expressed (Ding 2024). HRS cells lack CD45 (Carbone 2025). OCT2 and BOB1 are more often positive in lymphocyte-rich CHL than in other subtypes (Ding 2024). Fascin, GATA3 and STAT6 are more often positive in HRS cells than in lymphocyte predominant (LP) cells of NLPHL (Ding 2024).
Genetics. HRS cells show alterations in the NF-κB and JAK/STAT pathways, including SOCS1 mutations, and 9p24.1 aberrations with JAK2 amplification and increased PD-1 ligand expression. TNFAIP3 or NFKBIA aberrations, rare in LP cells, are characteristic of HRS cells (Ding 2024).
Table 7. Subtypes of classic Hodgkin lymphoma (Carbone 2025; Ding 2024).
| Subtype | Histology | Clinical and EBV features |
|---|---|---|
| Nodular sclerosis | Fibrous bands dividing the node into nodules; lacunar HRS cells; eosinophils, plasma cells and neutrophils | Most common subtype; adolescents and young adults |
| Mixed cellularity | Diffuse infiltrate with classic HRS cells, eosinophils, histiocytes, plasma cells and small lymphocytes; no fibrous bands | Older adults and immunocompromised patients, especially HIV; strongly EBV-associated |
| Lymphocyte-rich | Usually nodular, with regressed germinal centers, intact mantle zones and HRS cells in the marginal zone around regressed follicles; few plasma cells and eosinophils | Older patients, male predominance; indolent course; prognosis somewhat better than other CHL subtypes |
| Lymphocyte-depleted | Numerous pleomorphic HRS cells with scant reactive cells and diffuse fibrosis | Least common; elderly and HIV-positive patients; frequently EBV-associated; worst prognosis |
Nodular lymphocyte predominant Hodgkin lymphoma (WHO-HAEM5) / nodular lymphocyte predominant B-cell lymphoma (ICC)
Terminology. WHO-HAEM5 keeps the name NLPHL within Hodgkin lymphoma to avoid interfering with clinical trials and considers NLPBL acceptable in preparation for a future change (Alaggio 2022). The ICC uses NLPBL and places it with the large B-cell lymphomas (Ferry 2024).
Clinical features. NLPHL accounts for about 5%–10% of Hodgkin lymphoma and affects patients aged 30–50 years with a male predominance. It usually presents with localized cervical, axillary or inguinal lymphadenopathy. About 20% present with advanced stage, and transformation to DLBCL occurs in 5%–10% (Carbone 2025; Ding 2024).
Morphology and phenotype. NLPHL has a nodular, or nodular and diffuse, pattern with enlarged follicular structures and expanded follicular dendritic cell meshworks. LP (popcorn) cells have large multilobated nuclei and nucleoli smaller than those of HRS cells (Ding 2024). LP cells strongly express OCT2 and BOB1, express CD20, CD79a, PAX5, PU.1, BCL6 and MEF2B and are usually MUM1-negative and CD10-negative. They are EBER-negative in 95%–97% of cases, and IgD is positive in 27%, particularly in young men (Ding 2024). PD-1-positive T follicular helper cells form tight rosettes around LP cells, and CD57-positive cells are common (Ding 2024). LP cells rarely express weak CD30 or CD15 (Ding 2024). Ultrasensitive κ/λ in situ hybridization can show light-chain restriction in LP cells but not in HRS cells (Ding 2024).
Table 8. Immunomorphologic patterns of NLPHL and the ICC grade (Alaggio 2022; Ding 2024; Ferry 2024).
| Fan pattern | Description | ICC grade |
|---|---|---|
| A | Classic B-cell-rich nodular | 1 |
| B | Serpiginous/interconnected nodular | 1 |
| C | Prominent extranodular LP cells | 1 |
| D | T-cell-rich nodular | 2 |
| E | Diffuse, T-cell/histiocyte-rich LBCL-like or DLBCL-like | 2 |
| F | Diffuse, moth-eaten, B-cell-rich | 2 |
Patterns A and B make up about 75% of cases (Ding 2024). Variant patterns C, D and E have been associated with more aggressive behavior (Alaggio 2022). WHO-HAEM5 describes the patterns without assigning grades (Ferry 2024).
Pattern E versus T-cell/histiocyte-rich LBCL. Residual nodules, scattered small B cells, remnants of follicular dendritic cell meshworks and PD-1-positive rosettes favor NLPHL pattern E. A CD8-predominant T-cell background with more histiocytes, fine fibrosis and necrosis favors T-cell/histiocyte-rich LBCL. Some cases cannot be separated on a small biopsy (Ding 2024; Alaggio 2022).
Relation to progressive transformation of germinal centers. Progressive transformation of germinal centers may precede, follow or accompany NLPHL. Isolated progressive transformation is not a significant risk for later NLPHL (Ding 2024).
Lymphoma staging and response: Lugano 2014
Lugano classification as the staging standard. Staging and response assessment of Hodgkin and non-Hodgkin lymphoma follow the Lugano classification (Cheson 2014). It modifies the Ann Arbor classification. A and B symptom suffixes are required only for Hodgkin lymphoma, and the Ann Arbor X designation for bulky disease is no longer used (Yoo 2022). Lugano 2014 remains current (Lugano Workshop 2025).
Bulky disease. For Hodgkin lymphoma, bulk is a single nodal mass of 10 cm or more, or a mass greater than one third of the transthoracic diameter at any level of the thoracic vertebrae on CT. No single size is defined for non-Hodgkin lymphoma; 6 cm has been suggested for follicular lymphoma and 6–10 cm for DLBCL, and the largest tumor diameter is recorded in place of the X designation (Cheson 2014). Tonsils, Waldeyer ring and spleen count as nodal tissue, and the E designation applies only to limited extranodal disease (Cheson 2014).
Imaging and marrow biopsy. FDG PET-CT is the standard for staging and response in Hodgkin lymphoma and FDG-avid non-Hodgkin lymphomas. Contrast-enhanced CT is used for histologies with low or variable FDG avidity. Focal nodal or extranodal uptake on PET-CT is considered involvement (Yoo 2022). Marrow biopsy is no longer indicated in PET-CT-staged Hodgkin lymphoma. In DLBCL, it is needed only when PET-CT is negative and identification of discordant histology would change management. Other histologies retain unilateral marrow biopsy (Yoo 2022).
Table 9. Lugano 2014 staging, a modification of Ann Arbor (Yoo 2022; Cheson 2014).
| Stage | Definition |
|---|---|
| I (limited) | 1 node or a group of adjacent nodes, or a single extranodal lesion without nodal involvement |
| II (limited) | 2 or more nodal groups on the same side of the diaphragm |
| I or II with E (limited) | Nodal stage I or II with limited contiguous extranodal involvement |
| II bulky | Stage II with bulky disease; treated as limited or advanced according to histology and prognostic factors (Cheson 2014) |
| III (advanced) | Nodes on both sides of the diaphragm, or nodes above the diaphragm with spleen involvement |
| IV (advanced) | Additional noncontiguous extralymphatic involvement |
Table 10. Deauville 5-point scale and metabolic response (Yoo 2022).
| Score | Definition |
|---|---|
| 1 | No uptake |
| 2 | Uptake ≤ mediastinum |
| 3 | Uptake > mediastinum but ≤ liver |
| 4 | Uptake moderately increased compared with liver |
| 5 | Uptake markedly increased compared with liver and/or new lesions |
| X | New areas of uptake unlikely to be related to lymphoma |
Complete metabolic response is a score of 1, 2 or 3 at nodal or extranodal sites with or without a residual mass. A score of 4 or 5 with reduced uptake from baseline is a partial metabolic response. A score of 4 or 5 with no significant change is no metabolic response. A score of 4 or 5 with increased uptake, or new FDG-avid foci, is progressive metabolic disease (Yoo 2022). End-of-treatment PET-CT is generally performed 6–8 weeks after completion of therapy, and routine surveillance scans after remission are discouraged, especially in DLBCL and Hodgkin lymphoma (Yoo 2022).
Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas
Definition and classification. The 5th edition of the WHO Classification of Haematolymphoid Tumours (WHO-HAEM5) places mature T-cell and NK-cell neoplasms within "T-cell and NK-cell lymphoid proliferations and lymphomas" and groups them into 9 families by cell of origin, clinical scenario, site and cytomorphology. T-cell and NK-cell neoplasms are not separated into 2 categories, because extranodal NK/T-cell lymphoma, EBV-positive nodal T- and NK-cell lymphoma and chronic active EBV disease include NK, T, hybrid or indeterminate phenotypes (Alaggio 2022).
Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (T-cell clonality by flow cytometry, TRBC1 and the T-cell IHC panel) Related page: Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow (paracortical hyperplasia, Kikuchi disease, ALPS and dermatopathic lymphadenopathy) Related page: Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging (classic Hodgkin lymphoma and EBV-positive B-cell proliferations in immune deficiency) Related page: B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease (T-lymphoblastic lymphoma and indolent T-lymphoblastic proliferation) Related page: Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen (hemophagocytosis in tissue and red pulp lymphoma patterns) Related page: Peripheral T-Cell Lymphomas and Anaplastic Large Cell Lymphoma in Cytology (nodal T-cell lymphoma classification and TRBC1 on FNA) Related page: Metastases, Lymphoma, Breast Implant-Associated ALCL and Axillary Node Cytology (BIA-ALCL in seroma fluid) Related page: Angiosarcoma, Lymphoma and Metastases in the Breast (BIA-ALCL histology, capsule and staging) Related page: Benign Mesenchymal and Inflammatory Lesions of the Breast (implant capsule findings) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (intestinal T- and NK-cell lymphomas and indolent GI lymphoproliferations) Related page: Small Intestinal Mucosal Disease: Celiac Disease and Its Mimics, Infections, Drug Injury and Immune Enteropathies (refractory celiac disease and enteropathy-associated T-cell lymphoma) Related page: Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma (hepatosplenic T-cell lymphoma in liver biopsies) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (HLH-2004 criteria and the 2024 revision, neutropenia and lymphocytosis workup) Related page: Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products (extracorporeal photopheresis for Sézary syndrome) Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (large granular lymphocytes and Sézary cells on the smear)
Mature T- and NK-cell neoplasms in WHO-HAEM5 and ICC 2022, with WHO-HAEM4R as the previous rule
Table 1. Entities whose names or status differ between WHO-HAEM4R, the International Consensus Classification (ICC 2022) and WHO-HAEM5 (Campo 2022; Ferry 2024; Alaggio 2022; Ondrejka 2025).
| WHO-HAEM4R (2017, previous rule) | ICC 2022 | WHO-HAEM5 |
|---|---|---|
| Angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma and nodal peripheral T-cell lymphoma (PTCL) with T-follicular helper (TFH) phenotype | Follicular helper T-cell lymphoma (FhTCL): angioimmunoblastic type, follicular type, NOS | Nodal T-follicular helper cell lymphoma (nTFHL): angioimmunoblastic-type (nTFHL-AI), follicular-type (nTFHL-F), NOS (nTFHL-NOS) |
| T-cell large granular lymphocytic leukemia | T-cell large granular lymphocytic leukemia | T-large granular lymphocytic leukemia (T-LGLL) |
| Chronic lymphoproliferative disorder of NK cells (provisional) | Chronic lymphoproliferative disorder of NK cells (definite) | NK-large granular lymphocytic leukemia (NK-LGLL) |
| Anaplastic large cell lymphoma (ALCL), ALK-positive; ALCL, ALK-negative | Same names | ALK-positive ALCL; ALK-negative ALCL |
| Breast implant-associated ALCL (provisional) | Definite entity | Definite entity |
| EBV-positive nodal T/NK lymphoma within PTCL, NOS | Primary nodal EBV-positive T-cell/NK-cell lymphoma (provisional) | EBV-positive nodal T- and NK-cell lymphoma |
| Extranodal NK/T-cell lymphoma, nasal type | Same name | Extranodal NK/T-cell lymphoma |
| Chronic active EBV infection of T- and NK-cell type, systemic form | Chronic active EBV disease, systemic (T- and NK-cell phenotype) | Systemic chronic active EBV disease |
| Hydroa vacciniforme-like lymphoproliferative disorder | Hydroa vacciniforme lymphoproliferative disorder, classic and systemic | Same as ICC |
| Refractory celiac disease type II discussed only | Included under enteropathy-associated T-cell lymphoma | Discussed only |
| No counterpart (cases classified as PTCL, NOS) | No counterpart | Primary cutaneous peripheral T-cell lymphoma, NOS |
T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, Sézary syndrome, aggressive NK-cell leukemia, mycosis fungoides, enteropathy-associated and monomorphic epitheliotropic intestinal T-cell lymphomas, hepatosplenic T-cell lymphoma and PTCL, NOS keep their names in both systems (Ferry 2024). WHO-HAEM5 lists Sézary syndrome with the mature T- and NK-cell leukemias. The ICC lists it beside mycosis fungoides (Piccaluga 2023).
Diagnostic approach to a nodal T-cell lymphoma
Immunohistochemical sequence. An initial panel separates B-cell lymphoma, Hodgkin lymphoma and reactive processes from T-cell lymphoma (CD3, CD5, CD4, CD8, CD10, CD20, CD21, CD30, CD45 and PAX5). Additional T-cell antigens, TFH markers, cytotoxic markers, TCRγ, TCRβF1, ALK, TCL1, TdT, CD56 and EBER in situ hybridization follow (Ondrejka 2025).
- CD30 branch. Strong uniform CD30 suggests ALCL, and ALK separates ALK-positive from ALK-negative ALCL. The ALK-negative differential includes ATLL, mycosis fungoides with large cell transformation, extranodal T-cell lymphomas in a node and PTCL, NOS with CD30 in >80% of cells (Ondrejka 2025).
- TFH branch. PD-1, CXCL13, ICOS, BCL6 and CD10 are the recommended TFH markers. A TFH phenotype ideally requires 3 markers, and 2 convincingly expressed markers are acceptable in the right context (Ondrejka 2025). WHO-HAEM5 defines the TFH phenotype as at least 2 TFH markers in addition to CD4 (Alaggio 2022).
- Cytotoxic branch. In CD8-positive, CD4/CD8 double-negative or non-TFH CD4-positive lymphomas, TIA1, granzyme B and perforin are assessed with a positivity threshold of >50% of tumor cells. A cytotoxic lymphoma raises the possibility of nodal spread of an extranodal T- or NK-cell lymphoma, and EBER separates cytotoxic PTCL, NOS from EBV-positive nodal T/NK lymphoma. A non-cytotoxic, non-TFH lymphoma is classified as PTCL, NOS (Ondrejka 2025).
- Immaturity. Monotonous blast-like cells, or dual CD4/CD8 positivity or negativity, prompt TdT, CD34 and CD1a to exclude T-lymphoblastic lymphoma and indolent T-lymphoblastic proliferation (Ondrejka 2025).
Flow cytometry and molecular studies. TRBC1/TRBC2 restriction is assessed as described in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology. γδ T cells lack both isoforms, and TRBC1 cannot be interpreted when surface CD3 is lost (Ondrejka 2025). Features favoring T-cell lymphoma over reactive hyperplasia include loss of surface CD3, CD7 or CD5, CD4-positive CD10-positive T cells, monotypic TRBC1/TRBC2 and a clonal TR rearrangement. Isolated TET2 or DNMT3A variants may reflect clonal hematopoiesis and are interpreted with caution (Ondrejka 2025).
Nodal T-follicular helper cell lymphomas
Shared features of the nTFHLs. The 3 entities share the phenotype, gene expression signature and mutation profile of T-follicular helper (TFH) cells, with clinical and immunophenotypic overlap and plasticity (Alaggio 2022). Together they make up 27% of PTCL, with a median age of 60–65 years (Ondrejka 2025). On core biopsies, the generic term nTFHL is recommended to avoid misclassification from limited sampling (Alaggio 2022). Nodal involvement by cutaneous T-cell lymphoma must be excluded in both systems (Ondrejka 2025).
Angioimmunoblastic type. The node is effaced by a polymorphous infiltrate of small to medium atypical cells with clear cytoplasm, small lymphocytes, histiocytes, immunoblasts, eosinophils and plasma cells. Arborizing high endothelial venules and disrupted, proliferated follicular dendritic cell (FDC) meshworks are characteristic (Ondrejka 2025). Pattern 1 shows large hyperplastic germinal centers with attenuated mantles and perifollicular clear cells, and pattern 2 shows regressed follicles that mimic Castleman disease (Ondrejka 2025). Patients have B symptoms, generalized lymphadenopathy, polyclonal hypergammaglobulinemia, hemolytic anemia, skin rash and rheumatologic symptoms (Ondrejka 2025).
EBV-positive B cells. EBV-positive B blasts and plasma cells, polyclonal or clonal, are common in nTFHL. Large CD30-positive B cells may resemble HRS cells, and some patients develop aggressive EBV-positive B-cell proliferations (Ondrejka 2025).
Genetics. The stem-cell origin of TET2 and DNMT3A mutations and the TFH-cell origin of RHOA and IDH2 mutations are described in Peripheral T-Cell Lymphomas and Anaplastic Large Cell Lymphoma in Cytology (Alaggio 2022). TET2 is mutated in 30%–40% of nTFHL-AI, and RHOA G17V is the most common hotspot (Piccaluga 2023). IDH2 R172 mutations, CD28 fusions with ICOS or CTLA4 and ITK::SYK also occur (Ondrejka 2025).
Table 2. Nodal TFH-cell lymphomas (Alaggio 2022; Ondrejka 2025; Piccaluga 2023).
| Entity (ICC term) | Architecture and follicular dendritic cells | Characteristic genetics |
|---|---|---|
| nTFHL-AI (FhTCL, angioimmunoblastic type) | Effaced node; polymorphous infiltrate with clear cells; arborizing high endothelial venules; expanded and disrupted FDC meshworks | TET2, DNMT3A, RHOA G17V, IDH2 R172 |
| nTFHL-F (FhTCL, follicular type) | Follicular lymphoma-like or progressive transformation of germinal center-like nodules of atypical pale cells surrounded by mantle-type small lymphocytes | t(5;9)(q33;q22) with ITK::SYK in a subset |
| nTFHL-NOS (FhTCL, NOS) | Diffuse sheets or T-zone pattern without FDC expansion | Profile similar to nTFHL-AI |
Peripheral T-cell lymphoma, NOS
Definition. PTCL, NOS remains a heterogeneous diagnosis of exclusion whose differential includes the nTFHLs (Alaggio 2022). It makes up 26%–27% of PTCL with a median age of 60 years. The cells range from small and irregular to medium or large, with variable loss of pan-T-cell antigens, CD4, CD8, double-positive or double-negative profiles, αβ more often than γδ TCR and LEF1 expression. The Lennert pattern occurs in <10% (Ondrejka 2025).
Biologic variants. PTCL-TBX21 and PTCL-GATA3 reflect T-helper 1 and T-helper 2 programs. PTCL-GATA3 has a uniform genetic profile, and PTCL-TBX21 is heterogeneous with a cytotoxic, aggressive subgroup. WHO-HAEM5 does not grant them formal subtype status (Alaggio 2022). PTCL-GATA3 has a worse prognosis and complex genetics. An IHC algorithm with TBX21, CXCR3, GATA3 and CCR4 approximates the 2 groups (Piccaluga 2023).
Anaplastic large cell lymphomas
ALCL family in WHO-HAEM5. ALCLs are mature T-cell lymphomas of pleomorphic cells with uniform strong CD30 and often defective T-lineage antigen expression. WHO-HAEM5 includes ALK-positive ALCL, ALK-negative ALCL and breast implant-associated ALCL (BIA-ALCL). Primary cutaneous ALCL belongs to the primary cutaneous T-cell lymphoid proliferations (Alaggio 2022).
Table 3. Anaplastic large cell lymphomas (Ondrejka 2025; Wu 2023; Alaggio 2022).
| Feature | ALK-positive ALCL | ALK-negative ALCL | BIA-ALCL |
|---|---|---|---|
| Frequency and age | 16% of PTCL; median age 30–35 years | 8%–9% of PTCL; median age 54 years | Associated with textured-surface implants |
| Morphology | Hallmark cells with horseshoe nuclei; common, lymphohistiocytic, small cell, Hodgkin-like and spindle cell patterns; sinusoidal spread | Hallmark cells; common pattern | Usually noninvasive |
| Phenotype | CD30, ALK, EMA; often CD2, CD4, CD43 and cytotoxic markers; CD3, CD5 and CD7 frequently lost; EBV negative | Strong uniform CD30; partial T-antigen loss; EMA and cytotoxic markers variable | CD30-positive T cells; PD-L1 overexpression with 9p24.1 amplification in >50% |
| Genetics | NPM1::ALK from t(2;5)(p23;q35) in about 80%, nuclear and cytoplasmic ALK; TPM3::ALK t(1;2)(q25;p23) in about 15%, cytoplasmic ALK | DUSP22 rearrangement in 20%–30%; TP63 rearrangement in 2%–8%; JAK-STAT activation | STAT3, STAT5B, JAK1 and JAK2 activating mutations; SOCS1 and SOCS3 loss-of-function mutations |
| Outcome | Better than ALK-negative ALCL | Poor with TP63 rearrangement, TP53 loss or IL-2Rα overexpression | Excellent when noninvasive; worse with invasion of adjacent structures |
ALK-negative ALCL subgroups. DUSP22-rearranged ALCL shows "doughnut" cells, sheet-like growth and less pleomorphism, and LEF1 expression may serve as a surrogate marker (Alaggio 2022). Its prognosis is disputed. The ICC recommends DUSP22 FISH because the subgroup is important biologically and for prognosis (Ondrejka 2025), its prognosis is listed as mostly favorable (Fend 2024), and 5-year overall survival of about 85%–90% has been reported (Wu 2023). WHO-HAEM5 states that the initially reported survival comparable to ALK-positive ALCL was not confirmed by more recent studies (Alaggio 2022). Strong uniform LEF1 has high positive and negative predictive value for the rearrangement (Ondrejka 2025). TP63-rearranged cases, often TBL1XR1::TP63 from inv(3)(q26q28), had a 5-year overall survival of 17% (Wu 2023). DUSP22 and TP63 rearrangements are mutually exclusive (Wu 2023). Truncated ERBB4 is expressed in about 25% of ALK-negative ALCL, often with Hodgkin-like morphology, and JAK2-rearranged cases are more anaplastic (Wu 2023; Alaggio 2022).
BIA-ALCL. BIA-ALCL is usually a noninvasive neoplasm associated with textured-surface implants, and a TH2 allergic inflammatory response is implicated (Alaggio 2022).
Primary cutaneous ALCL. Primary cutaneous ALCL has the phenotype of ALK-negative ALCL with CD30 in >75% of tumor cells, and no systemic ALCL may be present at diagnosis or within 6 months. About 30% carry a DUSP22 rearrangement, and 10-year overall survival is about 90% (Ortiz-Hidalgo 2023).
Mature T-cell and NK-cell leukemias
T-prolymphocytic leukemia (T-PLL). Unified diagnostic criteria require T lymphocytosis >5 × 10⁹/L with an appropriate phenotype, T-cell monoclonality and a structural variant involving TCL1A or MTCP1 or expression of TCL1 (Alaggio 2022). Prolymphocytes are of moderate size with an irregular nuclear membrane, a single prominent nucleolus and basophilic cytoplasm with blebs (Piccaluga 2023). inv(14) or t(14;14) is found in about 77% of patients. The cells are TdT- and CD1a-negative and CD2-, CD3-, CD5- and CD7-positive, with weak membrane CD3 in some cases, high CD52 and possible CD4/CD8 coexpression (Piccaluga 2023). MTCP1 at Xq28 is homologous to TCL1A/TCL1B. JAK/STAT mutations occur in up to 75% and ATM deletion or mutation is common. TCL1 rearrangement by FISH or TCL1 expression is diagnostic (Fend 2024).
T-large granular lymphocytic leukemia (T-LGLL). T-LGLL is a clonal expansion of large granular lymphocytes that infiltrate marrow, spleen and liver (Piccaluga 2023). The diagnosis is suspected when blood LGLs exceed 2 × 10⁹/L, and clonality is confirmed by TCRγ PCR, the preferred method. Flow cytometric Vβ analysis is less sensitive (Park 2023). Typical cells are CD3-, TCRαβ-, CD8-, CD16-, CD45RA- and CD57-positive and CD4-, CD27-, CD28- and CD45RO-negative with dim CD5. CD5 and/or CD7 loss is common, and CD57 and CD16 are expressed in >80% (Park 2023). CD4-positive and TCRγδ-positive cases are uncommon variants. Marrow involvement is interstitial or intrasinusoidal, usually <50% of cellularity, and is best shown with CD3, CD8 and CD57 immunostains (Park 2023). About 50% of patients have neutropenia and about 20% severe neutropenia, and rheumatoid arthritis occurs in about 15% (Park 2023). STAT3 sequence alterations are present in about 40% (Park 2023). STAT3 mutation is found preferentially in CD8-positive and γδ T-LGLL and is associated with neutropenia and poorer survival. STAT5B mutation occurs in up to 30% of CD4-positive T-LGLL and is adverse only in CD8-positive cases (Alaggio 2022).
NK-large granular lymphocytic leukemia (WHO-HAEM5) / chronic lymphoproliferative disorder of NK cells (ICC). The cells are CD2-positive, CD3-, CD4- and CD8-negative, CD16- and CD56-positive, with weak CD57. The median NK-cell count is 2.3 × 10⁹/L, and neutropenia is less severe than in T-LGLL (Piccaluga 2023). WHO-HAEM5 renamed the entity because the expansion is monoclonal or oligoclonal and resembles T-LGLL (Alaggio 2022).
Adult T-cell leukemia/lymphoma (ATLL). ATLL arises from CD4-positive T cells latently infected with HTLV-1 and is most common in endemic areas of Asia and the Caribbean. Generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions and CNS and skin lesions are common (Piccaluga 2023). The cells are FOXP3- and CD25-positive (Ondrejka 2025). The Shimoyama classification divides ATLL into acute, lymphoma, chronic and smoldering types using the blood lymphocyte count, the percentage of abnormal lymphocytes, flower cells, LDH, corrected calcium and organ involvement. The chronic type requires a total lymphocyte count ≥4,000/μL (Fuji 2026). Immune evasion events include CTLA4::CD28 and ICOS::CD28 fusions, REL truncations, HLA-A and HLA-B alterations and structural variants of the CD274 3′ untranslated region. Aggressive subtypes carry more alterations, and STAT3 mutations are more frequent in indolent subtypes (Alaggio 2022). CCR4 expression is an adverse prognostic factor and the target of mogamulizumab in relapsed CCR4-positive disease (Hermine 2018). CCR4 was detected by immunostaining in 91 of 103 cases (88.3%), was associated with skin involvement and was an independent adverse prognostic factor (Ishida 2003). Gain-of-function CCR4 mutations, the most frequent mutations in ATLL, occur in about 30%–40% of cases (Samaha 2026).
Aggressive NK-cell leukemia (ANKL). ANKL affects younger adults (median age 20–40 years) in East Asia and Central and South America and is strongly EBV-associated (Luniewski 2026). Patients present with fever, hepatosplenomegaly, cytopenias, liver dysfunction, disseminated intravascular coagulation and HLH, and median survival without therapy is under 2–3 months (Luniewski 2026). Blood, marrow, liver and spleen are most often involved. The cells are CD2-positive, cytoplasmic CD3ε-positive, surface CD3-negative and CD56-positive with cytotoxic molecules, usually CD4- and CD8-negative, and TCR genes are germline (Luniewski 2026). Mutations involve JAK/STAT, RAS/MAPK, TET2, CREBBP, KMT2D and CD274/PDCD1LG2 (Alaggio 2022). WHO-HAEM5 describes intravascular NK/T-cell lymphoma under ANKL (Alaggio 2022).
Mycosis fungoides and Sézary syndrome
Mycosis fungoides (MF). MF presents with patches, plaques or papules and may progress to tumors and erythroderma (Lee 2023). Patch and plaque lesions show epidermotropism of neoplastic T cells. Small cerebriform lymphocytes line the basal layer in early lesions, and Pautrier microabscesses, uncommon but specific, form as the infiltrate becomes band-like. Tumor-stage lesions show dense dermal nodular or diffuse infiltrates (Lee 2023). The cells are predominantly CD4-positive with a high CD4/CD8 ratio and loss of CD2, CD3, CD5 or CD7 (Lee 2023). Folliculotropic MF, pagetoid reticulosis and granulomatous slack skin remain MF subtypes. WHO-HAEM5 distinguishes early-stage and advanced-stage folliculotropic MF because of their different outcomes (Alaggio 2022). Lymph nodes are the most common extracutaneous site, involved in 30% of MF/SS (Lee 2023).
Sézary syndrome (SS). SS is defined by erythroderma (T4) with >1,000/μL Sézary cells in blood (B2), and its stage ranges from IVA1 to IVB (Lee 2023). Sézary cells have grooved cerebriform nuclei and are usually CD3-, CD4-positive and CD8-negative, with loss of CD7 or CD26. Loss of CD7 or CD26 is sensitive and highly specific for SS (Lee 2023). KIR3DL2 (CD158k) is widely expressed by malignant T cells in advanced MF/SS and is the target of lacutamab (García-Díaz 2021). Required blood findings include a CD4/CD8 ratio ≥10, CD4+CD7− cells ≥40% or CD4+CD26− cells ≥30% and loss of 1 or more T-cell antigens (Piccaluga 2023). Blood stage is the most recently added TNMB component. The 2022 ISCL/USCLC/EORTC update emphasizes absolute counts with clonality subcategories, and the 2023 EORTC update recommends flow cytometry for blood tumor burden (Liao 2026; Lee 2023).
Table 4. Blood classification of MF/SS in the revised TNMB system with the 2022 ISCL/USCLC/EORTC update (Lee 2023).
| Class | Definition |
|---|---|
| B0 | No significant blood involvement: ≤5% Sézary cells; for clinical trials, <250/μL Sézary cells or CD4+CD26− and/or CD4+CD7− cells <15% by flow cytometry |
| B0a | B0, clone negative or equivocal |
| B0b | B0, clone positive and identical to skin |
| B1 | Low blood tumor burden: criteria for B0 or B2 not met |
| B1a | B1, clone negative |
| B1b | B1, clone positive |
| B2 | High blood tumor burden: positive clone plus ≥1,000/μL Sézary cells, CD4/CD8 ≥10, CD4+CD7− cells ≥40% or CD4+CD26− cells ≥30%; for clinical trials, >1,000/μL CD4+CD26− or CD4+CD7− cells |
Table 5. Skin, node and visceral classes and clinical stages of MF/SS (Lee 2023).
| Class or stage | Definition |
|---|---|
| T1 | Patches, plaques or papules <10% of body surface area (T1a patch only; T1b plaque or papule) |
| T2 | Patches, plaques or papules ≥10% of body surface area (T2a patch only; T2b plaque or papule) |
| T3 | 1 or more tumors ≥1 cm |
| T4 | Confluent erythema ≥80% of body surface area |
| N1, N2, N3 | Clinically abnormal nodes with Dutch grade 1, 2 or 3–4 (NCI LN 0–2, LN 3 or LN 4); subclass a clone negative or equivocal, b clone positive |
| M1a, M1b | Marrow-only visceral involvement; non-marrow visceral involvement |
| IA / IB | T1 or T2, N0, M0, B0–B1; median overall survival 35.5 and 21.5 years |
| IIA / IIB | T1–T2 with N1–N2, or T3 with N0–N2; M0, B0–B1 |
| IIIA / IIIB | T4, N0–N2, M0 with B0 (IIIA) or B1 (IIIB) |
| IVA1 / IVA2 / IVB | B2 (IVA1), N3 (IVA2) or M1 (IVB); median overall survival 3.8, 2.1 and 1.4 years |
B1 blood involvement upstages erythrodermic disease from IIIA to IIIB (Liao 2026). In a validation cohort of 1,502 patients, B0b blood status (clone-positive without reaching B1) independently predicted poorer survival and progression (Liao 2026). In advanced disease, age >60 years, stage IV, elevated LDH and large cell transformation are adverse factors in the Cutaneous Lymphoma International Consortium index (Lee 2023). Large cell transformation is defined as large cells in >25% of the lymphoid infiltrate. The large cells are often CD30-positive, and transformation is adverse (Lee 2023; Liao 2026).
Intestinal T-cell and NK-cell lymphoid proliferations and hepatosplenic T-cell lymphoma
Intestinal entities. Indolent T-cell lymphoma and indolent NK-cell lymphoproliferative disorder of the GI tract, enteropathy-associated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) are classified and described in Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine, and refractory celiac disease in Small Intestinal Mucosal Disease: Celiac Disease and Its Mimics, Infections, Drug Injury and Immune Enteropathies. EATL cells are CD3-, CD7- and CD103-positive, CD4-, CD8- and CD5-negative, mostly CD30-positive and CD56-negative, with an activated cytotoxic phenotype (Abdullah 2023). The indolent NK-cell lesion is EBV-negative and carries JAK3 mutations, which separates it from extranodal NK/T-cell lymphoma (Alaggio 2022).
Hepatosplenic T-cell lymphoma (HSTCL). HSTCL is an aggressive extranodal lymphoma with hepatosplenic disease without lymphadenopathy. The cells are CD3-positive, CD56 variably positive, CD4-negative and usually CD5-negative (Piccaluga 2023). About 75% express TCRγδ; the sinusoidal pattern and the full TCR and age distribution are in Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma. MDS-like dyspoiesis in marrow smears has no clinical impact (Alaggio 2022). Isochromosome 7q (80%) and trisomy 8 (50%) occur regardless of αβ or γδ derivation. Inactivating SETD2 mutations (70%) and alterations of other chromatin-modifier genes (INO80, TET3, SMARCA2) are frequent (Fend 2024).
EBV-positive T-cell and NK-cell lymphomas and lymphoproliferations
Extranodal NK/T-cell lymphoma (ENKTL). WHO-HAEM5 drops "nasal type" from the name because the disease presents at many extranodal sites, and the ICC keeps it (Alaggio 2022; Ferry 2024). ENKTL shows an angiocentric and angiodestructive infiltrate with plasma cells, histiocytes and eosinophils and often extensive necrosis. The cells are mostly cytotoxic NK cells, less often T cells, and frequently express cytoplasmic CD3 and CD56. EBV is detected in nearly all cases (Luniewski 2026). Recurrent alterations include 6q21–25 deletion and mutations of JAK-STAT genes, epigenetic regulators, TP53, MGA and DDX3X (Alaggio 2022). L-asparaginase-based chemotherapy with radiotherapy has markedly improved outcomes, and checkpoint inhibitors are active in relapsed disease (Alaggio 2022). Detectable plasma EBV DNA is a component of the PINK-E prognostic model with age >60 years, stage III/IV, non-nasal disease and distant nodal involvement (Chan 2025).
EBV-positive nodal T- and NK-cell lymphoma. This entity was previously a subtype of PTCL, NOS. It occurs mostly in East Asians, presents with lymphadenopathy, advanced stage and B symptoms and has a dismal prognosis (Alaggio 2022). It resembles DLBCL, lacks the coagulative necrosis and angioinvasion of ENKTL, more often has a cytotoxic T-cell than NK-cell phenotype and is EBV-positive by definition. TET2 is the most commonly mutated gene (Alaggio 2022). The cells are usually CD8-positive and CD56-negative, and nasal involvement must be excluded (Ondrejka 2025).
EBV-positive T- and NK-cell lymphoproliferations of childhood. Chronic active EBV disease ranges from localized forms (severe mosquito bite allergy and classic hydroa vacciniforme lymphoproliferative disorder) to systemic disease with fever, hepatosplenomegaly and lymphadenopathy (Alaggio 2022). These disorders occur mainly in Asian and Native American populations (Alaggio 2022). Systemic chronic active EBV disease replaced "chronic active EBV infection, systemic form" because the outcome is usually fatal without hematopoietic stem cell transplantation (Alaggio 2022). Systemic EBV-positive T-cell lymphoma of childhood follows primary EBV infection, presents with fever, hepatosplenomegaly, cytopenias and HLH and progresses to death within days to weeks. Its cytotoxic T cells are usually CD8-positive after acute infection and CD4-positive when the disease arises from systemic chronic active EBV disease (Luniewski 2026). Severe mosquito bite allergy causes necrotizing skin lesions after bites, with EBV-positive NK cells in most cases (Luniewski 2026).
Differential diagnosis of mature T- and NK-cell neoplasms
Table 6. Distinguishing features of mature T- and NK-cell neoplasms.
| Neoplasm | Usual site | Phenotype and EBV status | Genetic hallmark | Source |
|---|---|---|---|---|
| nTFHL-AI | Lymph nodes, systemic | CD4 with ≥2 TFH markers; expanded CD21-positive FDC meshworks; EBV-positive B blasts in the background | TET2, DNMT3A, RHOA G17V, IDH2 R172 | Ondrejka 2025; Alaggio 2022 |
| PTCL, NOS | Nodes and extranodal sites | Variable T-antigen loss; LEF1; TBX21 or GATA3 programs | CDKN2A and PTEN deletions, TP53 alterations | Ondrejka 2025 |
| ALK-positive ALCL | Nodes; median age 30–35 years | CD30, ALK, EMA, cytotoxic markers; EBV negative | NPM1::ALK in about 80% | Ondrejka 2025; Wu 2023 |
| ALK-negative ALCL | Nodes | Strong uniform CD30; EBV negative | DUSP22 or TP63 rearrangement | Ondrejka 2025 |
| T-PLL | Blood, marrow | CD4, CD8 or both; TCL1 | inv(14) or t(14;14) | Piccaluga 2023; Fend 2024 |
| T-LGLL | Blood, marrow, spleen, liver | CD8, CD57, CD16 | STAT3 in about 40% | Park 2023; Piccaluga 2023 |
| ATLL | Blood, nodes, skin | CD4, CD25, FOXP3; HTLV-1 infected | CTLA4::CD28, ICOS::CD28 | Piccaluga 2023; Ondrejka 2025; Alaggio 2022 |
| HSTCL | Spleen, liver, marrow | CD3, variable CD56, CD4 negative; TCRγδ in 75% | i(7q), trisomy 8, SETD2 | Piccaluga 2023; Fend 2024 |
| ENKTL | Nasal and other extranodal sites | Cytoplasmic CD3, CD56, cytotoxic markers; EBV positive | 6q deletion; DDX3X | Luniewski 2026; Alaggio 2022 |
| EBV-positive nodal T/NK lymphoma | Lymph nodes | CD8, cytotoxic markers, CD56 negative; EBV positive | TET2 | Ondrejka 2025; Alaggio 2022 |
| ANKL | Blood, marrow, liver, spleen | Surface CD3 negative, CD56, cytotoxic markers; EBV positive in most | JAK/STAT, RAS/MAPK, TP53 | Luniewski 2026; Piccaluga 2023 |
| MF/SS | Skin, blood | CD4 with CD7 or CD26 loss | TP53, RB1, PTEN, DNMT3A and CDKN1B deletions in SS | Lee 2023; Liao 2026 |
Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases
Definition. Plasma cell neoplasms arise from monoclonal expansion of terminally differentiated, immunoglobulin-secreting B cells. They almost always secrete a monoclonal immunoglobulin (M protein, paraprotein). The group includes monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma of bone, extramedullary plasmacytoma, plasma cell myeloma (multiple myeloma, MM) and rare neoplasms with paraneoplastic syndromes (Chuang 2026). Plasma cell myeloma is a bone marrow-based, multifocal clonal plasma cell proliferation, very frequently with a serum and/or urine M protein and end-organ damage. Its diagnosis integrates pathologic and clinical findings (CAP 2025).
Epidemiology. Multiple myeloma accounts for 1% of all cancers and about 10% of hematologic malignancies. The US age-adjusted incidence is about 4 per 100,000 per year, the median age at diagnosis is about 65 years, and the disease is twice as common in African Americans as in White Americans. Almost all cases evolve from MGUS. MGUS is present in about 5% of people older than 50 years and progresses to myeloma or a related malignancy at about 1% per year (Rajkumar 2024).
Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (serum and urine protein electrophoresis, immunofixation, serum free light chains and the κ/λ ratio, mass spectrometry for M protein, cryoglobulin testing, therapeutic antibody interference) Related page: Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition (renal amyloid typing by mass spectrometry, monoclonal immunoglobulin deposition disease and MGRS lesions in the kidney) Related page: Nephritic and Hematuric Glomerular Diseases: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Infection-Related, Cryoglobulinemic, ANCA and Anti-GBM Glomerulonephritis, Alport Syndrome (cryoglobulinemic glomerulonephritis and proliferative glomerulonephritis with monoclonal immunoglobulin deposits) Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (plasma cell flow cytometry methods, gating and light-chain restriction) Related page: Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia (lymphoplasmacytic lymphoma, Waldenström macroglobulinemia and marginal zone lymphoma with plasmacytic differentiation) Related page: Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging (plasmablastic lymphoma) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (laboratory diagnosis of cold agglutinin hemolysis) Related page: Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor (complement findings in cryoglobulinemia) Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (marrow evaluation and the plasma cell association of VEXAS syndrome) Related page: Diagnostic Enzymes and Serum Tumor Markers (β2-microglobulin and lactate dehydrogenase)
Classification by WHO-HAEM5 and ICC 2022, with WHO-HAEM4R as the previous rule
WHO-HAEM5 names the family "plasma cell neoplasms and other diseases with paraproteins." It groups cold agglutinin disease (CAD), IgM MGUS, non-IgM MGUS and monoclonal gammopathy of renal significance (MGRS) as monoclonal gammopathies. It groups the diseases with abnormal monoclonal immunoglobulin deposits together and moves the heavy chain diseases into the plasma cell section (Alaggio 2022). The ICC prefers the term "multiple myeloma" over "plasma cell myeloma" and divides myeloma into mutually exclusive cytogenetic groups (Campo 2022).
Table 1. Plasma cell neoplasms and paraprotein diseases: WHO-HAEM5 (Alaggio 2022), ICC 2022 (Campo 2022; Ferry 2024) and WHO-HAEM4R (Alaggio 2022, Table 1).
| Disease group | WHO-HAEM5 | ICC 2022 | WHO-HAEM4R (previous rule) |
|---|---|---|---|
| Monoclonal gammopathies | Cold agglutinin disease; IgM MGUS; non-IgM MGUS; MGRS | Primary cold agglutinin disease, IgM MGUS of plasma cell type and IgM MGUS, NOS, listed with lymphoplasmacytic lymphoma among mature B-cell neoplasms; non-IgM MGUS listed under plasma cell neoplasms. MGRS and monoclonal gammopathy of clinical significance (MGCS) are descriptive terms added to the underlying diagnosis | IgM MGUS and non-IgM MGUS; cold agglutinin disease and MGRS not included |
| Myeloma | Plasma cell myeloma | Multiple myeloma (plasma cell myeloma): NOS, or with recurrent genetic abnormality (CCND family translocation, MAF family translocation, NSD2 translocation, hyperdiploidy) | Plasma cell myeloma |
| Plasmacytoma | Plasmacytoma | Solitary plasmacytoma of bone; extraosseous plasmacytoma; minimal marrow involvement incorporated into the diagnosis | Plasmacytoma |
| Monoclonal immunoglobulin deposition | Immunoglobulin-related (AL) amyloidosis; monoclonal immunoglobulin deposition disease | Ig light chain amyloidosis (AL); localized AL amyloidosis; light chain and heavy chain deposition disease | Primary amyloidosis; light chain and heavy chain deposition disease |
| Heavy chain diseases | Mu, gamma and alpha heavy chain disease, placed in the plasma cell section | Mu, gamma and alpha heavy chain disease, listed among mature B-cell neoplasms | Mu, gamma and alpha heavy chain disease |
| Paraneoplastic syndromes | POEMS, TEMPI and AESOP syndromes | POEMS and TEMPI syndromes in a 2024 WHO/ICC comparison (Ferry 2024); not named in the ICC report (Campo 2022) | POEMS syndrome and TEMPI syndrome (provisional); AESOP syndrome not included |
Reporting. The CAP Plasma Cell Malignancies and Immunoglobulin Deposition Related Disorders protocol (version 1.0.0.1, September 2025) bases its final integrated diagnosis on WHO-HAEM5. It covers plasma cell myeloma, smoldering myeloma, solitary plasmacytoma of bone, extramedullary plasmacytoma, plasma cell leukemia, systemic and localized AL amyloidosis, heavy chain amyloidosis, the three types of monoclonal immunoglobulin deposition disease and the three heavy chain diseases. Monoclonal gammopathies (CAD, IgM MGUS and non-IgM MGUS) and plasmablastic lymphoma are reported with other protocols. TEMPI and AESOP syndromes are not case summary entities. The protocol is recommended for clinical care and is not required for accreditation. (CAP 2025).
CAP case summary elements (CAP 2025).
- Site of involvement: non-targeted bone marrow and blood, each with the percentage of clonal cells; targeted bone, lymph node, extranodal or mucosal site with location.
- Final integrated diagnosis. "Plasma cell neoplasm involving bone marrow (clinical information required)" is used when CRAB and biomarker data are unavailable to the pathologist. "Other plasma cell neoplasm" allows a preliminary diagnosis or an ICC diagnosis.
- Immunoglobulin depositions: not detected on H&E, not detected on Congo red, amyloid on Congo red, or non-amyloid deposition.
- Immunohistochemistry, flow cytometry, conventional cytogenetics, FISH and optional molecular alterations. Flow cytometry may markedly underestimate the plasma cell percentage. Antigen intensity is reported semiquantitatively, for example CD20 dim+, CD56+, CD38++ and CD45 −/+ heterogeneous.
- FISH choices: hyperdiploidy; 13q (RB1) deletion; 1q21 gain or amplification; 1p32 (CDKN2C) deletion; t(11;14) CCND1::IGH; t(4;14) FGFR3::IGH; t(14;16) IGH::MAF; t(6;14) CCND3::IGH; t(12;14) CCND2::IGH; t(14;20) IGH::MAFB; t(8;14) MYC::IGH; 17p13 (TP53) deletion.
IMWG diagnostic criteria for MGUS, smoldering myeloma and myeloma, with the IMWG 2003 rule as the previous rule
The 2014 International Myeloma Working Group (IMWG) update added validated biomarkers to the attributable CRAB features (hypercalcemia, renal failure, anemia and bone lesions). The biomarkers identify patients with near-inevitable progression who would otherwise be classified as smoldering myeloma (Rajkumar 2014). WHO-HAEM5 incorporated the updated criteria (CAP 2025).
Table 2. Diagnostic criteria for non-IgM MGUS, smoldering myeloma and multiple myeloma: IMWG 2014 (Rajkumar 2024, Table 1, modified from Rajkumar 2014; CAP 2025, Table 1) and IMWG 2003 (IMWG 2003; Mateos 2020).
| Disorder | IMWG 2014 (current) | IMWG 2003 (previous rule) |
|---|---|---|
| Non-IgM MGUS | All 3: serum non-IgM M protein <3 g/dL; clonal marrow plasma cells <10%; no CRAB attributable to the plasma cell disorder | M protein <3 g/dL and marrow clonal plasma cells <10%, without related organ or tissue impairment (IMWG 2003) |
| Smoldering myeloma | Both: serum IgG or IgA M protein ≥3 g/dL or urinary M protein ≥500 mg/24 h, and/or clonal marrow plasma cells 10%–60%; no myeloma-defining event or amyloidosis | Serum M protein ≥3 g/dL (or urinary ≥500 mg/24 h, or both) and/or marrow plasma cells ≥10%, without CRAB features (Mateos 2020) |
| Multiple myeloma | Both: clonal marrow plasma cells ≥10% or a biopsy-proven bony or extramedullary plasmacytoma, and ≥1 myeloma-defining event (CRAB or a SLiM biomarker) | Symptomatic myeloma required related organ or tissue impairment (CRAB) |
Table 3. Myeloma-defining events, IMWG 2014 (Rajkumar 2024; CAP 2025).
| Event | Threshold |
|---|---|
| Hypercalcemia (C) | Serum calcium >0.25 mmol/L (>1 mg/dL) above the upper limit of normal, or >2.75 mmol/L (>11 mg/dL) |
| Renal insufficiency (R) | Creatinine clearance <40 mL/min or serum creatinine >177 µmol/L (>2 mg/dL) |
| Anemia (A) | Hemoglobin >2 g/dL below the lower limit of normal, or <10 g/dL |
| Bone lesions (B) | ≥1 osteolytic lesion on skeletal radiography, CT or PET-CT |
| Sixty percent (S) | Clonal marrow plasma cells ≥60% |
| Light chains (Li) | Involved/uninvolved serum free light chain ratio ≥100, with involved free light chain ≥100 mg/L |
| MRI (M) | >1 focal lesion ≥5 mm on MRI |
Table 4. Other plasma cell disorders, IMWG (Rajkumar 2024, Table 1).
| Disorder | Criteria |
|---|---|
| IgM MGUS | All 3: serum IgM M protein <3 g/dL; marrow lymphoplasmacytic infiltration <10%; no anemia, constitutional symptoms, hyperviscosity, lymphadenopathy or hepatosplenomegaly attributable to the lymphoproliferative disorder |
| Light-chain MGUS | All: free light chain ratio <0.26 or >1.65; increased level of the involved light chain; no heavy chain on immunofixation; no attributable end-organ damage; clonal marrow plasma cells <10%; urinary M protein <500 mg/24 h |
| Solitary plasmacytoma | All 4: biopsy-proven solitary lesion of bone or soft tissue with clonal plasma cells; normal marrow without clonal plasma cells; normal skeletal survey and MRI (or CT) of spine and pelvis apart from the primary lesion; no attributable CRAB |
| Solitary plasmacytoma with minimal marrow involvement | Criteria for solitary plasmacytoma, with clonal marrow plasma cells <10%. A solitary plasmacytoma with ≥10% clonal marrow plasma cells is classified as multiple myeloma |
| Plasma cell leukemia | Meets myeloma criteria, and ≥5% plasma cells in the white blood cell differential of a conventional blood smear |
ICC definitions. The ICC diagnoses IgM MGUS with an IgM paraprotein, <10% marrow plasma cells and insufficient lymphoplasmacytic aggregates for lymphoplasmacytic lymphoma. IgM MGUS of plasma cell type shows clonal plasma cells without a detectable B-cell component and with wild-type MYD88, including cases with t(11;14) or other myeloma-type abnormalities. It is a precursor of myeloma. IgM MGUS, NOS includes all MYD88-mutated cases and cases with monotypic B cells without diagnostic aggregates. Routine FISH and MYD88 testing are recommended in IgM MGUS (Campo 2022).
Marrow deferral in MGUS. A marrow examination can be deferred in low-risk MGUS (IgG type, M protein <1.5 g/dL, normal free light chain ratio) without clinical features of myeloma (Rajkumar 2024). Measurable disease and non-secretory myeloma are defined in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.
MGUS risk stratification
Mayo model. In 1,148 patients with MGUS followed for a median of 15 years, progression occurred in 7.6%: 9% at 10 years, 20% at 20 years and 30% at 25 years. An abnormal κ/λ free light chain ratio (<0.26 or >1.65) was present in 33% and carried a hazard ratio of 3.5 for progression (Rajkumar 2005).
Table 5. Risk of progression of MGUS at 20 years by the number of adverse factors: serum M protein ≥1.5 g/dL, non-IgG type and abnormal free light chain ratio (Rajkumar 2005).
| Risk group | Adverse factors | Patients (n) | Relative risk | Absolute risk at 20 years |
|---|---|---|---|---|
| Low | None | 449 | 1 | 5% |
| Low-intermediate | Any 1 | 420 | 5.4 | 21% |
| High-intermediate | Any 2 | 226 | 10.1 | 37% |
| High | All 3 | 53 | 20.8 | 58% |
Updated MGUS risk model in WHO-HAEM5. WHO-HAEM5 applies an updated model to IgM and non-IgM MGUS. All 3 factors (abnormal free light chain ratio, IgA or IgM type and serum M protein >1.5 g/dL) indicate high risk, with about 50%–60% risk of progression at 20 years. The risk is 5% with none (Alaggio 2022). Progression risk also depends on cytogenetic type: t(4;14), del(17p) and gain(1q) raise the risk of progression from MGUS or smoldering myeloma to myeloma (Rajkumar 2024).
Monoclonal gammopathy of renal and clinical significance
MGRS. MGRS is a plasma cell or B-cell proliferation that does not meet criteria for malignancy but secretes a monoclonal immunoglobulin or fragment that injures the kidney. About 1.5% of patients who would otherwise be classified as MGUS have MGRS (Alaggio 2022). The term MGRS is applied only when a specific renal lesion is proven on biopsy, for example proliferative glomerulonephritis with monoclonal immunoglobulin deposits, monoclonal immunoglobulin deposition disease (MIDD) or AL amyloidosis (Sra 2026).
MGCS. MGCS is an overarching term for non-malignant disorders caused directly by a monoclonal protein from a clonal plasma cell or B-cell disorder. It covers renal, neurologic, cutaneous, hematologic, ocular and multisystem disorders. A specific disorder must be established before the term is applied (Sra 2026).
Table 6. Selected disorders grouped as monoclonal gammopathy of clinical significance (Sra 2026; Alaggio 2022; Campo 2022).
| Organ system | Disorder | Defining features |
|---|---|---|
| Peripheral nerve | Distal acquired demyelinating symmetric neuropathy with M protein (DADS-M) | Slowly progressive, length-dependent, demyelinating sensory neuropathy; IgM antibodies against myelin-associated glycoprotein (MAG) or other myelin components |
| Peripheral nerve | CANOMAD | Chronic ataxic neuropathy, ophthalmoplegia, IgM M protein, cold agglutinins and anti-disialosyl (anti-GD1b) antibodies, without anti-MAG |
| Blood | Cold agglutinin disease | Autoimmune hemolytic anemia from monoclonal IgM cold agglutinins, caused by a clonal B-cell proliferation that does not meet criteria for lymphoma; incidence 1–1.8 per million per year, four-fold higher prevalence in colder countries; no MYD88 L265P (Campo 2022; Ferry 2024); ICC: trisomies 3, 12 and 18; KMT2D and CARD11 mutations |
| Skin and multisystem | Schnitzler syndrome | Chronic urticarial rash with a monoclonal gammopathy, most often IgM κ; recurrent fever, arthralgia, lymphadenopathy and organomegaly; interleukin-1-mediated |
| Multisystem | TEMPI syndrome | Telangiectasias, elevated erythropoietin with erythrocytosis, monoclonal gammopathy, perinephric fluid collection and intrapulmonary shunting; marrow usually unremarkable, a few cases with erythroid hyperplasia and a small light-chain-restricted plasma cell population |
| Multisystem | AESOP syndrome | Adenopathy and an extensive skin patch overlying a solitary bone plasmacytoma, most often rib (55%) or sternum (20%); λ restriction in >80%; skin with dermal capillary proliferation and mucin; nodes with Castleman-like change in about 40% |
AESOP syndrome can identify POEMS syndrome at a curable stage. Radiation of the plasmacytoma leads to regression of the skin lesion and lymphadenopathy within months (Sra 2026).
Plasma cell myeloma: marrow morphology and immunophenotype
Morphology. Normal plasma cells have a single eccentric round nucleus with clock-face chromatin, amphophilic cytoplasm and a perinuclear hof. Benign plasma cells are occasionally binucleated. Neoplastic plasma cells range from mature to immature, plasmablastic and pleomorphic forms. They show nuclear convolution, multilobation and multinucleation, and may contain cytoplasmic inclusions (Russell bodies) and intranuclear inclusions (Dutcher bodies). Nuclear immaturity and pleomorphism are reliable indicators of malignancy (Chuang 2026). A plasma cell filled with Russell bodies is a Mott cell (Kobayashi 2024).
Plasmablastic morphology. Plasmablastic myeloma has a large nucleus with fine reticular chromatin, a large nucleolus, little or no hof, and cytoplasm less than half of the nuclear area. Plasmablastic myeloma and plasmablastic lymphoma have nearly identical morphology and immunophenotype. EBV is far more common in plasmablastic lymphoma (Chuang 2026). Plasmablastic lymphoma occurs in immunosuppressed or elderly patients, often with MYC rearrangement, and is excluded with Ki-67 and EBER studies when a plasma cell neoplasm shows plasmablastic morphology (CAP 2025). Myeloma-defining features such as an M protein and CRAB support myeloma (Chuang 2026).
Small-cell variant. The small-cell (lymphoplasmacytoid) variant was described in WHO-HAEM4R and is not described in WHO-HAEM5. It accounted for 3.4% of 351 myelomas. The cells usually express CD20 and cyclin D1 and carry t(11;14) IGH::CCND1, which mimics mantle cell lymphoma. Lack of CD45, presence of CD138 and the clinical presentation of myeloma separate it from B-cell lymphoma. In contrast to mantle cell lymphoma, the plasma cells lack CD5, CD19 and SOX11 (Chuang 2026). Lytic lesions, wild-type MYD88 and a high free light chain ratio favor myeloma over lymphoplasmacytic lymphoma (Chuang 2026).
Crystal-storing histiocytosis. Histiocytes accumulate crystalline immunoglobulin, often in plasma cell neoplasms such as myeloma. In a reported duodenal case, CD68-positive histiocytes contained PAS-positive, diastase-resistant, λ-restricted material (Koga 2025).
Table 7. Immunophenotype of normal and neoplastic plasma cells (Chuang 2026; Flores-Montero 2017; CAP 2025).
| Antigen | Normal or reactive plasma cells | Neoplastic plasma cells |
|---|---|---|
| CD38, CD138, IRF4/MUM1 | Positive (CD38 bright) | Positive (CD38 bright) |
| Light chain | Polytypic | Monotypic |
| CD19 | Positive | Lost in >95% of cases |
| CD56 | Negative or low | Positive in 60%–80% of myelomas |
| CD117 | Negative | Positive in 3% to one third of cases |
| CD45 | Expressed during early development | Usually negative; positive in up to 14% of myelomas, more often in MGUS and smoldering myeloma |
| CD20 | Negative | Usually negative; positive in the small-cell variant |
| Cyclin D1 | Negative | Positive by IHC in about one quarter of myelomas, associated with t(11;14) |
| CD3, CD4 | Negative | Rarely positive, associated with plasmablastic or anaplastic morphology and aggressive behavior |
By flow cytometry, 65% of myelomas were CD19−/CD56+, 30% CD19−/CD56 low and 5% CD19+/CD56+, whereas all normal plasma cells were CD19+/CD56 negative or low (Chuang 2026). In 63 myelomas compared with normal and reactive marrow plasma cells, the markers that most often separated aberrant from normal plasma cells were CD19 (97% of cases), CD45 (89%), CD56 (86%), CD81 (86%), cytoplasmic λ (73%), CD27 (71%), CD117 (60%) and cytoplasmic κ (56%) (Flores-Montero 2017). Plasma cell gating and hemodilution controls are taught in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology. Light-chain clonality is assessed by flow cytometry, IHC or in situ hybridization, and neoplastic plasma cells are CD19-negative by IHC and surface CD19-negative with cytoplasmic CD19 by flow cytometry (Chuang 2026). Flow cytometry is usually more sensitive than IHC, while IHC can detect cytoplasmic antigens negative on surface analysis (CAP 2025).
Lymphoma with plasmacytic differentiation. Plasma cells in B-cell lymphoma are more often CD45+, CD19+, CD56− and surface light chain positive. Background clonal B cells by flow cytometry, atypical B cells with aberrant CD43 or BCL2, and MYD88 mutation support lymphoma (Chuang 2026). Marginal zone lymphoma with marked plasmacytic differentiation is separated from extramedullary plasmacytoma by a mature B-cell phenotype (CD19+, CD20 of more than moderate intensity), IgM expression, absence of the plasma cell neoplasm phenotype and monotypic B cells by flow cytometry (CAP 2025).
Myeloma cytogenetics and FISH
Primary abnormalities. Myeloma has 2 main cytogenetic groups. IGH translocations occur in 40%–50% of patients. Up to 55% lack IGH translocations and are hyperdiploid, and a small subset fits neither group. These primary abnormalities are present in precursor states and persist through the disease course (Campo 2022). Secondary abnormalities, including gain(1q), del(1p), del(17p), del(13) and secondary MYC translocations, arise during the disease course (Rajkumar 2024). Gain of 1q21 is often an early event, whereas translocations and further 1q21 amplification emerge later (Alaggio 2022).
Table 8. Primary cytogenetic groups of myeloma with ICC subtype and clinical significance (Rajkumar 2024, Tables 2 and 3; Campo 2022; Chuang 2026; Shaughnessy 2001).
| Abnormality | Gene | Approximate frequency | ICC 2022 group | Smoldering myeloma: progression | Myeloma: prognosis |
|---|---|---|---|---|---|
| Hyperdiploidy | Trisomies of odd-numbered chromosomes except 1, 13 and 21 | 45% | MM with hyperdiploidy | Intermediate risk; median time to progression 3 years | Standard risk; median overall survival 7–10 years |
| t(11;14)(q13;q32) | CCND1 | 20% | MM with CCND family translocation | Standard risk; 5 years | Standard risk; 7–10 years; cyclin D1 expression and venetoclax sensitivity |
| t(6;14)(p21;q32) | CCND3 | 5% | MM with CCND family translocation | Standard risk; 5 years | Standard risk; 7–10 years |
| t(4;14)(p16;q32) | NSD2 (FGFR3) | 10% | MM with NSD2 translocation | High risk; 2 years | Intermediate risk; median 5 years |
| t(14;16)(q32;q23) | MAF | 4% | MM with MAF family translocation | Standard risk; 5 years | High risk; median 3 years; high free light chains, acute renal failure in 25% |
| t(14;20) | MAFB | <1% | MM with MAF family translocation | Standard risk; 5 years | High risk; median 3 years |
Secondary abnormalities. Gain(1q21) and del(17p) each carry a high risk of progression from smoldering myeloma (median time to progression 2 years). In myeloma, gain(1q21) is intermediate risk (median overall survival 5 years) and del(17p) is high risk (median 3 years). Trisomies coexisting with an IGH translocation may ameliorate the adverse effect of high-risk translocations and del(17p) (Rajkumar 2024). The ICC identifies high-risk disease by t(4;14), t(14;16) and the secondary changes del(17p), amp1q and del(1p) (Campo 2022). Translocation t(8;14) involving MYC is often a secondary progression event and is frequent in plasmablastic lymphoma (Chuang 2026).
FISH testing in myeloma. Interphase FISH is the method of choice in the ICC, with published consensus FISH panels (Campo 2022). The initial FISH panel detects t(11;14), t(4;14), t(14;16), t(6;14), t(14;20), trisomies and del(17p). Karyotyping adds limited risk information once FISH is done (Rajkumar 2024). In the R-ISS cohort, interphase FISH was performed after CD138 plasma cell purification (Palumbo 2015). Myeloma carries more than 400 somatic mutations per patient, most often in immunoglobulin genes, NRAS, KRAS and BRAF (Rajkumar 2024).
High-risk myeloma. The International Myeloma Society (IMS)/IMWG 2025 consensus defines high-risk newly diagnosed myeloma by genomic features and captured about 20% of patients with poor outcome on current therapy. 1q+ is gain (3 copies) or amplification (≥4 copies) of 1q. Interphase FISH alone is no longer sufficient: FISH is performed on plasma cells enriched to ≥70% purity, the percentage of abnormal cells is corrected for purity, and TP53 mutations and small 1p deletions require sequencing (Avet-Loiseau 2025).
Table 9. Definitions of high-risk myeloma: IMS/IMWG 2025 (Avet-Loiseau 2025) with the previous rules (Palumbo 2015; Rajkumar 2024).
| System | High-risk features |
|---|---|
| IMS/IMWG 2025 (current) | At least 1 of: del(17p) in >20% of clonal cells and/or TP53 mutation; t(4;14), t(14;16) or t(14;20) with 1q+ and/or del(1p32); monoallelic del(1p32) with 1q+, or biallelic del(1p32); β2-microglobulin >5.5 mg/L with normal creatinine (<1.2 mg/dL) |
| R-ISS (previous rule) | del(17p), t(4;14) or t(14;16) by interphase FISH |
| Mayo mSMART (previous rule) | Any 1 of t(4;14), t(14;16), t(14;20), del(17p), gain(1q) or del(1p) (40% of newly diagnosed patients); any 2 is double-hit myeloma and 3 or more is triple-hit myeloma. Standard risk: trisomies, t(11;14) and t(6;14) (60%) |
Staging: ISS, R-ISS and R2-ISS
WHO-HAEM5 adopted the IMWG Revised International Staging System (R-ISS) (Alaggio 2022). R-ISS was derived from 3,060 of 4,445 patients with newly diagnosed myeloma in 11 international trials. It combines the ISS with high-risk chromosomal abnormalities by interphase FISH and serum lactate dehydrogenase (LDH) (Palumbo 2015). The Durie-Salmon system and the ISS were the earlier measures of tumor burden (Rajkumar 2024).
Table 10. ISS and R-ISS (Palumbo 2015).
| Stage | ISS (previous system, 2005) | R-ISS (2015) |
|---|---|---|
| I | Serum β2-microglobulin <3.5 mg/L and serum albumin ≥3.5 g/dL | ISS stage I, standard-risk chromosomal abnormalities and normal LDH |
| II | Neither stage I nor stage III | Neither R-ISS stage I nor stage III |
| III | Serum β2-microglobulin ≥5.5 mg/L | ISS stage III and either high-risk chromosomal abnormalities (del(17p), t(4;14) or t(14;16)) or LDH above the upper limit of normal |
R-ISS outcomes. At a median follow-up of 46 months, 5-year overall survival was 82% for R-ISS I, 62% for R-ISS II and 40% for R-ISS III, and 5-year progression-free survival was 55%, 36% and 24% (Palumbo 2015).
R2-ISS. The second revision (R2-ISS) was developed by the European Myeloma Network from 10,843 patients in 16 trials. It assigns points by impact on overall survival and adds 1q gain or amplification (1q+). In the training set, median overall survival was not reached in R2-ISS I and was 109.2, 68.5 and 37.9 months in R2-ISS II, III and IV (D'Agostino 2022).
Table 11. R2-ISS points and risk groups (D'Agostino 2022; Cho 2024).
| Risk feature | Points |
|---|---|
| ISS II | 1 |
| ISS III | 1.5 |
| del(17p) | 1 |
| High LDH | 1 |
| t(4;14) | 1 |
| 1q+ | 0.5 |
| Risk group (proportion of training set) | Total score |
| R2-ISS I, low (19.2%) | 0 |
| R2-ISS II, low-intermediate (30.8%) | 0.5–1 |
| R2-ISS III, intermediate-high (41.2%) | 1.5–2.5 |
| R2-ISS IV, high (8.8%) | 3–5 |
Smoldering myeloma and the IMWG 20/2/20 model
Natural history. Smoldering myeloma is present in about 0.5% of people 40 years of age or older. It progresses to myeloma at about 10% per year for the first 5 years, 3% per year for the next 5 years and 1.5% per year thereafter (Rajkumar 2024).
IMWG 2020 risk model. In 1,996 patients meeting the 2014 IMWG definition of smoldering myeloma, 3 factors predicted progression at 2 years: serum M protein >2 g/dL, involved/uninvolved serum free light chain ratio >20 and marrow plasma cells >20% (Mateos 2020).
Table 12. IMWG 2020 risk stratification of smoldering myeloma (Mateos 2020).
| Model | Risk group | Factors present | Patients | Progression at 2 years |
|---|---|---|---|---|
| 20/2/20 | Low | 0 | 38% | 6% |
| 20/2/20 | Intermediate | 1 | 33% | 18% |
| 20/2/20 | High | 2 or 3 | 29% | 44% |
| 20/2/20 plus FISH (t(4;14), t(14;16), +1q, del(13q)/monosomy 13; 689 patients) | Low | 0 | 33% | 6% |
| 20/2/20 plus FISH | Low-intermediate | 1 | 33% | 23% |
| 20/2/20 plus FISH | Intermediate | 2 | 26% | 46% |
| 20/2/20 plus FISH | High | ≥3 | 9% | 63% |
Solitary plasmacytoma of bone and extramedullary plasmacytoma
Definition and sites. A plasmacytoma is a solitary clonal plasma cell neoplasm without clinical or pathologic evidence of myeloma or attributable end-organ damage. Biopsies of solitary plasmacytoma of bone usually target a lytic lesion of the axial skeleton, frequently spine, pelvis, ribs or skull. Extramedullary plasmacytoma most often involves the upper respiratory tract and less often lymph nodes, lung or other sites (CAP 2025).
CAP essential criteria. A biopsy-proven clonal plasma cell neoplasm of bone or an extramedullary site; no clonal B cells; no other lesions on examination or imaging; no CRAB due to the plasma cell neoplasm; and <10% clonal plasma cells on non-targeted marrow sampling. The diagnosis requires exclusion of myeloma, and this is stated in the report comment (CAP 2025).
Minimal marrow involvement. Solitary plasmacytoma of bone and primary extramedullary plasmacytoma carry a low to moderate risk of progression to myeloma. Minimal marrow involvement detected by flow cytometry is of major prognostic importance, particularly in solitary plasmacytoma of bone (Campo 2022).
Extramedullary disease. Extramedullary disease, defined as soft-tissue plasmacytoma from hematogenous spread without contact with bone, occurs in 7%–18% of patients with myeloma and is more frequent with plasmablastic and pleomorphic morphology (Chuang 2026).
Plasma cell leukemia
Current definition. The 2021 IMWG consensus defines primary plasma cell leukemia as ≥5% circulating plasma cells in the peripheral blood of a patient otherwise meeting criteria for myeloma (Fernández de Larrea 2021). The count is made on the white blood cell differential of a conventional blood smear (Rajkumar 2024). WHO-HAEM5 lowered the threshold to ≥5%. A differential of at least 100–200 nucleated blood cells is recommended in newly diagnosed myeloma (CAP 2025).
Previous rule. The criteria established by Kyle in 1974 required both >20% circulating plasma cells and an absolute plasma cell count >2 × 10⁹/L. In 2013 the IMWG noted that these criteria might be too restrictive, and many series accepted either criterion alone. Under the old criteria, about 1%–2% of patients with myeloma had plasma cell leukemia at diagnosis (Fernández de Larrea 2021).
Evidence for the 5% threshold. In 482 Catalan patients, median overall survival was 47, 50, 6 and 14 months with 0%, 1%–4%, 5%–20% and >20% circulating plasma cells. In 176 Mayo Clinic patients with circulating plasma cells, median overall survival was 17, 13 and 13 months with 1%–4%, 5%–19% and ≥20%, compared with 53 months without circulating plasma cells (Fernández de Larrea 2021).
Primary and secondary forms. Primary plasma cell leukemia presents de novo without previous myeloma. Secondary plasma cell leukemia is leukemic transformation of relapsed or refractory myeloma. About 60%–70% of cases are primary (Fernández de Larrea 2021).
Response criteria and measurable residual disease in myeloma
IMWG 2016. The IMWG response categories are stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD) and progressive disease (PD). The 2016 criteria added MRD categories (Lim 2026; Kumar 2016). If some but not all criteria of a level are met, the response is downgraded to the next lower category (Gan 2026).
Table 13. IMWG response categories (Gan 2026; Dejoie 2019, Table 1; Lim 2026; Kumar 2016).
| Category | Criteria |
|---|---|
| Sustained MRD-negative | Marrow MRD negativity by next-generation flow (NGF) or next-generation sequencing (NGS) at a sensitivity of at least 1 in 10⁵ nucleated cells, confirmed on evaluations at least 1 year apart |
| MRD-negative | In a patient with CR, no clonal aberrant plasma cells at 1 in 10⁵ marrow cells by multiparameter flow cytometry or NGS |
| Imaging plus MRD-negative | MRD negativity plus disappearance of PET-CT-avid lesions to below mediastinal blood pool uptake (≤Deauville 2) or surrounding normal tissue |
| Stringent CR | CR plus normal free light chain ratio and no clonal cells in the marrow biopsy by IHC |
| CR | Negative serum and urine immunofixation, disappearance of soft-tissue plasmacytomas and <5% plasma cells in the marrow aspirate |
| VGPR | Serum and urine M protein detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M protein plus urine M protein <100 mg/24 h |
| PR | ≥50% reduction in serum M protein, ≥90% reduction in 24-hour urinary M protein or to <200 mg/24 h, and ≥50% reduction in soft-tissue plasmacytoma size |
| MR | 25%–49% reduction in serum M protein and 50%–89% reduction in 24-hour urinary M protein |
| SD | Criteria for sCR, CR, VGPR, PR, MR and PD not met |
| PD | 25% increase from the lowest confirmed value with an absolute serum M protein increase ≥0.5 g/dL or urinary increase ≥200 mg/24 h; or, without measurable M protein, rise in the involved–uninvolved free light chain difference >10 mg/dL, marrow plasma cell increase ≥10%, new lesions, or ≥50% increase in circulating plasma cells (minimum 200 cells/µL) |
Next-generation flow (NGF). The EuroFlow NGF panel contains CD38, CD138, CD45, CD19, CD56, CD27, CD81, CD117 and cytoplasmic Igκ and Igλ, with automated plasma cell gating. In 110 marrow samples from patients in VGPR or CR, NGF detected MRD in 47% compared with 34% by conventional 8-color flow cytometry. One quarter of patients negative by conventional flow were positive by NGF. Progression-free survival was longer in MRD-negative than MRD-positive patients in CR by NGF. NGF was applicable in 31 of 31 samples tested in parallel, and NGS in 27 of 31 (87%) (Flores-Montero 2017). Tube design, cell acquisition and hemodilution controls are taught in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology.
Molecular and serum methods for residual disease. Molecular MRD methods target the clonal VDJ and VJ rearrangements of the immunoglobulin heavy and light chain loci. Serum protein electrophoresis and immunofixation detect M protein down to about 0.1 g/dL and 0.05 g/dL. Mass spectrometry detects lower concentrations and separates the M protein from therapeutic monoclonal and bispecific antibodies such as daratumumab and isatuximab (Lim 2026). Mass spectrometry methods and therapeutic antibody interference are taught in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.
Amyloidosis: tissue diagnosis and typing
Definition and morphology. AL amyloidosis is extracellular accumulation of linear, non-branching fibrils produced by clonal plasma cells or B cells, with end-organ dysfunction. On H&E, amyloid is amorphous and pink, often with artifactual cracking, and may be bordered by histiocytes and foreign-body giant cells (CAP 2025). Amyloid fibrils have a β-pleated sheet structure (Halloush 2010).
Congo red. Congo red with bright-field and polarized microscopy for apple-green birefringence is more sensitive than H&E, and Congo red fluorescence microscopy is more sensitive still (CAP 2025). Interpretation requires high-quality optics, a strong light source, darkness and a standardized protocol (Riefolo 2022).
Table 14. CAP essential criteria for AL amyloidosis (CAP 2025, Table 2, from WHO-HAEM5).
| Criterion type | Requirement |
|---|---|
| Essential | Amyloid-related organ dysfunction on clinical examination (soft tissue deposition, polyneuropathy, autonomic neuropathy), supported by abnormal organ function tests |
| Essential | Monoclonal protein in serum or urine, or abnormal serum free light chains |
| Essential | Amyloid on tissue biopsy (abdominal fat, marrow, salivary gland or affected organ) by Congo red or a similar thioflavin stain, or typical fibrils by electron microscopy |
| Essential | Typing of the fibril protein by laser capture microdissection with mass spectrometry, or by IHC or immunoelectron microscopy |
| Desirable | Imaging confirmation of organ involvement (echocardiography or cardiac MRI for the heart) |
| Desirable | Testing for hereditary amyloidosis genes when light-chain involvement is uncertain, especially when mass spectrometry is unavailable or inconclusive |
Typing by mass spectrometry. Laser microdissection with tandem mass spectrometry (LMD-MS/MS) has virtually 100% sensitivity and specificity, confirms AL type and excludes hereditary amyloidosis more definitively (CAP 2025). In a French cohort of 741 validation specimens, LMD-MS/MS identified the amyloid protein in 95.0% and found 19 amyloid types; AL, ATTR and AA accounted for 89.6%. In AL and ATTR cases with equivocal or negative IHC or immunofluorescence, light-chain antibodies gave false-negative results in 48.5% and false-positive results in 41.5%, and transthyretin antibodies in 12.0% and 56.8%. Serum amyloid P component, apolipoprotein E and apolipoprotein A4 formed a universal amyloid signature in 81.6% of cases. AL patients were a decade younger than ATTR patients (Colombat 2022).
Table 15. Major amyloid types (Feitosa 2022; Riefolo 2022; Colombat 2022).
| Type | Precursor protein | Acquired or hereditary | Typical organs and setting |
|---|---|---|---|
| AL | Immunoglobulin light chain | Acquired | All organs except the central nervous system; clonal plasma cell or B-cell disorder; cardiac involvement in 50%–80% |
| AH | Immunoglobulin heavy chain | Acquired | All organs except the central nervous system |
| AA | Serum amyloid A | Acquired or hereditary | Kidney and liver; long-standing inflammation, chronic infection or hereditary autoinflammatory disease |
| ATTRwt | Transthyretin, wild type | Acquired, aging-related | Heart, lung, ligaments, tenosynovium |
| ATTRv | Transthyretin variants | Hereditary | Peripheral and autonomic nerves, heart, eye, leptomeninges |
| ALECT2 | Leukocyte chemotactic factor 2 | Acquired | Kidney; third commonest cause of renal amyloidosis in the United States; predominantly Hispanic, Egyptian, Indian and Pakistani patients |
| Aβ2M | β2-microglobulin, wild type | Acquired, iatrogenic | Musculoskeletal system; long-term dialysis |
| AFib | Fibrinogen Aα chain variants | Hereditary | Kidney |
Renal amyloid type frequencies are taught in Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition.
Screening biopsies. Skin punch or surgical subcutaneous fat biopsy yields more material than needle aspiration (Riefolo 2022). The performance of fat pad aspiration is taught in Non-Neoplastic and Reactive Soft Tissue and Skin Lesions on FNA.
Localized AL amyloidosis. The ICC separates localized AL amyloidosis (amyloid tumor), a rare disorder with excellent prognosis and rare progression to systemic disease, from systemic AL amyloidosis (Campo 2022).
Monoclonal immunoglobulin deposition disease
MIDD is tissue accumulation of non-amyloidogenic monoclonal immunoglobulin, secondary to a plasma cell neoplasm or less often (2%–3%) a B-cell neoplasm, usually lymphoplasmacytic lymphoma or chronic lymphocytic leukemia. Its 3 subtypes are light chain, light and heavy chain, and heavy chain deposition disease. The deposit type is determined by immunofluorescence on renal biopsies and by IHC or mass spectrometry in other tissues. In the kidney, the diagnosis requires IHC and electron microscopy, except that IHC alone suffices when light chain cast nephropathy coexists. Light chain cast nephropathy, AL amyloidosis and light chain proximal tubulopathy can coexist with MIDD in the same kidney (CAP 2025).
POEMS syndrome
POEMS syndrome is a paraneoplastic syndrome caused by an underlying plasma cell neoplasm. Neuropathy, endocrine dysfunction and volume overload are the main features. Bone pain, heavy marrow plasmacytosis and renal failure are uncommon. VEGF correlates best with disease activity (Dispenzieri 2026).
Table 16. Diagnostic criteria for POEMS syndrome (Dispenzieri 2026). The diagnosis requires both mandatory major criteria, 1 other major criterion and 1 minor criterion.
| Criterion type | Criteria |
|---|---|
| Mandatory major | Polyneuropathy, typically demyelinating; monoclonal plasma cell proliferative disorder, almost always λ (an M protein, a nonsecretory plasmacytoma or a small marrow clone) |
| Other major (1 required) | Castleman disease; sclerotic bone lesions; VEGF elevation |
| Minor (1 required) | Organomegaly (splenomegaly, hepatomegaly or lymphadenopathy); extravascular volume overload (edema, pleural effusion or ascites); endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic; diabetes or thyroid disease alone does not qualify); skin changes (hyperpigmentation, hypertrichosis, glomeruloid hemangiomata, plethora, acrocyanosis, flushing, white nails); papilledema; thrombocytosis or polycythemia |
| Other signs | Clubbing, weight loss, hyperhidrosis, pulmonary hypertension or restrictive lung disease, thrombotic diatheses, diarrhea, low vitamin B12 |
A Castleman disease variant of POEMS without a clonal plasma cell disorder is considered separately (Dispenzieri 2026).
Marrow findings. In 67 pretreatment marrow biopsies, megakaryocytic hyperplasia was present in 54% and megakaryocyte clustering in 93%, without JAK2 V617F. One third of patients had no clonal plasma cells in the iliac crest biopsy; these patients had solitary or multiple solitary plasmacytomas. In the remaining two thirds, 91% of the clonal plasma cells were λ, and the median plasma cell percentage was <5%. Lymphoid aggregates were present in 49%, rimmed by plasma cells in all but 1 case, with λ rimming in 75% and κ in 4%. Rimming was absent in normal, MGUS, myeloma and amyloidosis marrows, and was seen otherwise only in lymphoplasmacytic lymphoma. IHC is more sensitive than 6-color flow cytometry because it shows architecture. Only 12% of iliac crest biopsies were normal. Half of patients have thrombocytosis or erythrocytosis, and cytopenias are unusual unless Castleman disease is present (Dispenzieri 2026).
Heavy chain diseases
Heavy chain diseases are rare B-cell neoplasms that produce a truncated monotypic immunoglobulin heavy chain without associated light chain. The heavy chain mutations prevent assembly of intact immunoglobulin (CAP 2025).
Table 17. Heavy chain diseases (CAP 2025, Table 3 and explanatory note).
| Disease | Morphology and distribution | Essential criteria | Other features |
|---|---|---|---|
| Mu (μ) heavy chain disease | Vacuolated plasma cells and small round lymphocytes resembling chronic lymphocytic leukemia; spleen, liver, lymph node and marrow, in that order of frequency; lytic bone lesions possible | Serum immunofixation with anti-μ reactivity without light chain; marrow or tissue involvement by small round lymphocytes and vacuolated plasma cells | Frequent κ Bence Jones proteinuria; B cells with cytoplasmic IgM negative for light chains |
| Gamma (γ) heavy chain disease | Heterogeneous; resembles lymphoplasmacytic or marginal zone lymphoma; lymph node, marrow and extranodal sites | Serum or urine immunofixation with a γ band without light chain, which may be the only finding in autoimmune disease | Lymphoplasmacytic proliferation expressing IgG without light chains; MYD88 wild type; underlying autoimmune disease in some patients |
| Alpha (α) heavy chain disease | Variant of extranodal marginal zone lymphoma, typically gastrointestinal, with chronic watery diarrhea; more prevalent in Mediterranean countries; linked to failure to clear infections such as Campylobacter jejuni | Tissue biopsy with features of extranodal marginal zone lymphoma with extensive plasmacytic differentiation expressing IgA without light chains | Serum immunofixation with anti-α reactivity without light chain. Also called immunoproliferative small intestinal disease (IPSID): young adults (mean age 32 years) in poor hygienic conditions, with malabsorption, intermittent diarrhea and abdominal pain; serum IgA elevated in about half and the anomalous α heavy chain detected in 20%–90% (Ishikawa 2022) |
Cryoglobulinemia: types and hematologic associations
The definition of cryoglobulins, specimen handling at 37 °C and the cryocrit are taught in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.
Table 18. Brouet classification of cryoglobulinemia (Ferri 2026; Sra 2026).
| Type | Composition | Main associations | Clinical pattern |
|---|---|---|---|
| I (monoclonal) | A single monoclonal cryoprecipitable immunoglobulin, usually IgG or IgM | B-cell neoplasms: MGUS, Waldenström macroglobulinemia, myeloma, B-cell lymphoma, chronic lymphocytic leukemia | Thrombotic, non-inflammatory microangiopathy; cold-induced skin necrosis and ulceration |
| II (mixed) | Polyclonal IgG with monoclonal or oligoclonal IgM rheumatoid factor | HCV infection, other infections, lymphoproliferative and autoimmune disorders; most cases caused by a clonal B-cell or plasma cell disorder | Immune-complex leukocytoclastic vasculitis with complement consumption: palpable purpura, arthralgia, glomerulonephritis, neuropathy |
| III (mixed) | Polyclonal IgG with polyclonal IgM rheumatoid factor | Polyclonal immune activation in infection or autoimmune disease | As type II |
Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen
Definition. Histiocytoses are disorders defined by accumulation of macrophage-, dendritic cell- or monocyte-derived cells in tissues. More than 100 subtypes are described. The 2016 Histiocyte Society classification places them in 5 groups: L (Langerhans), C (cutaneous and mucocutaneous), M (malignant histiocytoses), R (Rosai-Dorfman disease) and H (hemophagocytic lymphohistiocytosis) (Emile 2016). A histiocyte is a morphologic term for a tissue-resident macrophage. Macrophages clear apoptotic cells, debris and pathogens, whereas dendritic cells present antigen and activate naive T cells (Emile 2016).
Shared pathogenesis. Langerhans cell histiocytosis (LCH), Langerhans cell sarcoma, Erdheim-Chester disease (ECD), juvenile xanthogranuloma (JXG), Rosai-Dorfman disease (RDD) and histiocytic sarcoma commonly carry mutations in MAPK pathway genes such as BRAF, ARAF, MAP2K1, NRAS and KRAS, at highly variable frequencies. BRAF and MEK inhibitors are effective targeted therapy (Khoury 2022). A smaller subset shows PI3K pathway activation. BRAF V600E is not specific to any entity and occurs in isolated LCH, ECD and histiocytic and dendritic cell sarcomas (Campo 2022).
Related page: Bone FNA (LCH and Erdheim-Chester disease on fine-needle aspiration) Related page: Spleen and Thymus FNA and Pediatric Lymph Node Cytology (splenic fine-needle aspiration) Related page: Pheochromocytoma, Metastases and Lymphoma in Adrenal FNA (primary adrenal lymphoma) Related page: Mediastinal Mass FNA by Compartment and Mediastinal Cysts (mediastinal fine-needle aspiration and thymic context) Related page: Thymoma and Thymic Carcinoma on FNA (thymic epithelial tumors in the mediastinal differential) Related page: AML, Myelodysplasia-Related, AML Defined by Differentiation, Myeloid Neoplasms Post Cytotoxic Therapy and of Down Syndrome, Myeloid Sarcoma, BPDCN and Acute Leukemias of Ambiguous Lineage (blastic plasmacytoid dendritic cell neoplasm) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (HLH-2004 criteria, ferritin and HScore) Related page: Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow (sinus histiocytosis, Castleman disease and IgG4-related disease in lymph node; fresh-tissue triage for flow cytometry, cytogenetics and imprints) Related page: Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia (splenic marginal zone lymphoma, hairy cell leukemia and other splenic B-cell lymphomas) Related page: Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas (hepatosplenic T-cell lymphoma and T-cell large granular lymphocytic leukemia) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (laboratory diagnosis of hereditary spherocytosis and other hemolytic anemias)
Classification by WHO-HAEM5 and ICC 2022, with WHO-HAEM4R as the previous rule
WHO-HAEM5 places histiocytic and dendritic cell neoplasms after the myeloid neoplasms because they derive from common myeloid progenitors. Its key changes are inclusion of clonal plasmacytoid dendritic cell (pDC) diseases, transfer of follicular dendritic cell (FDC) sarcoma and fibroblastic reticular cell (FRC) tumour to a new category of stroma-derived neoplasms of lymphoid tissues, and addition of RDD and ALK-positive histiocytosis (Khoury 2022). FDCs are of mesenchymal origin (Alaggio 2022).
Table 1. Histiocytic, dendritic cell and lymphoid stromal neoplasms: WHO-HAEM5 (Khoury 2022; Alaggio 2022), ICC 2022 (Campo 2022) and WHO-HAEM4R (Ferry 2024, Table 5; Khoury 2022; Alaggio 2022).
| Entity | WHO-HAEM5 | ICC 2022 | WHO-HAEM4R (previous rule) |
|---|---|---|---|
| Plasmacytoid dendritic cell neoplasms | Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm; blastic plasmacytoid dendritic cell neoplasm (BPDCN) | Absent from the ICC mature lymphoid and histiocytic table | Outside the histiocytic and dendritic cell category |
| Langerhans cell neoplasms | Langerhans cell histiocytosis; Langerhans cell sarcoma | Langerhans cell histiocytosis; Langerhans cell sarcoma | Langerhans cell histiocytosis; Langerhans cell sarcoma |
| Other dendritic cell neoplasms | Indeterminate dendritic cell tumour; interdigitating dendritic cell sarcoma | Indeterminate dendritic cell histiocytosis; interdigitating dendritic cell sarcoma | Indeterminate dendritic cell histiocytosis; interdigitating dendritic cell sarcoma |
| Juvenile xanthogranuloma | Juvenile xanthogranuloma | Disseminated juvenile xanthogranuloma | Disseminated juvenile xanthogranuloma |
| Erdheim-Chester disease | Erdheim-Chester disease | Erdheim-Chester disease | Erdheim-Chester disease |
| Rosai-Dorfman disease | Rosai-Dorfman disease, new entity | Rosai-Dorfman-Destombes disease; a subset neoplastic on the basis of clonal genetic alterations | Not a disease type in the classification |
| ALK-positive histiocytosis | New entity | Accepted as an entity | Not a disease type in the classification |
| Histiocytic sarcoma | Histiocytic sarcoma | Histiocytic sarcoma | Histiocytic sarcoma |
| Follicular dendritic cell sarcoma | Moved to stroma-derived neoplasms of lymphoid tissues | Listed with histiocytic and dendritic cell neoplasms | Follicular dendritic cell sarcoma, in the histiocytic and dendritic cell category |
| EBV-positive inflammatory FDC sarcoma | Separate entity among stroma-derived neoplasms | EBV-positive inflammatory FDC/FRC tumor; "tumor" preferred for its indolent behavior | Inflammatory pseudotumour-like follicular/fibroblastic dendritic cell sarcoma |
| Fibroblastic reticular cell neoplasm | Fibroblastic reticular cell tumour, stroma-derived | Fibroblastic reticular cell sarcoma | Fibroblastic reticular cell tumour, in the histiocytic and dendritic cell category |
| Intranodal palisaded myofibroblastoma | Myofibroblastic tumour, stroma-derived, new | Absent from the ICC mature lymphoid and histiocytic table | Not included |
| Spleen-specific vascular-stromal tumours | Littoral cell angioma; splenic hamartoma; sclerosing angiomatoid nodular transformation (SANT) | Absent from the ICC mature lymphoid and histiocytic table | Not included |
Soft tissue tumors that are not specific to lymph node or spleen, such as hemangioma, Kaposi sarcoma and angiosarcoma, are classified in the WHO soft tissue and bone volume (Alaggio 2022). Overlap or hybrid cases that resist precise classification among LCH, Langerhans cell sarcoma, indeterminate dendritic cell tumour, interdigitating dendritic cell sarcoma and histiocytic sarcoma are rare (Khoury 2022).
Langerhans cell histiocytosis
Epidemiology. The annual incidence of LCH is about 5–9 per million children younger than 15 years and 1 per million older patients. Adult pulmonary LCH is strongly associated with smoking (Emile 2016).
Morphology and phenotype. LCH cells are mononuclear cells with coffee bean- or kidney-shaped (grooved) nuclei, often with abundant eosinophils and multinucleated giant cells. Detection of Langerhans cell markers is mandatory for diagnosis. CD1a and CD207 (langerin) IHC on formalin-fixed tissue has largely replaced electron microscopy for Birbeck granules. Biopsies are fixed in buffered formalin for <72 hours to allow IHC and molecular testing (Emile 2016). Indeterminate dendritic cell tumour (indeterminate cell histiocytosis) is separated from LCH by absence of CD207 (Emile 2016).
Genetics. BRAF V600E is present in about half of LCH samples. MAP2K1 mutations occur in 19% and are mutually exclusive with BRAF mutations. BRAF mutation in CD34-positive marrow cells of some patients with high-risk LCH indicates derivation from hematopoietic progenitors. LCH usually has a normal karyotype and fewer than 5 somatic mutations (Emile 2016). Testing for BRAF V600E and MAP2K1 is recommended in diagnostically difficult samples. Detection in LCH and ECD requires sensitive methods because the allele fraction can be <10% (Emile 2016).
Extent of disease. Histiocyte Society guidelines define 4 groups by the number of organs or systems involved, lung involvement and involvement of a risk organ (liver, spleen or bone marrow): single system (SS), single system with lung involvement (lung+), multisystem with risk-organ involvement (MS-RO+) and multisystem without risk-organ involvement (MS-RO−) (Emile 2016).
Erdheim-Chester disease
Clinical features. The mean age at diagnosis is 55–60 years and the male-to-female ratio is 3:1. Skeletal involvement occurs in >95%, and bilateral, symmetric cortical osteosclerosis of the diaphyses and metaphyses is highly suggestive. Cardiovascular involvement occurs in at least 50%. Periaortic fibrosis, among the most frequent cardiovascular lesions, appears on CT as a "coated aorta" (Mazor 2013). One third develop retroperitoneal fibrosis around the kidneys and ureters, seen on CT as "hairy kidney." CNS involvement, diabetes insipidus or exophthalmos occur in 20%–30%, and eyelid xanthelasma is the most frequent skin finding (Emile 2016). Restrictive pericarditis is typical (Goyal 2020).
Histology. Tissues contain foamy mononuclear histiocytes with small nuclei, frequent Touton or other multinucleated cells, fibrosis and reactive lymphocytes, plasma cells and neutrophils. The histiocytes are CD68- and CD163-positive and CD1a-negative, and some are S100-positive. Histology alone is not specific, and the diagnosis requires clinical and radiologic context (Emile 2016).
Genetics and mixed disease. About 50% of patients have BRAF V600E. MAP2K1, NRAS, KRAS, ARAF and PIK3CA mutations also occur. About 20% of patients with ECD also have LCH lesions, sometimes in the same biopsy (Emile 2016). Extracutaneous or disseminated JXG with a BRAF, NRAS, KRAS or MAP2K1 gain-of-function mutation is classified as ECD (Emile 2016). Histiocytoses can occur with myeloproliferative neoplasms and clonal hematopoiesis, sharing mutations with CD34-positive myeloid progenitors (Khoury 2022).
Rosai-Dorfman disease
Clinical forms. Classic RDD presents with bilateral, massive, painless cervical lymphadenopathy, with or without fever, night sweats and weight loss. Retroperitoneal nodes are uncommonly involved. Extranodal disease occurs in 43% and multisystem disease in 19%. Prognosis correlates with the number of nodal groups and extranodal systems involved (Abla 2018).
Histology and phenotype. Nodal RDD shows sinus expansion by large histiocytes with abundant pale, "watery-clear" cytoplasm, a large hypochromatic nucleus and a prominent nucleolus. Plasma cells are numerous in medullary cords and around venules. Emperipolesis (intact leukocytes within the histiocyte cytoplasm) is helpful but is not required, because it can be focal, especially at extranodal sites. Extranodal lesions have more fibrosis and fewer RDD cells. The histiocytes express cytoplasmic and nuclear S100, fascin and CD68, with variable CD163 and CD14, and lack CD1a (Abla 2018). They lack langerin and ALK, and frequently express cyclin D1, OCT2 and PU.1 (Younes 2026).
Genetics and associations. NRAS, KRAS, MAP2K1 and ARAF mutations occur in a subset, and BRAF V600E was absent in 23 samples studied (Abla 2018). RDD-like histology occurs with Hodgkin and non-Hodgkin lymphoma, preceding, following or coexisting in the same node. Some extranodal RDD (liver, lung, colon) has increased IgG4-positive plasma cells, whereas other series show low IgG4/IgG ratios (<40%) compared with IgG4-related disease. The IgG4/IgG ratio is evaluated in all patients with RDD (Abla 2018).
ALK-positive histiocytosis
ALK-positive histiocytosis is defined by an ALK translocation, most commonly KIF5B::ALK, and responds to ALK inhibitors. The multisystem form in infants involves liver, spleen and/or marrow and often resolves slowly. Other multisystem and single-system cases occur at any age, most often in the nervous system and skin. The histiocytes are large oval, foamy or spindle cells, sometimes with Touton giant cells or emperipolesis, and overlap with JXG. ALK IHC is recommended for histiocytic proliferations that do not fit a defined entity (Khoury 2022).
Histiocytic and dendritic cell sarcomas
Malignant histiocytoses. Malignant histiocytic neoplasms have anaplastic histology. Prominent mitotic activity with atypical mitoses and cellular atypia are both mandatory. The phenotype excludes other tumors (negative keratins, EMA, Melan-A, HMB45, B- and T-cell markers and FDC markers) and shows at least 2 of CD68, CD163, CD4 and lysozyme. S100, CD1a and CD207 assign the histiocytic, interdigitating, Langerhans or indeterminate subtype. In contrast to LCH, malignant histiocytoses usually show frequent chromosomal gains or losses (Emile 2016). A 2026 Histiocyte Society consensus on histiocytic, Langerhans cell and interdigitating dendritic cell sarcomas recommends a unified "malignant histiocytic neoplasm" designation, a minimum immunophenotypic panel, broad molecular profiling and documentation of any previous hematopoietic malignancy (Goyal 2026).
Table 2. Histiocytic and dendritic cell sarcomas (Emile 2016; Li 2026; Boyko 2026; Facchetti 2021; Xiao 2025).
| Tumor | Cell of origin | Positive markers | Negative markers and other features |
|---|---|---|---|
| Histiocytic sarcoma | Mature histiocyte | CD163, lysozyme, CD68, CD14 | S100, CD1a and langerin negative; up to 1% of lymph node or soft tissue neoplasms; median age 51 years; usually extranodal (gastrointestinal tract, CNS, dermis, spleen, marrow) |
| Langerhans cell sarcoma | Langerhans cell | Histiocytic markers with S100, CD1a and CD207 defining the Langerhans subtype | Anaplastic cytology and frequent mitoses separate it from LCH |
| Interdigitating dendritic cell sarcoma | Interdigitating dendritic cell | Strong S100 outlining dendritic processes; vimentin; variable CD163, fascin and CD45; CD68 often focal | Negative for FDC markers (CD21, CD23, CD35), langerin and B- and T-cell markers (CD20, CD3); CD1a usually negative, with rare positive cases; rare BRAF V600E |
| Follicular dendritic cell sarcoma | Follicular dendritic cell (mesenchymal) | CD21, CD23, CD35, clusterin, CXCL13, podoplanin (D2-40) | Spindled, oval or epithelioid cells with indistinct, often syncytial borders; antigen loss is frequent, so a marker panel is used; 79.4% extranodal; hyaline-vascular Castleman disease in 7%–10% |
| EBV-positive inflammatory FDC sarcoma | Follicular dendritic or fibroblastic reticular cell | 1 or more of CD21, CD23 and CD35; SMA; PD-L1; SSTR2a; EBER | Spindle cells in a dense lymphoplasmacytic background; liver and spleen |
Transdifferentiation. A subset of histiocytic neoplasms follows or accompanies lymphoma or leukemia, most commonly follicular lymphoma, chronic lymphocytic leukemia and T- or B-lymphoblastic leukemia. The histiocytic neoplasm usually shares the clonal markers or hallmark genetic change of the lymphoma, and each component often has additional exclusive alterations, consistent with divergent differentiation from a common lymphoid progenitor (Khoury 2022). Shared immunoglobulin rearrangement, t(14;18), BRAF mutation or chromosomal alteration have demonstrated the clonal relationship (Emile 2016).
EBV-positive inflammatory follicular dendritic cell sarcoma
The liver (52.6% of cases) and spleen (44.7%) are the most common sites. Patients range from 21 to 84 years of age, with a median of 52–56.5 years and a slight female predominance, and cases are reported more often in Asia. Tumors measure 1.5–23 cm, mean about 6.5 cm, and are circumscribed with a gray-white to yellow cut surface, often with hemorrhage, necrosis or cysts. Spindle to oval cells are admixed with abundant lymphocytes and plasma cells. FDC markers may be partially lost, so a panel of CD21, CD23 and CD35 is used. EBER in situ hybridization is the diagnostic standard: nearly all cases show strong nuclear positivity, with monoclonal EBV and latency type II (EBNA1, LMP1, LMP2A). The differential includes classic FDC sarcoma, Hodgkin and T-cell lymphoma, vascular tumors, inflammatory myofibroblastic tumor and granulomatous disease (Xiao 2025).
Hemophagocytic lymphohistiocytosis in tissue
Definition. HLH is a rare, often fatal syndrome of intense immune activation with fever, cytopenias, hepatosplenomegaly and hyperferritinemia. Immune dysregulation produces hypercytokinemia and accumulation of activated macrophages in organs and tissues (Emile 2016).
Hemophagocytosis as a criterion. Tissue hemophagocytosis is 1 of the HLH-2004 criteria taught in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders and is neither required for the diagnosis nor sufficient alone (Emile 2016). The 2024 revision for familial HLH retains hemophagocytosis as 1 of 7 clinical criteria, of which 5 are required (Henter 2024). Hemophagocytosis by lesional cells is also a feature of littoral cell angioma of the spleen (Teja 2026).
Table 3. Primary and secondary HLH (Emile 2016, H group).
| Category | Examples |
|---|---|
| Primary HLH with lymphocyte cytotoxic defects | FHL2 (PRF1), FHL3 (UNC13D), FHL4 (STX11), FHL5 (STXBP2), XLP1 (SH2D1A), Griscelli syndrome type 2 (RAB27A), Chediak-Higashi syndrome (LYST) |
| Primary HLH with inflammasome abnormalities | XLP2 (BIRC4), NLRC4 |
| Infection-associated HLH | EBV, CMV and other herpesviruses, HIV, influenza; bacterial, parasitic and fungal infection |
| Malignancy-associated HLH | T-lymphoblastic and other T-cell lymphomas, B-cell leukemias and lymphomas, Hodgkin lymphoma, NK-cell lymphomas and leukemias, myeloid neoplasms, solid tumors |
| HLH with rheumatologic disease (macrophage activation syndrome) | Systemic juvenile idiopathic arthritis, adult-onset Still disease, systemic lupus erythematosus, vasculitis |
| Other | Transplant-related HLH; HLH from iatrogenic immune activation; HLH during chemotherapy |
Primary HLH usually becomes evident in the first years of life, although adult onset is reported. Acute episodes may be triggered by infection or vaccination. Hematopoietic stem cell transplantation is the only cure for primary HLH (Emile 2016).
Normal spleen: structure, size and function
Structure. The spleen has a fibroelastic capsule containing some smooth muscle and is divided into lobules. White pulp forms 25% of the volume. Central arteries are surrounded by T-cell-rich periarteriolar lymphoid sheaths and B-cell follicles. The marginal zone between white and red pulp is rich in macrophages and dendritic cells and filters microorganisms and particulate antigens from the blood. Red pulp forms 75% of the volume and consists of cords, venous sinuses and perisinusoidal macrophages (Suttorp 2021).
Circulation and filtration. About 5% of the cardiac output passes through the spleen each minute, and 90% of it enters the red pulp. The microcirculation is mostly open: blood leaves arterioles into the cords and re-enters the circulation through slits between sinus endothelial cells. Senescent red cells and red cells with reduced deformability from membrane defects (spherocytosis, elliptocytosis) or hemoglobinopathies (sickle cell disease, thalassemia) cannot pass the slits and are phagocytosed by red pulp macrophages. The spleen also synthesizes IgG, properdin and tuftsin (Suttorp 2021).
Size and weight. An autopsy reference range for spleen weight is 150–250 g (Piubelli 2019). In adults, a spleen <14 cm in craniocaudal length is normal, 14–20 cm is moderately enlarged and >20 cm severely enlarged. A spleen of 500–1,000 g is splenomegalic and >1,000 g is massive (Suttorp 2021). Splenomegaly alone is unreliable for lymphoma staging, because 30% of normal-sized spleens contain lymphoma and splenomegaly can occur without infiltration (Han 2026).
Splenomegaly and hypersplenism
Hypersplenism. Hypersplenism is splenomegaly with peripheral cytopenia. Secondary hypersplenism can accompany any cause of splenomegaly, most often cirrhotic portal hypertension. Proposed mechanisms are retention of blood cells by congestion, increased phagocytosis by activated macrophages, and cytokine-mediated marrow suppression (Han 2026).
Table 4. Splenomegaly by mechanism (Han 2026, Table 1 and text).
| Mechanism | Examples | Pathologic findings |
|---|---|---|
| Congestive | Cirrhosis and portal hypertension, splenic or portal vein thrombosis, congestive heart failure | Red pulp congestion with vascular proliferation, fibrosis and activated lymphoid hyperplasia; Gamna-Gandy bodies |
| Infectious, acute | Infectious mononucleosis (splenomegaly in about 50%), cytomegalovirus, HIV, toxoplasmosis | Splenomegaly from immune activation without abscess; rapid enlargement occasionally causes rupture |
| Infectious, tropical and parasitic | Malaria, leishmaniasis, schistosomiasis | Massive splenomegaly in malaria and leishmaniasis |
| Infiltrative, non-malignant | Gaucher disease, Niemann-Pick disease, amyloidosis, sarcoidosis | Storage cells, amyloid deposits or granulomas; Gaucher disease is a cause of massive splenomegaly |
| Rheumatic | Felty syndrome, systemic lupus erythematosus | Splenomegaly with neutropenia in Felty syndrome |
| Hematologic neoplasms | Myeloproliferative neoplasms, lymphomas, leukemias | Neoplastic infiltration; extramedullary hematopoiesis in myeloproliferative neoplasms |
| Increased clearance of blood cells | Hereditary spherocytosis, sickle cell disease, thalassemia, autoimmune cytopenias | Retention and phagocytosis of red cells in the red pulp cords; iron overload in transfused patients |
Gamna-Gandy bodies. Gamna-Gandy bodies (siderotic nodules) are yellow-brown foci of iron pigment and calcium salts with fibrosis and foreign-body giant cells. They arise from small hemorrhages in portal hypertension and, in sickle cell disease, from vaso-occlusion and periarteriolar hemorrhage in the white pulp (Piubelli 2019). They usually measure <10 mm (Han 2026).
Extramedullary hematopoiesis. Extramedullary hematopoiesis develops when marrow production is inadequate, as in primary myelofibrosis, marrow infiltration and hemoglobinopathies. In the abdomen it usually produces hepatosplenomegaly, with or without masses that can mimic lymphoma (Han 2026).
Splenic rupture, infarction, asplenia and hemoglobinopathies
Rupture and hematoma. The splenic capsule is thin, and an enlarged spleen is susceptible to rupture (Han 2026). Hematoma is present in 77% of blunt splenic injuries, mostly in young adult men after motor vehicle accidents or falls. Grossly, hematoma is a broad dark red to purple area with or without capsular laceration or rupture. Microscopically, it shows hemorrhage, fibrin and variable neutrophils (Teja 2026).
Infarction. Splenic infarction is ischemic necrosis from occlusion of the splenic artery or its branches. Its mechanisms are cardiac embolism (atrial fibrillation, valvular disease, infective endocarditis, mural thrombus), in situ thrombosis in hypercoagulable states (myeloproliferative neoplasms, hemoglobinopathies, antiphospholipid syndrome, malignancy) and local vascular disease (vasculitis, atherosclerosis, aneurysm, torsion of a wandering spleen). In 67 patients, hematologic disorders were the commonest identified cause (31.3%: acute and chronic myeloid leukemia, myelofibrosis, polycythemia vera, myelodysplastic syndrome, chronic myelomonocytic leukemia, paroxysmal nocturnal hemoglobinuria and sickle cell anemia), and 4 of 16 tested patients (25%) carried a JAK2 mutation. No cause was found in 23.9% (Karabulut 2026).
Sickle cell disease and other hemolytic disorders. Repeated vaso-occlusion causes ischemia, infarction and eventual autosplenectomy (Han 2026). In an autopsy of an adult with sickle cell anemia, the spleen weighed 4 g, with fibrinous capsule and Gamna-Gandy bodies (Piubelli 2019). In hereditary spherocytosis and other disorders of red cell deformability, abnormal red cells are retained in the red pulp cords and phagocytosed (Suttorp 2021), with splenomegaly from increased clearance (Han 2026).
Asplenia and hyposplenism. Howell-Jolly bodies in circulating red cells are common in asplenic or hyposplenic patients. Asplenic patients lack splenic macrophages that filter and phagocytose encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis. Overwhelming post-splenectomy infection can progress to fulminant sepsis with a case-fatality rate of 40%–54%, and Capnocytophaga canimorsus from dog or cat bites is a recognized cause (Hsia 2026).
Splenic cysts and benign vascular-stromal lesions
Table 5. Splenic cysts and benign tumors (Teja 2026; Wang 2022; Cao 2019; Kaza 2010; Song 2025; Lin 2026).
| Lesion | Key features | Immunophenotype and associations |
|---|---|---|
| Epithelial (true) cyst | 10% of benign nonparasitic splenic cysts; children and young adults; thin fibrous wall lined by squamous, columnar or cuboidal epithelium; thought to arise from mesothelial invagination | Epithelial lining separates it from pseudocyst |
| Pseudocyst | 70%–80% of nonparasitic cysts; dense fibrous wall without epithelium; may calcify | Previous trauma or infection |
| Hydatid cyst | 0.5%–0.8% of echinococcal disease; laminated acellular outer wall, inner germinal layer and daughter cysts | Echinococcus |
| Lymphangioma | 80%–90% in children younger than 2 years; thin-walled cysts lined by a single layer of flattened endothelium | Lymphatic endothelium |
| Hemangioma | Most common benign primary splenic neoplasm; mean age about 60 years; usually solitary and <4 cm; thin-walled vascular channels | Spongy red-blue nodules; larger cavernous lesions with infarction or necrosis |
| Littoral cell angioma | Usually multiple; mean age 56 years; anastomosing sinus-like channels and cyst-like spaces lined by tall cells with hemosiderin and hemophagocytosis, without atypia or significant mitoses | Histiocytic markers CD163 (63/63), CD68 (99.7%) and lysozyme (99.1%); endothelial CD31, factor VIII (98.4%) and ERG (97.2%); CD34 in 54.3%, CD21 in 57.1% and CD8 in only 11.7%; WT1 negative; comorbid malignancy in 13.8%, and comorbid immune dysfunction (Wang 2022); littoral cell hemangioendothelioma and angiosarcoma share the phenotype (Lin 2026) |
| Sclerosing angiomatoid nodular transformation (SANT) | Ages 30–60 years, slight female predominance; angiomatoid nodules in fibrosclerotic stroma, often with a stellate central scar | CD31 throughout the angiomatoid nodules; CD34 in capillary-type lining and surrounding spindle cells; CD8 in sinusoid-type lining cells; focal CD68 (Cao 2019) |
| Splenic hamartoma | About 3 per 200,000 splenectomies; 20% in children (Song 2025); malformed red pulp elements without organized lymphoid follicles (Kaza 2010) | CD8-positive sinus lining; hypersplenism symptoms in 15% (Song 2025) |
| Inflammatory pseudotumor | Middle-aged and older adults, female predominance; inflammatory cells and spindle cells in collagenous stroma | Spindle cells suggest an EBV-positive lesion |
Littoral cells line the venous sinuses of the red pulp, show endothelial and histiocytic differentiation and sequester and phagocytose senescent red cells (Tohfa 2026). Splenic angiosarcoma is rare and aggressive, with pleomorphic malignant endothelial cells (Teja 2026). Atypia, mitotic activity and destructive growth separate it from littoral cell angioma (Tohfa 2026).
Lymphoma and leukemia in the spleen
Primary splenic lymphoma, confined to the spleen and hilar nodes, accounts for <1%–2% of non-Hodgkin lymphomas. Secondary involvement is frequent. Diffuse large B-cell lymphoma is the commonest lymphoma involving the spleen (23%–46%). Splenic lymphomas show white pulp, red pulp and nodular patterns (Teja 2026).
Table 6. Patterns of lymphoma and leukemia in the spleen (Schmieg 2021, Table 1; de Leval 2023, Table 4; Sinit 2020; Teja 2026; Hanna 2025).
| Gross and microscopic pattern | Entities |
|---|---|
| Diffuse miliary small white nodules (white pulp) | Splenic marginal zone lymphoma (white pulp with secondary red pulp extension); secondary involvement by follicular lymphoma, mantle cell lymphoma and CLL/SLL; classic Hodgkin lymphoma rarely |
| Large mass-like nodules, solitary or multiple | Diffuse large B-cell lymphoma, with primary splenic DLBCL centered on the white pulp; higher-grade follicular lymphoma; classic Hodgkin lymphoma |
| Homogeneous beefy red cut surface (diffuse red pulp) with atrophic white pulp | Hairy cell leukemia; splenic diffuse red pulp small B-cell lymphoma; splenic B-cell lymphoma/leukemia with prominent nucleoli (WHO-HAEM5) or HCL variant (ICC); hepatosplenic T-cell lymphoma (sinuses and cords); T-prolymphocytic leukemia |
| Red pulp with often hyperplastic white pulp | T-large granular lymphocytic leukemia |
| Subtle red pulp and vessel-wall infiltration | Aggressive NK-cell leukemia |
Among the CD5-negative, CD10-negative small B-cell neoplasms, splenic marginal zone lymphoma is the only one centered on the white pulp. CLL/SLL, follicular lymphoma and mantle cell lymphoma can produce the same miliary pattern but are usually CD5-positive or CD10-positive and involve the spleen secondarily (Schmieg 2021).
Blood, marrow and immunophenotypic features of the splenic B-cell lymphomas are compared in Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia. Large B-cell and T-cell lymphomas are taught in Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging and Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas.
Accessory spleen and splenosis
Accessory spleen. An accessory spleen results from incomplete fusion of the embryonic splenic buds. It occurs in 10% of the population, most often at the splenic hilum; the pancreatic tail is the second most common site (Saunders 2016; Filardi 2025). Intrapancreatic accessory spleen and its distinction from a pancreatic neuroendocrine tumor are taught in Normal pancreas, gastrointestinal contaminants and EUS-guided sampling.
Splenosis. Splenosis is autotransplantation of viable splenic tissue after splenectomy, abdominal trauma or splenic rupture. Implants on the serosa of the bowel, parietal peritoneum and mesentery are relatively common. Intrahepatic splenosis is rare and mimics hepatocellular carcinoma, adenoma and focal nodular hyperplasia (Toh 2020).
References
- Abbondanzo SL, Irey NS, Frizzera G. Dilantin-associated lymphadenopathy. Spectrum of histopathologic patterns. Am J Surg Pathol. 1995;19(6):675–686. doi:10.1097/00000478-199506000-00008. PMID 7755154 (abstract)
- Abdullah SAA, Goa P, Vandenberghe E, et al. Update on the pathogenesis of enteropathy-associated T-cell lymphoma. Diagnostics (Basel). 2023;13(16):2629. doi:10.3390/diagnostics13162629. PMID 37627888
- Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131(26):2877–2890. doi:10.1182/blood-2018-03-839753. PMID 29720485
- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2. PMID 35732829
- Amin SE, Gite S, Wanger A, et al. Whipple disease initial presentation as supraclavicular lymphadenopathy in a patient with rheumatoid arthritis: a diagnostic challenge. Int J Surg Pathol. 2025;33(8):1816–1823. doi:10.1177/10668969251342475. PMID 40398847 (case report)
- Aruga Y, Ikeda C, Matsushita H, et al. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype. Sci Rep. 2024;14(1):13452. doi:10.1038/s41598-024-64398-6. PMID 38862612
- Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43(24):2739–2751. doi:10.1200/JCO-24-01893. PMID 40489728
- Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477–5485. doi:10.1182/blood-2008-01-132837. PMID 18388178
- Boyko G, Makarov I. Difficult diagnosis of interdigitating dendritic cell sarcoma of the retroperitoneum: a case report and a brief review of the literature. Turk Patoloji Derg. 2026;42(1):59–63. doi:10.5146/tjpath.2024.13546. PMID 39171855 (case report)
- Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229–1253. doi:10.1182/blood.2022015851. PMID 35653592
- Cao P, Wang K, Wang C, Wang H. Sclerosing angiomatoid nodular transformation in the spleen: a case series study and literature review. Medicine (Baltimore). 2019;98(17):e15154. doi:10.1097/MD.0000000000015154. PMID 31027058
- Carbone A, Alibrahim MN. Hodgkin lymphoma classification: from historical concepts to current refinements. Cancers (Basel). 2025;17(17):2929. doi:10.3390/cancers17172929. PMID 40941026
- Chan WL, Hue SS, Deng L, et al. Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications. Lancet Reg Health West Pac. 2025;62:101550. doi:10.1016/j.lanwpc.2025.101550. PMID 41132165
- Chen LYC, Zhang L, Fajgenbaum DC. Expert perspective: diagnosis and treatment of Castleman disease. Arthritis Rheumatol. 2026;78(1):12–25. doi:10.1002/art.43269. PMID 40457814
- Chen X, Wu L, Kuang C, et al. Pediatric acute lymphoblastic leukemia relapse and prognosis: key predictors and therapeutic implications. Front Pediatr. 2025;13:1710578. doi:10.3389/fped.2025.1710578. PMID 41488897
- Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800. PMID 25113753
- Cho H, Kim K, Yoon SE, et al. Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: a nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202). Hemasphere. 2024;8(1):e33. doi:10.1002/hem3.33. PMID 38434530
- Cho J. Basic immunohistochemistry for lymphoma diagnosis. Blood Res. 2022;57(S1):55–61. doi:10.5045/br.2022.2022037. PMID 35483927
- Chuang SS, Chang CC. Diagnostic challenges posed by the wide morphological and immunophenotypic spectrum of plasma cell neoplasms. Blood Res. 2026;61(1):61. doi:10.1007/s44313-026-00179-6. PMID 42826002
- Clinical and Laboratory Standards Institute. Validation of Assays Performed by Flow Cytometry. 1st ed. CLSI guideline H62. October 27, 2021. https://clsi.org/shop/standards/h62/ (product page accessed 2026-11-17) (CLSI 2021)
- College of American Pathologists. Protocol for the Examination of Plasma Cell Malignancies and Immunoglobulin Deposition Related Disorders, version 1.0.0.1. September 2025. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17) (CAP 2025)
- College of American Pathologists. Protocol for the Examination of Specimens From Patients With Precursor and Mature Lymphoid Malignancies, version 1.0.0.2. September 2026. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17) (CAP 2026)
- Colombat M, Gaspard M, Camus M, et al. Mass spectrometry-based proteomics in clinical practice amyloid typing: state-of-the-art from a French nationwide cohort. Haematologica. 2022;107(12):2983–2987. doi:10.3324/haematol.2022.281431. PMID 35924579
- Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–156. doi:10.1016/S1470-2045(08)70314-0. PMID 19147408
- D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406–3418. doi:10.1200/JCO.21.02614. PMID 35605179 (abstract)
- Davis BH, Holden JT, Bene MC, et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B Clin Cytom. 2007;72 Suppl 1:S5–S13. doi:10.1002/cyto.b.20365. PMID 17803188 (abstract)
- Davis BH, Wood B, Oldaker T, Barnett D. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS – part I – rationale and aims. Cytometry B Clin Cytom. 2013;84(5):282–285. doi:10.1002/cyto.b.21104. PMID 24022850 (abstract)
- de Leval L, Feldman AL, Pileri S, Nakamura S, Gaulard P. Extranodal T- and NK-cell lymphomas. Virchows Arch. 2023;482(1):245–264. doi:10.1007/s00428-022-03434-0. PMID 36336765
- Dejoie T, Corre J, Caillon H, et al. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia. 2019;33(2):313–318. doi:10.1038/s41375-018-0339-y. PMID 30573778
- Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–1192. doi:10.1038/modpathol.2012.72. PMID 22596100 (abstract)
- Dharan M. Hyaline globules in ectopic decidua in a pregnant woman with cervical squamous cell carcinoma. Diagn Cytopathol. 2009;37(9):696–698. doi:10.1002/dc.21113. PMID 19526574 (case report; abstract)
- Di Rocco A, Petrucci L, Assanto GM, et al. Extranodal marginal zone lymphoma: pathogenesis, diagnosis and treatment. Cancers (Basel). 2022;14(7):1742. doi:10.3390/cancers14071742. PMID 35406516
- Dictor M, Ek S, Sundberg M, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica. 2009;94(11):1563–1568. doi:10.3324/haematol.2009.008474. PMID 19880779 (abstract)
- Ding Y, Jaffe ES. Histopathologic features and differential diagnosis in challenging cases of nodular lymphocyte predominant B-cell lymphoma/nodular lymphocyte predominant Hodgkin lymphoma. J Clin Transl Pathol. 2024;4(2):61–69. doi:10.14218/jctp.2024.00015. PMID 39070246
- Dispenzieri A. POEMS syndrome: 2026 update on diagnosis, risk-stratification, and management. Am J Hematol. 2026;101(10):2632–2651. doi:10.1002/ajh.70438. PMID 42411740
- Dorfman DM. The flow cytometric evaluation of B- and T-lymphoblastic leukemia/lymphoma. Cancers (Basel). 2025;17(7):1111. doi:10.3390/cancers17071111. PMID 40227608
- Duffield AS, Mullighan CG, Borowitz MJ. International Consensus Classification of acute lymphoblastic leukemia/lymphoma. Virchows Arch. 2023;482(1):11–26. doi:10.1007/s00428-022-03448-8. PMID 36422706
- Duminuco A, Scarso S, Del Fabro V, et al. Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk. Ann Hematol. 2025;104(10):4897–4911. doi:10.1007/s00277-025-06686-3. PMID 41114812
- Elbaz Younes I, Sokol L, Zhang L. Rosai-Dorfman disease between proliferation and neoplasia. Cancers (Basel). 2022;14(21):5271. doi:10.3390/cancers14215271. PMID 36358690
- Elieh-Ali-Komi D, Maurer M, Siebenhaar F. The impact of mast cells on the anatomy, cellular communication, and molecular immune network of lymph nodes. Clin Rev Allergy Immunol. 2025;68(1):35. doi:10.1007/s12016-025-09050-5. PMID 40175843
- Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681. doi:10.1182/blood-2016-01-690636. PMID 26966089
- Facchetti F, Simbeni M, Lorenzi L. Follicular dendritic cell sarcoma. Pathologica. 2021;113(5):316–329. doi:10.32074/1591-951X-331. PMID 34837090
- Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–1657. doi:10.1182/blood-2016-10-746933. PMID 28087540
- Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363(9424):1869–1870. doi:10.1016/S0140-6736(04)16356-3. PMID 15183626 (abstract)
- Feitosa VA, Neves PDMM, Jorge LB, Noronha IL, Onuchic LF. Renal amyloidosis: a new time for a complete diagnosis. Braz J Med Biol Res. 2022;55:e12284. doi:10.1590/1414-431X2022e12284. PMID 36197414
- Fend F, van den Brand M, Groenen PJ, et al. Diagnostic and prognostic molecular pathology of lymphoid malignancies. Virchows Arch. 2024;484(2):195–214. doi:10.1007/s00428-023-03644-0. PMID 37747559
- Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192. doi:10.1038/s41408-021-00587-0. PMID 34857730
- Ferrara G, Gualandi A. Epstein-Barr virus-related lymphoproliferative disorders of the skin. Dermatol Reports. 2024;16(Suppl 2):9916. doi:10.4081/dr.2024.9916. PMID 39295880
- Ferri C, Gragnani L, Zignego AL, Giuggioli D. Cryoglobulinemia, monoclonal and mixed cryoglobulinemia syndromes, cryoglobulinemic vasculitis: a proposal for comprehensive nomenclature and definition. Front Immunol. 2026;17:1754012. doi:10.3389/fimmu.2026.1754012. PMID 41798958
- Ferry JA, Hill B, Hsi ED. Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification. J Hematol Oncol. 2024;17(1):51. doi:10.1186/s13045-024-01570-5. PMID 38978094
- Filardi KFXC, Júnior JDM, Costa TN, et al. Intrapancreatic accessory spleen mimicking a pancreatic neuroendocrine tumour: an important but almost forgotten differential diagnosis. J Minim Access Surg. 2025;21(3):321–325. doi:10.4103/jmas.jmas_245_24. PMID 40485610 (case report)
- Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103. doi:10.1038/leu.2017.29. PMID 28104919
- Fuji S, Tokunaga M, Cook L, et al. Utility of flow cytometry for prognostic prediction in adult T-cell leukemia/lymphoma. EJHaem. 2026;7(4):e70345. doi:10.1002/jha2.70345. PMID 42405269
- Fujita R, Ono S, Sakamoto S, et al. Hodgkin lymphoma with sarcoid-like reaction: importance of clinicopathological correlation in granulomatous lymphadenopathy. Am J Case Rep. 2026;27:e954572. doi:10.12659/AJCR.954572. PMID 42862779 (case report; abstract)
- Gallan AJ, Antic T. Benign müllerian glandular inclusions in men undergoing pelvic lymph node dissection. Hum Pathol. 2016;57:136–139. doi:10.1016/j.humpath.2016.07.003. PMID 27438608 (abstract)
- Gan GG, Wong LLL, Abdul Rahman MHF, et al. Malaysian expert consensus guidelines for the diagnosis and management of multiple myeloma: a modified Delphi approach. Malays J Med Sci. 2026;33(4):7–36. doi:10.21315/mjms-03-2026-153. PMID 42936371
- García-Díaz N, Piris MA, Ortiz-Romero PL, et al. Mycosis fungoides and Sézary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy. Cancers (Basel). 2021;13(8):1931. doi:10.3390/cancers13081931. PMID 33923722
- García-Molina F, Cegarra-Navarro MF, Andrade-Gonzales RJ, Martinez-Díaz F. Cytologic and histologic features of COVID-19 post-vaccination lymphadenopathy. Cytojournal. 2021;18:34. doi:10.25259/Cytojournal_21_2021. PMID 35126612 (abstract)
- Gibson SE, Dojcinov S, Dotlic S, et al. Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology. Virchows Arch. 2023;483(6):733–749. doi:10.1007/s00428-023-03550-5. PMID 37530791
- Glencross D, Scott LE, Jani IV, et al. CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration. Cytometry. 2002;50(2):69–77. doi:10.1002/cyto.10068. PMID 12116348 (abstract)
- González-Peramato P, Jiménez-Heffernan JA, Sabater C, Vicandi B. Lipogranulomatous lymphadenopathy as a potential source of error in fine needle aspiration cytology. A case report. Acta Cytol. 2002;46(4):772–775. doi:10.1159/000326995. PMID 12146051 (case report; abstract)
- Goyal G, Abla O, Chan J, et al. Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas). Blood. 2026;148(3):275–288. doi:10.1182/blood.2026033049. PMID 41915766 (abstract)
- Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135(22):1929–1945. doi:10.1182/blood.2019003507. PMID 32187362 (abstract)
- Gutierrez-Lanz E, Smith LB, Perry AM. Syphilis in hematopathology practice: a diagnostic challenge. Arch Pathol Lab Med. 2024;148(6):633–641. doi:10.5858/arpa.2023-0078-RA. PMID 37535664 (abstract)
- Halcu G, Evsei-Seceleanu A, Cerbu M, et al. From biopsy to diagnosis: navigating aggressive B-cell lymphomas in practice. Medicina (Kaunas). 2025;61(5):842. doi:10.3390/medicina61050842. PMID 40428800
- Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi:10.1182/blood-2017-09-806398. PMID 29540348 (abstract; criteria cited from Hallek 2025)
- Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025;100(3):450–480. doi:10.1002/ajh.27546. PMID 39871707
- Halloush RA, Lavrovskaya E, Mody DR, Lager D, Truong L. Diagnosis and typing of systemic amyloidosis: the role of abdominal fat pad fine needle aspiration biopsy. Cytojournal. 2010;6:24. doi:10.4103/1742-6413.58950. PMID 20165547
- Han NY, Park Y, Kim MJ. Radiological approach to splenomegaly: etiologies, pathophysiologies, and diagnostic strategies. Korean J Radiol. 2026;27(2):122–136. doi:10.3348/kjr.2025.0848. PMID 41494793
- Hanna M, Trus M, DiMaria E. Splenic diffuse red pulp small B-cell lymphoma with overlapping clinical and immunophenotypic features with hairy cell leukaemia: a case report and a review of the literature. Genes (Basel). 2025;16(4):467. doi:10.3390/genes16040467. PMID 40282427 (case report)
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545. PMID 14504078 (abstract)
- Hartmann S, Winkelmann R, Metcalf RA, et al. Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma. Hum Pathol. 2015;46(11):1655–1661. doi:10.1016/j.humpath.2015.07.006. PMID 26410017 (abstract)
- Henter JI, Sieni E, Eriksson J, et al. Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited. Blood. 2024;144(22):2308–2318. doi:10.1182/blood.2024025077. PMID 39046779
- Hermine O, Ramos JC, Tobinai K. A review of new findings in adult T-cell leukemia-lymphoma: a focus on current and emerging treatment strategies. Adv Ther. 2018;35(2):135–152. doi:10.1007/s12325-018-0658-4. PMID 29411267
- Hicks DG, Judkins AR, Sickel JZ, et al. Granular histiocytosis of pelvic lymph nodes following total hip arthroplasty. The presence of wear debris, cytokine production, and immunologically activated macrophages. J Bone Joint Surg Am. 1996;78(4):482–496. doi:10.2106/00004623-199604000-00002. PMID 8609127 (abstract)
- Hicks J, Flaitz C. Progressive transformation of germinal centers: review of histopathologic and clinical features. Int J Pediatr Otorhinolaryngol. 2002;65(3):195–202. doi:10.1016/s0165-5876(02)00176-3. PMID 12242134 (abstract)
- Horna P, Weybright MJ, Ferrari M, et al. Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry. Blood Cancer J. 2024;14(1):34. doi:10.1038/s41408-024-01002-0. PMID 38424120
- Hsia M, Ahmad M, Hsia CC, Chin-Yee B. Overwhelming post-splenectomy sepsis from Capnocytophaga canimorsus. Int J Lab Hematol. 2026;48(6):1272–1273. doi:10.1111/ijlh.70190. PMID 42380042 (case report)
- Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–2539. doi:10.3324/haematol.2020.247031. PMID 33054110
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–757. doi:10.1046/j.1365-2141.2003.04355.x. PMID 12780789 (abstract) (IMWG 2003)
- Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–3634. PMID 14506150 (abstract)
- Ishikawa E, Nakamura M, Satou A, Shimada K, Nakamura S. Mucosa-associated lymphoid tissue (MALT) lymphoma in the gastrointestinal tract in the modern era. Cancers (Basel). 2022;14(2):446. doi:10.3390/cancers14020446. PMID 35053607
- Jabbour E, Kantarjian H. Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies. Blood Cancer J. 2026;16(1). doi:10.1038/s41408-026-01566-z. PMID 42401567
- Jabcuga CE, Jin L, Macon WR, et al. Broadening the morphologic spectrum of Bartonella henselae lymphadenitis: analysis of 100 molecularly characterized cases. Am J Surg Pathol. 2016;40(3):342–347. doi:10.1097/PAS.0000000000000552. PMID 26551620 (abstract)
- Jalal SD. The contribution of CD200 to the diagnostic accuracy of Matutes score in the diagnosis of chronic lymphocytic leukemia in limited resources laboratories. PLoS One. 2021;16(2):e0247491. doi:10.1371/journal.pone.0247491. PMID 33606850
- Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986–2010. doi:10.1038/leu.2012.122. PMID 22948490
- Karabulut Ü, Ebik B, Yolaçan R, et al. Underlying thrombotic conditions in patients with splenic infarction: a 10-year retrospective analysis. Thromb J. 2026;24(1):87. doi:10.1186/s12959-026-00922-0. PMID 42791562
- Kaspi E, Grosdidier C, Berda-Haddad Y, et al. Challenges and clinical relevance in diagnosing metastatic cells from non-hematopoietic malignancies in bone marrow aspirates. Cancer Med. 2025;14(3):e70645. doi:10.1002/cam4.70645. PMID 39907157
- Kaza RK, Azar S, Al-Hawary MM, Francis IR. Primary and secondary neoplasms of the spleen. Cancer Imaging. 2010;10:173–182. doi:10.1102/1470-7330.2010.0026. PMID 20713317
- Keyrouz E, Boueri M, Akl T, et al. Progressive transformation of germinal centers: a systematic review. Cureus. 2026;18(2):e104275. doi:10.7759/cureus.104275. PMID 41909388
- Khanlari M, Chapman JR. Follicular lymphoma: updates for pathologists. J Pathol Transl Med. 2022;56(1):1–15. doi:10.4132/jptm.2021.09.29. PMID 34942689
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1. PMID 35732831
- Kim HS, Yoon G, Kim BG, Song SY. Decidualization of intranodal endometriosis in a postmenopausal woman. Int J Clin Exp Pathol. 2015;8(1):1025–1030. PMID 25755813 (case report) (Kim 2015b)
- Kim HS, Yoon G, Lee YY, et al. Mesothelial cell inclusions in pelvic and para-aortic lymph nodes: a clinicopathologic analysis. Int J Clin Exp Pathol. 2015;8(5):5318–5326. PMID 26191233 (Kim 2015a)
- Kim NI, Lee HJ, Lee JS. Silicone lymphadenopathy of the axilla: a potential for misdiagnosis as metastatic carcinoma on fine-needle aspiration cytology. J Pathol Transl Med. 2026;60(6):726–731. doi:10.4132/jptm.2026.09.08. PMID 42973144 (abstract)
- Kittai AS, Marchetti M, Al-Sawaf O, et al. International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations. Blood. 2025;146(3):291–303. doi:10.1182/blood.2024028064. PMID 40239121 (abstract)
- Kobayashi G, Imai T, Sentani K. Distribution and clinicopathological features of Mott cells (plasma cells containing Russell bodies) in gastric cancer: presence of Mott cells is associated with favorable prognosis. J Clin Med. 2024;13(3):658. doi:10.3390/jcm13030658. PMID 38337351 (abstract)
- Koga S, Yang Z, Alipour Z. Crystal-storing histiocytosis of the duodenum in a patient with IgG-lambda multiple myeloma. Int J Surg Pathol. 2025;33(8):1846–1851. doi:10.1177/10668969251343639. PMID 40440188 (abstract; case report)
- Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. doi:10.1016/S1470-2045(16)30206-6. PMID 27511158 (abstract)
- Kurz KS, Kalmbach S, Ott M, et al. Follicular lymphoma in the 5th edition of the WHO-classification of haematolymphoid neoplasms: updated classification and new biological data. Cancers (Basel). 2023;15(3):785. doi:10.3390/cancers15030785. PMID 36765742
- Ladha A, Zhao J, Epner EM, et al. Mantle cell lymphoma and its management: where are we now? Exp Hematol Oncol. 2019;8:2. doi:10.1186/s40164-019-0126-0. PMID 30733891
- Lamps LW, Scott MA. Cat-scratch disease: historic, clinical, and pathologic perspectives. Am J Clin Pathol. 2004;121 Suppl:S71–S80. doi:10.1309/JC8YM53L4E0L6PT5. PMID 15298152 (abstract)
- Lecuit M, Chatelain D, Courpied JP, et al. Tissue reactions to wear debris of joint prostheses. Diagnostic problems. Apropos of 2 cases [in French]. Rev Chir Orthop Reparatrice Appar Mot. 1999;85(6):636–639. PMID 10575728 (case report; abstract)
- Lee H. Mycosis fungoides and Sézary syndrome. Blood Res. 2023;58(S1):66–82. doi:10.5045/br.2023.2023023. PMID 37105561
- Lee M, Alkhafaji H, Cantu M, et al. Grade 3 pulmonary lymphomatoid granulomatosis diagnosed by robotic-assisted bronchoscopy: a case report. Case Rep Pulmonol. 2026;2026:5840915. doi:10.1155/crpu/5840915. PMID 41808960 (case report)
- Leijnen F, Lammens T. Decoding NOTCH1: from T-cell development guardian to driver of pediatric T-cell lymphoblastic lymphoma. Int J Mol Sci. 2026;27(4):2083. doi:10.3390/ijms27042083. PMID 41752218
- Li M, Hu T, Liu Z, et al. Gastric histiocytic sarcoma: a case report and literature review. Front Surg. 2026;13:1884156. doi:10.3389/fsurg.2026.1884156. PMID 42609495 (case report)
- Liao V, Stuver RN, Geller S. Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome. Front Oncol. 2026;16:1881519. doi:10.3389/fonc.2026.1881519. PMID 42459326
- Liaskas A, Dimopoulou MN, Piperidou A, et al. Current issues and future perspectives of targeted therapies in primary mediastinal large B-cell lymphoma. J Clin Med. 2025;14(4):1191. doi:10.3390/jcm14041191. PMID 40004722
- Lim KJ, Pertile H, Spencer A. Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy. Front Immunol. 2026;17:1932648. doi:10.3389/fimmu.2026.1932648. PMID 42857591
- Lim MS, Straus SE, Dale JK, et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol. 1998;153(5):1541–1550. doi:10.1016/S0002-9440(10)65742-2. PMID 9811346 (abstract)
- Lin H, Wang X, Zhang L. Isolated splenic littoral cell angioma in a child: a case report. Front Oncol. 2026;16:1770088. doi:10.3389/fonc.2026.1770088. PMID 42382387 (case report)
- Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018;8:63–70. doi:10.2147/BLCTT.S142814. PMID 31360094
- Louissaint A Jr, Ferry JA, Soupir CP, et al. Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features. Mod Pathol. 2012;25(8):1149–1159. doi:10.1038/modpathol.2012.70. PMID 22627742 (abstract)
- Luniewski A, Chaudhary S, Goldfarb A, et al. EBV-driven NK/T-cell lymphoproliferative disorders: clinical diversity and molecular insights. Lymphatics. 2026;4(1):7. doi:10.3390/lymphatics4010007. PMID 41657941
- Luo J, Muffly L. Complexities of measurable residual disease assays in acute lymphoblastic leukemia: a guide for the practicing clinician. Acta Haematol. 2026;149(1):76–83. doi:10.1159/000547423. PMID 40652938
- Mahajan VK, Sharma V, Sharma N, Rani R. Kikuchi-Fujimoto disease: a comprehensive review. World J Clin Cases. 2023;11(16):3664–3679. doi:10.12998/wjcc.v11.i16.3664. PMID 37383134
- Malik IO, Malviya M. Herpes simplex virus necrotic lymphadenitis masquerading as lymphoma. Cureus. 2024;16(6):e62485. doi:10.7759/cureus.62485. PMID 39015865 (case report; abstract)
- Mandy FF, Nicholson JK, McDougal JS; CDC. Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. MMWR Recomm Rep. 2003;52(RR-2):1–13. PMID 12583540 (abstract)
- Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102. doi:10.1038/s41408-020-00366-3. PMID 33067414
- Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2013;8:137. doi:10.1186/1750-1172-8-137. PMID 24011030
- McKenna RW, Washington LT, Aquino DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98(8):2498–2507. doi:10.1182/blood.v98.8.2498. PMID 11588048 (abstract)
- McKinnon KM. Flow cytometry: an overview. Curr Protoc Immunol. 2018;120:5.1.1–5.1.11. doi:10.1002/cpim.40. PMID 29512141
- Mirandari A, Parker H, Ashton-Key M, et al. The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications. Explor Target Antitumor Ther. 2024;5(4):877–901. doi:10.37349/etat.2024.00253. PMID 39280243
- Mogensen BH, Nielsen TH, Pedersen MØ, et al. Core needle biopsies in patients with lymphoproliferative malignancies: an observational single-center cohort study. Eur J Haematol. 2026;116(1):85–92. doi:10.1111/ejh.70045. PMID 41074872 (abstract)
- Moore ME, Aguilera NS, Obiorah I, et al. Assessment for acceleration and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma using histologic and immunohistochemical features: a case series. J Hematop. 2024;17(3):139–147. doi:10.1007/s12308-024-00598-3. PMID 39042242
- Mori S. Demonstration of isolated follicular dendritic cells in lymphatic vessels around human immunodeficiency virus-infected lymph nodes. Virchows Arch. 1994;424(4):397–401. doi:10.1007/BF00190562. PMID 7515756 (abstract)
- Müller CSL, Müller SG, Vogt T, Pföhler C. Current concepts of ectopic nodal inclusions with special emphasis on nodal nevi. J Dtsch Dermatol Ges. 2021;19(8):1145–1157. doi:10.1111/ddg.14521. PMID 34390159 (abstract)
- Nguyen HTK, Terao MA, Green DM, Pui CH, Inaba H. Testicular involvement of acute lymphoblastic leukemia in children and adolescents: diagnosis, biology, and management. Cancer. 2021;127(17):3067–3081. doi:10.1002/cncr.33609. PMID 34031876
- Nishikori A, Nishimura MF, Fajgenbaum DC, et al. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): factors to differentiate from IgG4-related disease. J Clin Pathol. 2025;79(1):43–49. doi:10.1136/jcp-2023-209280. PMID 38378248
- Oh S, Koo DH, Suh C, et al. Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy. J Korean Med Sci. 2011;26(12):1556–1562. doi:10.3346/jkms.2011.26.12.1556. PMID 22147991
- Ondrejka SL, de Leval L. Modern approach to nodal T-cell lymphomas. Adv Anat Pathol. 2025;32(3):220–238. doi:10.1097/PAP.0000000000000492. PMID 40205889
- Organizing Committee of the Lugano Classification Workshop. Current status of revisions to the Lugano classification in lymphoma. Hematol Oncol. 2025;43(4):e70103. doi:10.1002/hon.70103. PMID 40525613 (Lugano Workshop 2025)
- Oršolić M, Sarač N, Balen Topić M. Vector-borne zoonotic lymphadenitis—the causative agents, epidemiology, diagnostic approach, and therapeutic possibilities—an overview. Life (Basel). 2024;14(9):1183. doi:10.3390/life14091183. PMID 39337966
- Ortiz-Hidalgo C, Pina-Oviedo S. Primary cutaneous anaplastic large cell lymphoma: a review of clinical, morphological, immunohistochemical, and molecular features. Cancers (Basel). 2023;15(16):4098. doi:10.3390/cancers15164098. PMID 37627126
- Paiva DD, Morais JC, Pilotto J, et al. Spectrum of morphologic changes of lymph nodes in HIV infection. Mem Inst Oswaldo Cruz. 1996;91(3):371–379. doi:10.1590/s0074-02761996000300023. PMID 9040859 (abstract)
- Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267. PMID 26240224
- Park SH, Lee YJ, Kim Y, et al. T-large granular lymphocytic leukemia. Blood Res. 2023;58(S1):S52–S57. doi:10.5045/br.2023.2023037. PMID 37026382
- Piccaluga PP, Khattab SS. A comparison of the fifth World Health Organization and the International Consensus Classifications of mature T-cell lymphomas. Int J Mol Sci. 2023;24(18):14170. doi:10.3390/ijms241814170. PMID 37762472
- Pires AM, Barreto JP, Caetano J, et al. Multiple myeloma laboratory diagnostics made simple: practical insights and key recommendations. J Clin Med. 2025;14(19):7115. doi:10.3390/jcm14197115. PMID 41096195
- Piubelli MLM, Clemente LC, Duarte-Neto AN. Gamna-Gandy bodies of the spleen in sickle cell disease. Autops Case Rep. 2019;9(2):e2018076. doi:10.4322/acr.2018.076. PMID 30963054 (case report)
- Rack KA, van den Berg E, Haferlach C, et al. European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia. 2019;33(8):1851–1867. doi:10.1038/s41375-019-0378-z. PMID 30696948
- Radhakrishnan VS, Lokireddy P, Parihar M, et al. Mantle cell lymphoma: a clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. Cancer Rep (Hoboken). 2022;5(7):e1590. doi:10.1002/cnr2.1590. PMID 34821081
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5. PMID 25439696 (abstract)
- Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812–817. doi:10.1182/blood-2005-03-1038. PMID 15855274
- Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802–1824. doi:10.1002/ajh.27422. PMID 38943315
- Rangan A, Reinig E, McPhail ED, Rech KL. Immunohistochemistry for LEF1 and SOX11 adds diagnostic specificity in small B-cell lymphomas. Hum Pathol. 2022;121:29–35. doi:10.1016/j.humpath.2022.01.001. PMID 35066013 (abstract)
- Ravindran A, Goyal G, Failing JJ, et al. Florid dermatopathic lymphadenopathy—a morphological mimic of Langerhans cell histiocytosis. Clin Case Rep. 2018;6(8):1637–1638. doi:10.1002/ccr3.1663. PMID 30147924 (case report)
- Rawstron AC, Kreuzer KA, Soosapilla A, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2018;94(1):121–128. doi:10.1002/cyto.b.21595. PMID 29024461
- Riefolo M, Conti M, Longhi S, Fabbrizio B, Leone O. Amyloidosis: what does pathology offer? The evolving field of tissue biopsy. Front Cardiovasc Med. 2022;9:1081098. doi:10.3389/fcvm.2022.1081098. PMID 36545023
- Robak T, Krawczynska A, Cebula-Obrzut B, et al. Atypical chronic lymphocytic leukemia: the current status. Cancers (Basel). 2023;15(18):4427. doi:10.3390/cancers15184427. PMID 37760396
- Rodolfi S, Della-Torre E, Bongiovanni L, et al. Lymphadenopathy in the rheumatology practice: a pragmatic approach. Rheumatology (Oxford). 2024;63(6):1484–1493. doi:10.1093/rheumatology/kead644. PMID 38109670
- Růžičková T, Kaščák M, Chyra Z, et al. Decoding Waldenström macroglobulinemia through genomics, epigenomics and cellular interactions. Int J Mol Sci. 2026;27(12):5173. doi:10.3390/ijms27125173. PMID 42352898
- Samaha Y, Hugo H, Asrani R. Adult T-cell leukemia/lymphoma: molecular pathogenesis, emerging therapies, and future directions. Front Oncol. 2026;16:1794939. doi:10.3389/fonc.2026.1794939. PMID 41988134
- Saunders TA, Miller TR, Khanafshar E. Intrapancreatic accessory spleen: utilization of fine needle aspiration for diagnosis of a potential mimic of a pancreatic neoplasm. J Gastrointest Oncol. 2016;7(Suppl 1):S62–S65. doi:10.3978/j.issn.2078-6891.2015.030. PMID 27034814 (case report)
- Schmieg JJ, Muir JM, Aguilera NS, Auerbach A. CD5-negative, CD10-negative low-grade B-cell lymphoproliferative disorders of the spleen. Curr Oncol. 2021;28(6):5124–5147. doi:10.3390/curroncol28060430. PMID 34940069
- Schwab C, Harrison CJ. Advances in B-cell precursor acute lymphoblastic leukemia genomics. Hemasphere. 2018;2(4):e53. doi:10.1097/HS9.0000000000000053. PMID 31723781
- Shah PV, Ng A, Shih A, et al. Classic hairy cell leukemia and related disorders: an updated review of molecular features and personalized therapies. J Pers Med. 2026;16(6):276. doi:10.3390/jpm16060276. PMID 42346587
- Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98(1):217–223. doi:10.1182/blood.v98.1.217. PMID 11418483 (abstract)
- Sigei AC, Bartow BB, Wheeler Y. Sentinel lymph node involvement by epithelial inclusions mimicking metastatic carcinoma: a diagnostic pitfall. Am J Case Rep. 2020;21:e926094. doi:10.12659/AJCR.926094. PMID 33245711 (case report; abstract)
- Sinit RB, Dorer RK, Flores JP, Aboulafia DM. Rare causes of isolated and progressive splenic lesions: challenges in differential diagnosis, evaluation, and treatment of primary splenic lymphomas. Clin Med Insights Blood Disord. 2020;13:1179545X20926188. doi:10.1177/1179545X20926188. PMID 32565679
- Skafi M, Caserta S, Martino EA, et al. Extranodal marginal zone lymphoma: integrating etiology, microenvironment, and genetics into clinical decision-making. Eur J Haematol. 2026;117(4):849–863. doi:10.1111/ejh.70245. PMID 42333714
- Song K, Huang Q. IgG4-related lymphadenopathy: benign but with rare recurrent. EJHaem. 2021;2(4):891–892. doi:10.1002/jha2.327. PMID 35845191
- Song SB, Noh BG, Oh MH, et al. Splenic hamartoma mimicking angiosarcoma: a case report. World J Clin Cases. 2025;13(26):107028. doi:10.12998/wjcc.v13.i26.107028. PMID 40881498 (case report)
- Sra MS, Rajkumar SV, Kumar S. Monoclonal gammopathy of clinical significance: a multisystem review. Blood Cancer J. 2026;16(1):128. doi:10.1038/s41408-026-01528-5. PMID 42215470
- Suttorp M, Classen CF. Splenomegaly in children and adolescents. Front Pediatr. 2021;9:704635. doi:10.3389/fped.2021.704635. PMID 34307263
- Tangri S, Vall H, Kaplan D, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS – part III – analytical issues. Cytometry B Clin Cytom. 2013;84(5):291–308. doi:10.1002/cyto.b.21106. PMID 24022852 (abstract)
- Teja R, Allarie E, Fung C. Common and uncommon splenic lesions: a review. Diagnostics (Basel). 2026;16(15):2462. doi:10.3390/diagnostics16152462. PMID 42587698
- Toh WS, Chan KS, Ding CSL, Tan CH, Shelat VG. Intrahepatic splenosis: a world review. Clin Exp Hepatol. 2020;6(3):185–198. doi:10.5114/ceh.2020.99509. PMID 33145425
- Tohfa SA, Riyad M, Faisel M, Arefin M, Jamila M. Littoral cell angioma of the spleen presenting with hypersplenism: a case report. Cureus. 2026;18(9):e116721. doi:10.7759/cureus.116721. PMID 42924120 (case report)
- Turner RR, Weaver DL, Cserni G, et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol. 2008;26(2):258–263. doi:10.1200/JCO.2007.13.0179. PMID 18182666 (abstract)
- van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–1975. doi:10.1038/leu.2012.120. PMID 22552007
- Ventura L, Zanelli M, Zizzo M, et al. Toxoplasma cyst detection in Piringer-Kuchinka lymphadenitis. Report of two cases and literature review. Pathologica. 2021;113(2):126–130. doi:10.32074/1591-951X-139. PMID 34042094
- Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77–87. doi:10.1136/annrheumdis-2019-216561. PMID 31796497 (abstract)
- Wang W, Qi G, Zhao X, et al. Clinical landscape of littoral cell angioma in the spleen based on a comprehensive analysis. Front Oncol. 2022;12:790332. doi:10.3389/fonc.2022.790332. PMID 35211400
- Wang XJ, Kim A, Li S. Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. Int J Clin Exp Pathol. 2014;7(7):4323–4328. PMID 25120816 (abstract)
- Weiss LM, O'Malley D. Benign lymphadenopathies. Mod Pathol. 2013;26 Suppl 1:S88–S96. doi:10.1038/modpathol.2012.176. PMID 23281438
- Wessels A, Bamford C, Lewis D, Martini M, Wainwright H. Syphilitic lymphadenitis clinically and histologically mimicking lymphogranuloma venereum. S Afr Med J. 2016;106(5):49–51. doi:10.7196/SAMJ.2016.v106i5.8723. PMID 27138664 (case report; abstract)
- Willard-Mack CL. Normal structure, function, and histology of lymph nodes. Toxicol Pathol. 2006;34(5):409–424. doi:10.1080/01926230600867727. PMID 17067937 (abstract)
- Wood B, Jevremovic D, Béné MC, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS – part V – assay performance criteria. Cytometry B Clin Cytom. 2013;84(5):315–323. doi:10.1002/cyto.b.21108. PMID 24022854 (abstract)
- Wood BL, Arroz M, Barnett D, et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom. 2007;72 Suppl 1:S14–S22. doi:10.1002/cyto.b.20363. PMID 17803189 (abstract)
- Wu R, Lim MS. Updates in pathobiological aspects of anaplastic large cell lymphoma. Front Oncol. 2023;13:1241532. doi:10.3389/fonc.2023.1241532. PMID 37810974
- Xiao Y, Li L, Zhan X, et al. Spleen EBV-positive inflammatory follicular dendritic cell sarcoma: a case report and literature review. Front Oncol. 2025;15:1640099. doi:10.3389/fonc.2025.1640099. PMID 40919160 (case report)
- Yao F, Long B, Fu M, Fu Y. Pathology features of lymph node enlargement after spontaneous silicone breast implant rupture: a case report. Gland Surg. 2026;15(10):296. doi:10.21037/gs-2026-0285. PMID 42996575 (case report; abstract)
- Yoo KH. Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT. Blood Res. 2022;57(S1):75–78. doi:10.5045/br.2022.2022055. PMID 35483930
- Younes S, Chinyengetere F, Russell V, et al. Elucidating the gene expression signature of Rosai-Dorfman disease: a study from the Atlas of Blood Cancer Genomes Initiative. Cancer Res Commun. 2026;6(10):2555–2564. doi:10.1158/2767-9764.CRC-25-0834. PMID 42862790
- Yu SC, Ko KY, Teng SC, et al. A clinicopathological study of cytomegalovirus lymphadenitis and tonsillitis and their association with Epstein-Barr virus. Infect Dis Ther. 2021;10(4):2661–2675. doi:10.1007/s40121-021-00528-1. PMID 34623624
- Zanelli M, Sanguedolce F, Zizzo M, et al. A diagnostic approach in large B-cell lymphomas according to the fifth World Health Organization and International Consensus Classifications and a practical algorithm in routine practice. Int J Mol Sci. 2024;25(23):13213. doi:10.3390/ijms252313213. PMID 39684922
- Zhang G, Hu J. Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms. Blood Adv. 2026;10(4):1012–1022. doi:10.1182/bloodadvances.2025017165. PMID 41296002
- Zhou L, Xu H, Zhou J, et al. A rare case of hairy cell leukemia with co-expression of CD5 and cyclin D1: a diagnostic pitfall. Mol Clin Oncol. 2020;13(6):74. doi:10.3892/mco.2020.2142. PMID 33005408 (case report)